GLP-1 Market
LLY $1251.61 ▲ +3.5% NVO $39.22 ▲ +2.9% PFE $29.44 ▲ +0.8% VKTX $27.37 ▲ +7.5% KLRA $11.71 ▲ +9.0% GPCR $22.19 ▲ +1.4% RHHBY $56.78 ▲ +2.0%
Market data delayed up to 20 min · Source: Twelve Data

Empowering you to have better conversations with your doctor.

Subscribe
About this data Sourced primarily from ClinicalTrials.gov — a listing isn't proof of safety or FDA approval.

Pipeline and clinical trial information here comes primarily from ClinicalTrials.gov. A listing on ClinicalTrials.gov means a study has been registered — not that a treatment is proven safe, effective, or FDA-approved. Investigational treatments may never be approved. Who can join a trial is decided only by that trial's own study team.

Not yet reported

Bortezomib

Company
Janssen Research & Development, LLC
Mechanism
Mechanism not yet reported
Route
Route not yet reported
Recruiting trials
87 recruiting

Efficacy results: Not yet reported

Find a Clinical Trial Near Me

87 recruiting studies currently listed on ClinicalTrials.gov.

Data source: ClinicalTrials.gov · trial data as of Oct 16, 2026

Find a Clinical Trial Near Me

See recruiting studies for Bortezomib and check eligibility with the study team.

Select conditions
Match
Treatment type

"Added to GLP-1" means the investigational treatment is being studied on top of an existing GLP-1-based therapy.

Your ZIP code is only used to calculate distance to trial sites — it isn't stored.

Trial details
  • Recruiting NCT NCT02343042

    Selinexor and Backbone Treatments of Multiple Myeloma Patients

    Not yet reported, Not yet reported Karyopharm Therapeutics Inc 300 participants Est. completion 2027-04 25 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT03136146

    Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma, Burkitt Lymphoma/Leukemia, or Double-Hit Lymphoma/Leukemia

    Not yet reported M.D. Anderson Cancer Center 42 participants Est. completion 2027-08-01 1 site Stand-alone
    Other conditions: Recurrent Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Burkitt Leukemia, Recurrent Burkitt Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Acute Lymphoblastic Leukemia, Refractory Burkitt Leukemia, Refractory Burkitt Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Lymphoblastic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT03590171

    International Study for Treatment of High Risk Childhood Relapsed ALL 2010

    Not yet reported Charite University, Berlin, Germany 250 participants Est. completion 2027-12-31 15 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia (ALL)
    View official trial listing →
  • Recruiting NCT NCT03643276

    Treatment Protocol for Children and Adolescents With Acute Lymphoblastic Leukemia - AIEOP-BFM ALL 2017

    Not yet reported Martin Schrappe 5000 participants Est. completion 2028-07-14 115 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Pediatric
    View official trial listing →
  • Recruiting NCT NCT03643549

    Bortezomib and Temozolomide in Recurrent Grade-4 Glioma Unmethylated MGMT Promoter (BORTEM-17)

    Not yet reported, Not yet reported Haukeland University Hospital 63 participants Est. completion 2026-12-31 2 sites Stand-alone
    Other conditions: Glioblastoma
    View official trial listing →
  • Recruiting NCT NCT03844360

    Dose Individualization of Antineoplastic Drugs and Anti-Infective Drug in Children With Hematoplastic Disease

    Not yet reported Wei Zhao 1500 participants Est. completion 2026-12-31 2 sites Stand-alone
    Other conditions: Hematological Neoplasms
    View official trial listing →
  • Recruiting NCT NCT03850366

    HLA-Haploidentical Peripheral Blood Stem Cell Transplantation With Post-transplant Cyclophosphamide and Bortezomib

    Not yet reported Henry Ford Health System 15 participants Est. completion 2028-01-01 1 site Stand-alone
    Other conditions: Hematological Malignancy
    View official trial listing →
  • Recruiting NCT NCT03993262

    Trial to Evaluate Efficacy and Safety of Bortezomib in Patients With Severe Autoimmune Encephalitis

    Not yet reported Jena University Hospital 50 participants Est. completion 2026-12-31 17 sites Stand-alone
    Other conditions: Autoimmune Encephalitis
    View official trial listing →
  • Recruiting NCT NCT04025450

    Comparation of Chidamide Plus VRD (Bortezomib, Lenalidomide, Dexamethasone) With VRD Regimen for Primary High-Risk Multiple Myeloma Patients

    Not yet reported, Not yet reported The First Affiliated Hospital of Soochow University 50 participants Est. completion 2029-07-15 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT04068597

    Study to Evaluate CCS1477 (Inobrodib) in Haematological Malignancies

    Not yet reported, Not yet reported CellCentric Ltd. 250 participants Est. completion 2027-03-31 39 sites Stand-alone
    Other conditions: Haematological Malignancy, Acute Myeloid Leukemia, Non Hodgkin Lymphoma, Multiple Myeloma, Higher-risk Myelodysplastic Syndrome, Peripheral T Cell Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04240054

    Bortezomib, Isatuximab, Cyclophosphamide and Dexamethasone Induction in Transplant-Eligible Multiple Myeloma Patients With Renal Insufficiency

    Not yet reported Medical College of Wisconsin 41 participants Est. completion 2030-12-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT04265872

    Bortezomib Followed by Pembrolizumab and Cisplatin in metTNBC

    Not yet reported Baylor Research Institute 20 participants Est. completion 2027-03-31 1 site Stand-alone
    Other conditions: Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT04268199

    A Multicentre, Non-Blinded Study Exploring Self-Administration of Chemotherapy in the Home Environment

    Not yet reported AHS Cancer Control Alberta 100 participants Est. completion 2026-12 2 sites
    Other conditions: Myeloma, Myeloma Multiple
    View official trial listing →
  • Recruiting NCT NCT04414475

    A Study of Selinexor (Seli) + Low-dose Dexamethasone (LDD) in Penta-refractory Multiple Myeloma (MM), Seli and Bortezomib + LDD in Triple-class Refractory MM.

    Not yet reported Karyopharm Therapeutics Inc 127 participants Est. completion 2028-01 16 sites Stand-alone
    Other conditions: Multiple Myeloma, Refractory
    View official trial listing →
  • Recruiting NCT NCT04566328

    Testing the Use of Combination Therapy in Adult Patients With Newly Diagnosed Multiple Myeloma, the EQUATE Trial

    Not yet reported ECOG-ACRIN Cancer Research Group 1450 participants Est. completion 2027-12-31 647 sites Stand-alone
    Other conditions: Plasma Cell Myeloma, RISS Stage I Plasma Cell Myeloma, RISS Stage II Plasma Cell Myeloma
    View official trial listing →
  • Recruiting NCT NCT04817956

    Improving Public Cancer Care by Implementing Precision Medicine in Norway

    Not yet reported Oslo University Hospital 3000 participants Est. completion 2045-04-30 17 sites Stand-alone
    Other conditions: Cancer Metastatic
    View official trial listing →
  • Recruiting NCT NCT04915248

    Study to Evaluate Combined Treatment of Daratumumab, Bortezomib and Dexamethasone in PBL Patients.

    Not yet reported Fondazione Italiana Linfomi - ETS 28 participants Est. completion 2027-07-01 18 sites Stand-alone
    Other conditions: Plasmablastic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT04991103

    Minimal Residual Disease Response-adapted Deferral of Transplant in Dysproteinemia (MILESTONE)

    Not yet reported University of Alabama at Birmingham 40 participants Est. completion 2028-08-27 1 site Stand-alone
    Other conditions: Multiple Myeloma, Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT05137054

    A Study to Examine the Effects of Novel Therapy Linvoseltamab in Combination With Other Cancer Treatments for Adult Participants With Multiple Myeloma That is Resistant to Current Standard of Care Treatments

    Not yet reported Regeneron Pharmaceuticals 317 participants Est. completion 2032-03-24 42 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05248633

    Chemotherapy Combined With Radiotherapy Versus Radiotherapy Alone for Solitary Plasmacytoma

    Not yet reported Peking Union Medical College Hospital 220 participants Est. completion 2026-10 1 site Stand-alone
    Other conditions: Solitary Plasmacytoma
    View official trial listing →
  • Recruiting NCT NCT05272826

    Study of Iberdomide, Bortezomib, Dexamethasone With Isatuximab Added on Demand for ND-NTE MM Patients

    Not yet reported Canadian Myeloma Research Group 75 participants Est. completion 2031-03 7 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05289167

    Post-Transplant Cyclophosphamide, Bortezomib and Abatacept for the Prevention of Graft-versus-Host-Disease (GvHD)

    Not yet reported, Not yet reported Northwell Health 74 participants Est. completion 2028-08 1 site Stand-alone
    Other conditions: Graft-versus-host Disease
    View official trial listing →
  • Recruiting NCT NCT05470491

    Trial of Allogeneic Reduced-Intensity, HLA-Haploidentical Allogeneic Hematopoietic Cell Bone Marrow Transplantation Followed by Graft-versus-Host-Disease (GVHD) Prophylaxis With Cyclophosphamide, Bortezomib and Maraviroc for Hematologic Malignancies ...

    Not yet reported, Not yet reported National Cancer Institute (NCI) 265 participants Est. completion 2028-07-30 1 site Stand-alone
    Other conditions: HIV, Hematologic Malignancies
    View official trial listing →
  • Recruiting NCT NCT05519085

    A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

    Not yet reported Celgene 810 participants Est. completion 2033-11-30 266 sites Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05558319

    NDMM Patients Candidates for ASCT Comparing Extended VRD Plus vs. Isa-VRD vs. Isa-V-Iberdomide

    Not yet reported PETHEMA Foundation 480 participants Est. completion 2029-04 68 sites Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05561387

    Comparing Combinations of Drugs to Treat Newly Diagnosed Multiple Myeloma (NDMM) When a Stem Cell Transplant is Not a Medically Suitable Treatment

    Not yet reported SWOG Cancer Research Network 510 participants Est. completion 2031-05-30 397 sites
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Recruiting NCT NCT05599880

    The Investigate Efficacy and Safety Evaluation of Bortezomib in Patients With Relapsed/Refractory Immune Thrombocytopenia

    Not yet reported Seoul National University Hospital 29 participants Est. completion 2028-12-31 4 sites Stand-alone
    Other conditions: Relapsed/Refractory Immune Thrombocytopenia
    View official trial listing →
  • Recruiting NCT NCT05623020

    A Study to Learn About the Effects of the Combination of Elranatamab, Daratumumab and Lenalidomide Compared With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Who Are Not Candidates for Transplant

    Not yet reported Pfizer 1060 participants Est. completion 2033-10-03 160 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05665140

    Expression-linked and R-ISS-adapted Stratification for First Line Therapy in Multiple Myeloma Patients

    Not yet reported, Not yet reported University Hopsital Schleswig Holstein Campus Lübeck 100 participants Est. completion 2028-10 6 sites Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05681260

    Capizzi Escalating Methotrexate Versus High Dose Methotrexate in Children With Newly Diagnosed T-cell Lymphoblastic Lymphoma (T-LBL)

    Not yet reported Children's Cancer Group, China 200 participants Est. completion 2029-12-31 2 sites Stand-alone
    Other conditions: T-cell Lymphoblastic Lymphoma
    View official trial listing →
  • Recruiting NCT NCT05695508

    GMMG-HD10 / DSMM-XX / 64007957MMY2003, MajesTEC-5

    Not yet reported University of Heidelberg Medical Center 160 participants Est. completion 2029-09-15 11 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT05736419

    A Study of Immune Suppression Treatment for People With Sickle Cell Disease or β-Thalassemia Who Are Going to Receive an Allogeneic Hematopoietic Cell Transplantation (HCT)

    Not yet reported Memorial Sloan Kettering Cancer Center 24 participants Est. completion 2027-02-09 6 sites Stand-alone
    Other conditions: Sickle Cell Disease, Thalassemia, Beta, Thalassemia
    View official trial listing →
  • Recruiting NCT NCT05848687

    TINI 2: Total Therapy for Infants With Acute Lymphoblastic Leukemia II

    Not yet reported, Not yet reported Tanja Andrea Gruber 90 participants Est. completion 2033-12 24 sites Stand-alone
    Other conditions: Lymphoblastic Leukemia
    View official trial listing →
  • Recruiting NCT NCT05979363

    A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd)-Based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With Primary Plasma Cell Leukemia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 20 participants Est. completion 2028-07-01 1 site Stand-alone
    Other conditions: Plasma Cell Leukemia
    View official trial listing →
  • Recruiting NCT NCT06022939

    Comparing Dara-VCD Chemotherapy Plus Stem Cell Transplant to Dara-VCD Chemotherapy Alone for People Who Have Newly Diagnosed AL Amyloidosis

    Not yet reported SWOG Cancer Research Network 338 participants Est. completion 2030-10-29 117 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06034561

    Bortezomib-based Regimen for Refractory or Relapsed Acute Lymphoblastic Leukemia

    Not yet reported Instituto do Cancer do Estado de São Paulo 50 participants Est. completion 2029-08 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
    View official trial listing →
  • Recruiting NCT NCT06039735

    Cardiac Toxicity and Prognostic Value of New Echocardiographic Indicators in the Treatment of Primary Multiple Myeloma

    Qilu Hospital of Shandong University 50 participants Est. completion 2028-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06083922

    A Study of CyBorD (Cyclophosphamide, Bortezomib, Dexamethasone) Plus Daratumumab in People With Monoclonal Gammopathy of Renal Significance (MGRS)

    Not yet reported Memorial Sloan Kettering Cancer Center 20 participants Est. completion 2026-10 11 sites Stand-alone
    Other conditions: Multiple Myeloma, Monoclonal Gammopathy of Renal Significance
    View official trial listing →
  • Recruiting NCT NCT06087653

    Safety, Efficacy, and Pharmacokinetics of Continuous Subcutaneous Lenalidomide in Multiple Myeloma (MM)

    Not yet reported, Not yet reported Starton Therapeutics, Inc 24 participants Est. completion 2028-03-31 2 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06140966

    Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

    Not yet reported Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 54 participants Est. completion 2027-10-20 1 site Stand-alone
    Other conditions: Multiple Myeloma, Primary Plasma Cell Leukemia, Extramedullary Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06142396

    Pilot Study Dara-CyBorD in Newly Diagnosed Multiple Myeloma Patients With Renal Failure

    Not yet reported Augusta University 30 participants Est. completion 2027-11-01 1 site Stand-alone
    Other conditions: Multiple Myeloma, Renal Failure
    View official trial listing →
  • Recruiting NCT NCT06152575

    MagnetisMM-32: A Study to Learn About the Study Medicine Called Elranatamab in People With Multiple Myeloma (MM) That Has Come Back After Taking Other Treatments (Including Prior Treatment With an Anti-CD38 Antibody and Lenalidomide)

    Not yet reported Pfizer 492 participants Est. completion 2027-12-30 270 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06158269

    DVRd in the Treatment of Patients With Newly Diagnosed Double-hit Multiple Myeloma

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 40 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06192979

    Optimize First-line Treatment for AL Amyloidosis With t (11; 14)

    Not yet reported Jin Lu, MD 41 participants Est. completion 2027-03-31 7 sites
    Other conditions: Amyloidosis; Systemic, AL Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06245629

    Bortezomib-bendamustine-melphalan vs Melphalan for Multiple Myeloma

    Uppsala University 100 participants Est. completion 2025-11-30 1 site
    Other conditions: Myeloma Multiple
    View official trial listing →
  • Recruiting NCT NCT06246162

    Mitoxantrone Hydrochloride Liposome Combination Regimen in the Treatment of High-risk/Extramedullary Multiple Myeloma

    Not yet reported, Not yet reported Affiliated Hospital of Nantong University 30 participants Est. completion 2026-11-30 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06342466

    Bortezomib, Pomalidomide, Dexamethasone for Systemic AL Amyloidosis

    Not yet reported Jin Lu, MD 40 participants Est. completion 2026-12 1 site Stand-alone
    Other conditions: Systemic Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06390319

    Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)

    Not yet reported St. Jude Children's Research Hospital 100 participants Est. completion 2033-12 4 sites Stand-alone
    Other conditions: T-cell Acute Lymphoblastic Leukemia, T-cell Lymphoma, Mixed Phenotype Acute Leukemia
    View official trial listing →
  • Recruiting NCT NCT06409702

    Treatment of High-risk Newly Diagnosed Multiple Myeloma With Minimal Residual Disease Detection

    Not yet reported The First Affiliated Hospital of Soochow University 59 participants Est. completion 2027-12-31 1 site Stand-alone
    Other conditions: Newly Diagnosed, High Risk, MRD, Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06418477

    Daratumumab, Bortezomib, Cyclophosphamide, and Dexamethasone Therapy for Patients with MIDD

    Not yet reported Peking University People's Hospital 20 participants Est. completion 2026-12-31 3 sites Stand-alone
    Other conditions: Monoclonal Gammopathy of Renal Significance
    View official trial listing →
  • Recruiting NCT NCT06463717

    Primary Multiple Myeloma Who Achieved MRD Negativity After Induction Therapy, ASCT or Not

    First Affiliated Hospital of Zhejiang University 210 participants Est. completion 2028-12 1 site
    Other conditions: Multiple Myeloma, Minimal Residual Disease
    View official trial listing →
  • Recruiting NCT NCT06464991

    A Phase III Study of Eque-cel in Subjects With Len-refractory RRMM (FUMANBA-03)

    Not yet reported Nanjing IASO Biotechnology Co., Ltd. 240 participants Est. completion 2030-12 28 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06497738

    A Prospective Study Comparing DRd With VRd-lite in Elderly Newly Diagnosed Multiple Myeloma

    The First Affiliated Hospital with Nanjing Medical University 112 participants Est. completion 2027-06-01 6 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06505369

    Bispecific T-cell Redirectors as Part of First Line Treatment in Transplant Eligible Multiple Myeloma Patients

    Not yet reported North Estonia Medical Centre 50 participants Est. completion 2028-10 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06572813

    Bortezomib Combined with PD-1 MAb and MFOLFIRINOX for Metastatic Pancreatic Cancer

    Not yet reported, Not yet reported First Affiliated Hospital of Zhejiang University 63 participants Est. completion 2028-03 1 site Stand-alone
    Other conditions: Pancreas Cancer
    View official trial listing →
  • Recruiting NCT NCT06627309

    Rapid dFLC Response Predict CHR in AL Amyloidosis

    Peking University People's Hospital 50 participants Est. completion 2026-12-31 8 sites
    Other conditions: Systemic AL Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT06636552

    An Investigator-Initiated, Phase II, Multicenter, Open-Label, Single-Arm, Prospective Clinical Trial to Evaluate the Efficacy and Safety of Alternating Bortezomib-Based Regimens in Combination With DaratUMumab Followed by Maintenance With Daratumumab in the Frontline Setting of Primary Plasma CEll L

    Not yet reported Hellenic Society of Hematology 43 participants Est. completion 2029-01-05 7 sites
    Other conditions: Primary Plasma Cell Leukemia
    View official trial listing →
  • Recruiting NCT NCT06648889

    Isatuximab in Adult Patients With Cytologic or Molecular Relapsed/Refractory CD38 Positive T-cell Acute Lymphoblastic Leukemia

    Not yet reported Goethe University 28 participants Est. completion 2030-06 15 sites Stand-alone
    Other conditions: T-ALL
    View official trial listing →
  • Recruiting NCT NCT06682156

    Conversion to Carfilzomib Therapy in Bortezomib Intolerant Newly Diagnosed Multiple Myeloma(NDMM) Patients

    The First Affiliated Hospital of Soochow University 50 participants Est. completion 2028-06-30 1 site
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT06796517

    Immunotherapy in Lymphoma

    Sung-Soo Park 72 participants Est. completion 2025-12-31 2 sites
    Other conditions: Relapsed/refractory High Grade B Cell Lymphoma, High Grade B-cell Lymphoma, Diffuse Large B Cell Lymphoma Relapsed, Primary Mediastinal Large B-Cell Lymphoma, Burkitt Lymphoma
    View official trial listing →
  • Recruiting NCT NCT06900647

    Bortezomib Plus Cisplatin in Recurrent or Metastatic Breast Cancer

    Not yet reported Sun Yat-sen University 20 participants Est. completion 2028-06-30 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer, Recurrent Breast Cancer
    View official trial listing →
  • Recruiting NCT NCT06918002

    Elranatamab/Lenalidomide Consolidation and/or Elranatamab Maintenance Versus Standard of Care After D-VRd Induction in Transplant-eligible NDMM Patients

    Not yet reported Intergroupe Francophone du Myelome 824 participants Est. completion 2036-05 69 sites Stand-alone
    Other conditions: Multiple Myeloma, Newly Diagnosed
    View official trial listing →
  • Recruiting NCT NCT06933277

    Observational Study on the Combination of Selinexor With Bortezomib and Dexamethasone for the Treatment of MM Patients

    Gruppo Italiano Malattie EMatologiche dell'Adulto 159 participants Est. completion 2028-08 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07008638

    Phase I/II Clinical Trial of Proteasome Inhibitor in Combination With CPX-351 for the Treatment of Newly-Diagnosed TP53-mutated Acute Myeloid Leukemia (AML)

    Not yet reported, Not yet reported Masonic Cancer Center, University of Minnesota 32 participants Est. completion 2028-01-27 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, TP53
    View official trial listing →
  • Recruiting NCT NCT07018050

    Phase II Study of QLS32015 Combination Therapy in the Treatment of Multiple Myeloma

    Not yet reported Qilu Pharmaceutical Co., Ltd. 160 participants Est. completion 2028-07 1 site Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07025005

    Fenofibrate Role in the Prophylaxis From Peripheral Neuropathy Induced by Bortezomib, Lenalidomide and Dexamethasone (VRd) Protocol in the Treatment of Patients With Multiple Myeloma (MM)

    Not yet reported Tanta University 44 participants Est. completion 2026-09-30 2 sites
    Other conditions: Peripheral Neuropathy, Multiple Myeloma, Neoplasms
    View official trial listing →
  • Recruiting NCT NCT07039877

    Efficacy of Low-dose Venetoclax With Itraconazole + TACL for R/R ALL Patients

    Not yet reported Hospital Universitario Dr. Jose E. Gonzalez 12 participants Est. completion 2026-04-30 1 site Stand-alone
    Other conditions: Acute Lymphobkastic Leukemia, Acute Lymphoblastic Leukaemia Recurrent, Philadelphia Chromosome Negative ALL
    View official trial listing →
  • Recruiting NCT NCT07045909

    Efficacy and Safety of Anitocabtagene Autoleucel in Participants With Newly Diagnosed Multiple Myeloma (GEM-AnitoFIRST)

    Not yet reported PETHEMA Foundation 30 participants Est. completion 2030-03-31 10 sites Stand-alone
    Other conditions: De Novo Multiple Myeloma, Anitocabtagene Autoleucel
    View official trial listing →
  • Recruiting NCT NCT07051850

    Quality of Life and Treatment Outcomes in RRMM Patients Receiving Advanced vs. Conventional Immunotherapies

    Sung-Soo Park 174 participants Est. completion 2025-12-31 1 site
    Other conditions: Multiple Myeloma, Relapsed, Multiple Myeloma (MM)
    View official trial listing →
  • Recruiting NCT NCT07085728

    Testing the Investigational Agent Combination of Daratumumab, Bortezomib, and Dexamethasone Compared to the Usual Treatment of Cyclophosphamide, Bortezomib, and Dexamethasone in Newly Diagnosed Multiple Myeloma Patients With Kidney Failure

    Not yet reported Eastern Cooperative Oncology Group 74 participants Est. completion 2038-09-11 1 site Stand-alone
    Other conditions: Myeloma Multiple
    View official trial listing →
  • Recruiting NCT NCT07149857

    A Study to Evaluate Efficacy and Safety of Ciltacabtagene Autoleucel

    Not yet reported Janssen Research & Development, LLC 60 participants Est. completion 2029-04-06 20 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07222761

    A Study to Compare Linvoseltamab Monotherapy and Linvoseltamab + Carfilzomib Combination Therapy With Standard-of-Care Combination Regimens in Adult Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

    Not yet reported Regeneron Pharmaceuticals 915 participants Est. completion 2034-08-23 39 sites Stand-alone
    Other conditions: Relapsed and/or Refractory Multiple Myeloma (RRMM)
    View official trial listing →
  • Recruiting NCT NCT07224672

    A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Cyclophosphamide, Bortezomib, and Dexamethasone in Adult Participants With Newly Diagnosed Amyloid Light Chain (AL) Amyloidosis

    Not yet reported GlaxoSmithKline 60 participants Est. completion 2033-01-12 5 sites Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT07227311

    A Study to Evaluate the Efficacy and Safety of Belantamab Mafodotin in Combination With Standard of Care in Participants With Relapsed-Refractory Multiple Myeloma (RRMM)

    Not yet reported GlaxoSmithKline 200 participants Est. completion 2030-08-30 59 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07285239

    Belantamab Mafodotin or Daratumumab With Bortezomib, Lenalidomide and Dexamethasone for Newly Diagnosed Multiple Myeloma

    Not yet reported PrECOG, LLC. 500 participants Est. completion 2034-06 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07297329

    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not yet reported Sinocelltech Ltd. 292 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Multiple Myeloma (MM)
    View official trial listing →
  • Recruiting NCT NCT07341867

    Systemic Anti-Cancer Therapy Dose Modifications for Individuals With Duffy Null Phenotype

    Not yet reported Andrew Hantel, MD 90 participants Est. completion 2029-03-31 1 site Stand-alone
    Other conditions: Multiple Myeloma, Triple Negative Breast Cancer, Duffy Blood Group, Chemokine Receptor Gene Mutation, Duffy Blood Group, Chemokine Receptor Gene C.-67T>C
    View official trial listing →
  • Recruiting NCT NCT07388602

    A Study to Evaluate the Safety and Efficacy of SCTC21C in Combination With Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Newly Diagnosed Systemic Light-Chain Amyloidosis (NDSLCA)

    Not yet reported Sinocelltech Ltd. 90 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Recruiting NCT NCT07391657

    A Study Comparing AZD0120, a Dual-targeted CAR-T Against B-cell Maturation Antigen (BCMA) and CD19, Versus Standard Regimens in Participants With Relapsed Refractory Multiple Myeloma (DURGA-4)

    Not yet reported AstraZeneca 508 participants Est. completion 2030-07-29 143 sites
    Other conditions: Relapsed Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07513129

    Venetoclax, Dexamethasone, Bortezomib, and Daratumumab For The Treatment Of Adolescent And Young Adults With Relapsed Or Refractory T-Cell Acute Lymphoblastic Leukemia And T-cell Acute Lymphoblastic Lymphoma

    Not yet reported M.D. Anderson Cancer Center 18 participants Est. completion 2031-12-31 1 site Stand-alone
    Other conditions: T-cell Acute Lymphoblastic Leukemia, Lymphoma
    View official trial listing →
  • Recruiting NCT NCT07579234

    A Multicenter, Randomized, Open-label, Parallel-group, Controlled, Superiority Phase III Clinical Study Comparing the Efficacy and Safety of F182112 Versus Standard of Care in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Shandong New Time Pharmaceutical Co., LTD 261 participants Est. completion 2029-01-25 1 site
    Other conditions: Relapsed or Refractory Multiple Myeloma (RRMM)
    View official trial listing →
  • Recruiting NCT NCT07623798

    A Study in Participants With Relapsed or Refractory Multiple Myeloma for IBI3003

    Not yet reported Innovent Biologics (Suzhou) Co. Ltd. 255 participants Est. completion 2029-12-31 1 site
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07624513

    D2 - Isa-Iber-VD Induction, Followed by Risk & Response Adapted Consolidation & Maintenance, in Transplant-Eligible NDMM

    Not yet reported Dana-Farber Cancer Institute 720 participants Est. completion 2038-03-01 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07652905

    CM336 Plus Isa-VR in Newly Diagnosed Primary Plasma Cell Leukemia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 24 participants Est. completion 2031-12-30 1 site Stand-alone
    Other conditions: Plasma Cell Leukemia (PCL)
    View official trial listing →
  • Recruiting NCT NCT07663253

    Isatuximab-VRd in Transplant-Ineligible Newly Diagnosed Multiple Myeloma Patients

    Shanghai Zhongshan Hospital 333 participants Est. completion 2030-09 13 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07665450

    A Study of Ramantamig Plus Daratumumab Versus Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (DVRd) or Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Participants With NDMM For Whom Stem Cell Transplant is Not Planned

    Not yet reported Janssen Research & Development, LLC 1000 participants Est. completion 2035-02-02 30 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Recruiting NCT NCT07764978

    Study of AZD0120 in Newly Diagnosed Multiple Myeloma Ineligible for ASCT

    Not yet reported AstraZeneca 750 participants Est. completion 2034-05-12 124 sites Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00004002

    PS-341 in Treating Patients With Advanced Solid Tumors or Lymphoma

    Not yet reported NYU Langone Health 5 sites
    Other conditions: Lymphoma, Small Intestine Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00005064

    PS-341 in Treating Patients With Refractory or Relapsed Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Chronic Myeloid Leukemia in Blast Phase, or Myelodysplastic Syndrome

    Not yet reported National Cancer Institute (NCI) 30 participants 1 site Stand-alone
    Other conditions: Adult Acute Promyelocytic Leukemia (M3), Blastic Phase Chronic Myelogenous Leukemia, Previously Treated Myelodysplastic Syndromes, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Refractory Anemia With Excess Blasts, Refractory Anemia With Excess Blasts in Transformation, Relapsing Chronic Myelogenous Leukemia
    View official trial listing →
  • Completed NCT NCT00006098

    PS-341 in Treating Patients With Hematologic Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center Est. completion 2001-10 1 site
    Other conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT00006184

    Chemotherapy, Stem Cell Transplantation and Donor and Patient Vaccination for Treatment of Multiple Myeloma

    Not yet reported National Cancer Institute (NCI) 20 participants Est. completion 2008-01-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00006362

    PS-341 in Treating Patients With Advanced Cancer

    Not yet reported Mayo Clinic Est. completion 2003-08 2 sites
    Other conditions: Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Precancerous Condition, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Terminated NCT NCT00006773

    Bortezomib in Treating Patients With Recurrent Glioma

    Not yet reported National Cancer Institute (NCI) 42 participants 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, Adult Glioblastoma, Recurrent Adult Brain Tumor
    View official trial listing →
  • Completed NCT NCT00007878

    Bortezomib, Fluorouracil, and Leucovorin Calcium in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed By Surgery

    Not yet reported National Cancer Institute (NCI) 30 participants 1 site Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00011778

    PS-341 and Radiation to Treat Advanced Cancer of the Head and Neck

    Not yet reported National Cancer Institute (NCI) 25 participants Est. completion 2013-02-08 1 site
    Other conditions: Squamous Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT00017199

    PS-341 in Treating Patients With Metastatic Neuroendocrine Tumors

    Not yet reported Ohio State University Comprehensive Cancer Center Est. completion 2007-05 2 sites
    Other conditions: Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
    View official trial listing →
  • Completed NCT NCT00017329

    PS-341 in Treating Patients With Metastatic Kidney Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 1 site
    Other conditions: Kidney Cancer
    View official trial listing →
  • Completed NCT NCT00021216

    Bortezomib in Treating Children With Advanced Solid Tumors

    Not yet reported National Cancer Institute (NCI) 36 participants Est. completion 2005-12 1 site Stand-alone
    Other conditions: Unspecified Childhood Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00023712

    Bortezomib in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer or Primary Peritoneal Cancer

    Not yet reported National Cancer Institute (NCI) 58 participants Est. completion 2010-01 1 site Stand-alone
    Other conditions: Primary Peritoneal Cavity Cancer, Recurrent Ovarian Epithelial Cancer
    View official trial listing →
  • Completed NCT NCT00023764

    Bortezomib in Treating Patients With Lymphoproliferative Disorders

    Not yet reported National Cancer Institute (NCI) 103 participants Est. completion 2009-03 1 site Stand-alone
    Other conditions: Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00023855

    PS-341 and Doxorubicin in Treating Patients With Advanced Solid Tumors

    Not yet reported University of Wisconsin, Madison 1 site
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Terminated NCT NCT00023881

    Bortezomib in Treating Patients With Chronic Myelogenous Leukemia

    Not yet reported M.D. Anderson Cancer Center 7 participants Est. completion 2005-03 1 site
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00024011

    PS-341 in Treating Patients With Metastatic Malignant Melanoma

    Not yet reported National Cancer Institute (NCI) 50 participants 1 site Stand-alone
    Other conditions: Recurrent Melanoma, Stage IV Melanoma
    View official trial listing →
  • Completed NCT NCT00025376

    PS-341 in Treating Patients With Metastatic Kidney Cancer

    Not yet reported University of Chicago 23 participants Est. completion 2006-03 10 sites
    Other conditions: Kidney Cancer
    View official trial listing →
  • Completed NCT NCT00025584

    PS-341 in Treating Women With Metastatic Breast Cancer

    Not yet reported National Cancer Institute (NCI) 35 participants 1 site Stand-alone
    Other conditions: Recurrent Breast Cancer, Stage IV Breast Cancer
    View official trial listing →
  • Completed NCT NCT00027716

    Bortezomib in Treating Patients With Advanced or Metastatic Sarcoma

    Not yet reported Memorial Sloan Kettering Cancer Center Est. completion 2004-05 6 sites
    Other conditions: Sarcoma
    View official trial listing →
  • Completed NCT NCT00027898

    Bortezomib and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

    Not yet reported National Cancer Institute (NCI) 27 participants 1 site Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00028587

    PS-341 and Combination Chemotherapy in Treating Patients With Advanced Solid Tumors

    Not yet reported National Cancer Institute (NCI) 96 participants 1 site Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00028639

    PS-341 in Treating Women With Metastatic Breast Cancer

    Not yet reported Northwestern University Est. completion 2003-11 1 site
    Other conditions: Breast Cancer
    View official trial listing →
  • Completed NCT NCT00028912

    Bortezomib and Carboplatin in Treating Patients With Recurrent or Progressive Ovarian Epithelial, Primary Peritoneal, or Fallopian Tube Cancer

    Not yet reported Memorial Sloan Kettering Cancer Center 1 site
    Other conditions: Fallopian Tube Cancer, Ovarian Cancer, Primary Peritoneal Cavity Cancer
    View official trial listing →
  • Completed NCT NCT00030368

    Bortezomib and Paclitaxel in Treating Patients With Locally Advanced or Metastatic Solid Tumors

    Not yet reported National Cancer Institute (NCI) 45 participants 1 site Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00030875

    Bortezomib in Treating Patients With Mantle Cell Lymphoma

    Not yet reported NCIC Clinical Trials Group 30 participants Est. completion 2009-12-21 10 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00038571

    Proteasome Inhibitor PS-341 Relapsed or Refractory B Cell Lymphomas Previously Treated With Chemotherapy

    Not yet reported M.D. Anderson Cancer Center 60 participants Est. completion 2005-03 1 site Stand-alone
    Other conditions: Lymphoma, B-Cell
    View official trial listing →
  • Terminated NCT NCT00040768

    Bortezomib in Treating Patients With Advanced Non-small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) 35 participants 1 site Stand-alone
    Other conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00045695

    Bortezomib in Treating Patients With Waldenstrom's Macroglobulinemia

    Not yet reported NCIC Clinical Trials Group 27 participants Est. completion 2009-12 12 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00048230

    PS-341 (VELCADE™) Versus High-Dose Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Millennium Pharmaceuticals, Inc. 620 participants Est. completion 2004-12 93 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00049088

    Bortezomib and Docetaxel in Treating Patients With Advanced Solid Tumors

    Not yet reported National Cancer Institute (NCI) 24 participants 1 site Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00051974

    Phase 2 Study of VELCADE Alone or VELCADE® Plus Docetaxel in Previously Treated Patients With Advanced Non-Small Cell Lung Cancer

    Not yet reported Millennium Pharmaceuticals, Inc. 155 participants 20 sites
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00051987

    Phase 2b Study of VELCADE Alone and VELCADE Plus Irinotecan in Patients With Relapsed or Refractory Colorectal Carcinoma

    Not yet reported Millennium Pharmaceuticals, Inc. 175 participants 22 sites
    Other conditions: Colorectal Carcinoma
    View official trial listing →
  • Completed NCT NCT00052338

    Bortezomib Plus Gemcitabine and Carboplatin in Treating Patients With Advanced or Recurrent Non-Small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) 34 participants 1 site Stand-alone
    Other conditions: Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00052507

    Bortezomib in Treating Patients With Metastatic or Recurrent Colorectal Cancer

    Not yet reported University Health Network, Toronto 4 sites
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT00052689

    Bortezomib With or Without Gemcitabine in Treating Patients With Metastatic Pancreatic Cancer

    Not yet reported National Cancer Institute (NCI) 88 participants 1 site Stand-alone
    Other conditions: Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT00054483

    Bortezomib in Treating Patients With Advanced Cancer and Kidney Dysfunction

    Not yet reported National Cancer Institute (NCI) 69 participants 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Adult Grade III Lymphomatoid Granulomatosis, Adult Nasal Type Extranodal NK/T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Multiple Myeloma, Splenic Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00054665

    PS-341 Alone and PS-341 Plus EPOCH Chemotherapy to Treat Non-Hodgkin's Lymphoma

    Not yet reported National Cancer Institute (NCI) 50 participants Est. completion 2009-07 2 sites
    Other conditions: B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00059618

    PS-341 Plus Carboplatin in Platinum and Taxane Resistant Recurrent Ovarian Cancer, Primary Peritoneal Cancer, and Fallopian Tube Cancer

    Not yet reported M.D. Anderson Cancer Center 21 participants Est. completion 2007-04 1 site Stand-alone
    Other conditions: Ovarian Cancer, Primary Peritoneal Cancer, Fallopian Tube Cancer
    View official trial listing →
  • Completed NCT NCT00059631

    Phase I Study of Weekly Intravenous PS-341 (Bortezomib) Plus Mitoxantrone

    Not yet reported M.D. Anderson Cancer Center 42 participants Est. completion 2015-06-17 1 site Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00061932

    Bortezomib With or Without Irinotecan in Treating Patients With Cancer of the Gastroesophageal Junction or Stomach

    Not yet reported National Cancer Institute (NCI) 41 participants Est. completion 2013-11 1 site Stand-alone
    Other conditions: Adenocarcinoma of the Gastroesophageal Junction, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Mixed Adenocarcinoma of the Stomach, Recurrent Gastric Cancer, Stage IIIB Gastric Cancer, Stage IIIC Gastric Cancer, Stage IV Gastric Cancer
    View official trial listing →
  • Completed NCT NCT00063713

    VELCADE in Subjects With Relapsed or Refractory Mantle Cell Lymphoma

    Not yet reported Millennium Pharmaceuticals, Inc. 152 participants 35 sites
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00063726

    A Study of PS-341 Given to Patients With Multiple Myeloma Who Experienced Progressive Disease After Receiving Dexamethasone in M34101-039

    Not yet reported Millennium Pharmaceuticals, Inc. 600 participants Est. completion 2005-07 76 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • No Longer Available NCT NCT00063791

    A Study to Assess Two Different Strategies of Combining Dexamethasone and VELCADE

    Millennium Pharmaceuticals, Inc. 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00064012

    Bortezomib With or Without Docetaxel in Treating Patients With Relapsed or Refractory Advanced Non-Small Cell Lung Cancer

    Not yet reported University of Wisconsin, Madison 4 participants Est. completion 2004-07 21 sites Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT00064610

    Phase I/II Dose Escalation Study of VELCADE® and Docetaxel in Patients With Advanced Androgen-Independent Prostate Cancer

    Not yet reported, Not yet reported Millennium Pharmaceuticals, Inc. 102 participants 4 sites
    Other conditions: Prostatic Neoplasms
    View official trial listing →
  • Terminated NCT NCT00064636

    Phase I Dose Escalation Study of VELCADE Plus Docetaxel in Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

    Not yet reported Millennium Pharmaceuticals, Inc. 46 participants
    Other conditions: Advanced Non-Small Cell Lung Cancer, Other Solid Tumors
    View official trial listing →
  • Completed NCT NCT00066352

    Bortezomib in Treating Patients With Advanced or Metastatic Transitional Cell Cancer of the Bladder, Renal Pelvis, or Ureter

    Not yet reported University Health Network, Toronto 15 sites
    Other conditions: Bladder Cancer, Transitional Cell Cancer of the Renal Pelvis and Ureter
    View official trial listing →
  • Completed NCT NCT00066508

    Bortezomib in Treating Patients With Diffuse Large B-Cell Lymphoma That Is Refractory To Chemotherapy

    Not yet reported Jonsson Comprehensive Cancer Center 7 participants 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT00066625

    Oxaliplatin and Bortezomib in Treating Patients With Advanced Cancer

    Not yet reported National Cancer Institute (NCI) 30 participants 1 site Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00068289

    Bortezomib in Treating Patients With Recurrent or Refractory Extensive-Stage Small Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy

    Not yet reported SWOG Cancer Research Network Est. completion 2007-07 91 sites
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT00068315

    Bortezomib and Fludarabine With or Without Rituximab in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma or Chronic Lymphocytic Leukemia

    Not yet reported National Cancer Institute (NCI) 18 participants 7 sites Stand-alone
    Obstructive sleep apnea Other conditions: Hematopoietic/Lymphoid Cancer, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00068484

    A Dose Finding Phase I Trial of the Combination of Topotecan and PS-341, a Novel Proteasome Inhibitor, in Advanced Malignancies

    Not yet reported National Cancer Institute (NCI) 25 participants 1 site Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00072150

    Phase II Trial Of PS-341 (Bortezomib) In Patients With Previously Treated Advanced Urothelial Tract Transitional Cell Carcinoma

    Not yet reported National Cancer Institute (NCI) 40 participants 1 site Stand-alone
    Other conditions: Metastatic Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Bladder Cancer, Recurrent Transitional Cell Cancer of the Renal Pelvis and Ureter, Recurrent Urethral Cancer, Stage III Bladder Cancer, Stage III Urethral Cancer, Stage IV Bladder Cancer, Stage IV Urethral Cancer, Transitional Cell Carcinoma of the Bladder, Ureter Cancer
    View official trial listing →
  • Completed NCT NCT00074009

    Bortezomib in Treating Patients With Unresectable or Metastatic Gastric Cancer or Gastroesophageal Junction Adenocarcinoma

    Not yet reported Memorial Sloan Kettering Cancer Center 4 sites
    Other conditions: Gastric Cancer
    View official trial listing →
  • Completed NCT NCT00075751

    Gemcitabine, Carboplatin, and Bortezomib in Advanced or Recurrent Non-Small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) 99 participants 1 site Stand-alone
    Other conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00075881

    Bortezomib in Treating Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported National Cancer Institute (NCI) 44 participants Est. completion 2012-10 1 site Stand-alone
    Other conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00077428

    Bortezomib Followed by the Addition of Doxorubicin at Disease Progression in Treating Patients With Locally Advanced, Recurrent, or Metastatic Adenoid Cystic Carcinoma (Cancer) of the Head and Neck

    Not yet reported National Cancer Institute (NCI) 37 participants 1 site Stand-alone
    Other conditions: Recurrent Adenoid Cystic Carcinoma of the Oral Cavity, Recurrent Salivary Gland Cancer, Salivary Gland Adenoid Cystic Carcinoma, Stage III Adenoid Cystic Carcinoma of the Oral Cavity, Stage III Salivary Gland Cancer, Stage IV Adenoid Cystic Carcinoma of the Oral Cavity, Stage IV Salivary Gland Cancer
    View official trial listing →
  • Completed NCT NCT00077441

    Bortezomib in Treating Patients With Hepatocellular Carcinoma (Liver Cancer)

    Not yet reported National Cancer Institute (NCI) 55 participants 1 site Stand-alone
    Other conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
    View official trial listing →
  • Completed NCT NCT00077467

    Bortezomib in Treating Young Patients With Refractory or Recurrent Leukemia

    Not yet reported National Cancer Institute (NCI) 36 participants 1 site Stand-alone
    Other conditions: Blastic Phase Chronic Myelogenous Leukemia, Childhood Acute Promyelocytic Leukemia (M3), Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00080405

    Repeat-Dose Pharmacokinetics and Pharmacodynamics of Bortezomib in Patients With Relapsed Multiple Myeloma

    Not yet reported Millennium Pharmaceuticals, Inc. 40 participants
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00081939

    UARK 2003-33, Total Therapy III

    Not yet reported University of Arkansas 303 participants Est. completion 2014-09 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00082784

    Bortezomib and Flavopiridol in Treating Patients With Recurrent or Refractory Indolent B-Cell Neoplasms

    Not yet reported National Cancer Institute (NCI) 93 participants Est. completion 2014-09 5 sites Stand-alone
    Obstructive sleep apnea Other conditions: Nodal Marginal Zone Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Refractory Plasma Cell Myeloma, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00082966

    Bortezomib in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Not yet reported National Cancer Institute (NCI) 43 participants 1 site Stand-alone
    Other conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT00083226

    Doxorubicin and Bortezomib in Treating Patients With Liver Cancer

    Not yet reported National Cancer Institute (NCI) 42 participants Est. completion 2012-08 1 site Stand-alone
    Other conditions: Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer
    View official trial listing →
  • Completed NCT NCT00083460

    Study of Combination PS-341 and Thalidomide in Multiple Myeloma

    Not yet reported University of Arkansas 86 participants Est. completion 2007-11 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00084747

    Adjuvant Bortezomib Maintenance Therapy After Autologous Peripheral Stem Cell Transplantation in Treating Patients With Intermediate or Advanced Multiple Myeloma

    Not yet reported, Not yet reported Jonsson Comprehensive Cancer Center 30 participants Est. completion 2013-01 1 site Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Terminated NCT NCT00085410

    Bortezomib in Treating Patients With Unresectable Locally Advanced or Metastatic Adenocarcinoma of the Bile Duct or Gallbladder

    Not yet reported National Cancer Institute (NCI) 20 participants Est. completion 2010-04 1 site Stand-alone
    Other conditions: Adenocarcinoma of the Extrahepatic Bile Duct, Adenocarcinoma of the Gallbladder, Advanced Adult Primary Liver Cancer, Gastrointestinal Cancer, Localized Unresectable Adult Primary Liver Cancer, Recurrent Adult Primary Liver Cancer, Recurrent Extrahepatic Bile Duct Cancer, Recurrent Gallbladder Cancer, Unresectable Extrahepatic Bile Duct Cancer, Unresectable Gallbladder Cancer
    View official trial listing →
  • Completed NCT NCT00085696

    VELCADE® (Bortezomib) With Rituximab in Subjects With Relapsed or Refractory Indolent B-Cell Lymphoma

    Not yet reported Millennium Pharmaceuticals, Inc. 66 participants 13 sites
    Other conditions: B-Cell Lymphoma, Follicular Lymphoma, Marginal Lymphoma
    View official trial listing →
  • Completed NCT NCT00087867

    Study of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

    Not yet reported Scios, Inc. 62 participants Est. completion 2005-09
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00088855

    Bortezomib and Pegylated Liposomal Doxorubicin Hydrochloride in Treating Patients With Previously Untreated Symptomatic Multiple Myeloma

    Not yet reported National Cancer Institute (NCI) 55 participants Est. completion 2008-01-08 25 sites Stand-alone
    Other conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT00091117

    Bortezomib in Treating Patients With Advanced Cancer and Liver Dysfunction

    Not yet reported National Cancer Institute (NCI) 80 participants 3 sites Stand-alone
    Other conditions: Hepatic Complications, Malignant Neoplasm
    View official trial listing →
  • Active, not recruiting NCT NCT00092222

    Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

    Not yet reported National Cancer Institute (NCI) 75 participants Est. completion 2026-10-01 1 site
    Other conditions: Lymphoproliferative Disorder, HHV-8, Malignancy, HIV
    View official trial listing →
  • Completed NCT NCT00093028

    Study of Bortezomib and Revlimid™ for Patients Relapsing or Progressing on Total Therapy II

    Not yet reported University of Arkansas 315 participants Est. completion 2006-01 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00093704

    Bortezomib and Ganciclovir in Treating Patients With Relapsed or Refractory Epstein Barr Virus-Positive Lymphoma

    Not yet reported Jonsson Comprehensive Cancer Center 1 participants 1 site Stand-alone
    Other conditions: Lymphoma, Lymphoproliferative Disorder
    View official trial listing →
  • Completed NCT NCT00093756

    Bortezomib, Paclitaxel, Carboplatin and Radiation Therapy for Non-Small Cell Lung Cancer

    Not yet reported, Not yet reported National Cancer Institute (NCI) 52 participants Est. completion 2013-05 143 sites Stand-alone
    Other conditions: Recurrent Non-small Cell Lung Cancer, Stage IIIA Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00093769

    Bortezomib and Rituximab in Treating Patients With Non-Hodgkin's Lymphoma

    Not yet reported Jonsson Comprehensive Cancer Center 15 participants 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00095680

    Extension Study of the Efficacy and Safety of Oral SCIO-469 in Relapsed, Refractory Patients With Multiple Myeloma

    Not yet reported Scios, Inc. 30 participants Est. completion 2006-02
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00096005

    Tanespimycin and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

    Not yet reported National Cancer Institute (NCI) 36 participants 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Adult Grade III Lymphomatoid Granulomatosis, AIDS-related Peripheral/Systemic Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00098982

    Bortezomib, Fluorouracil, Leucovorin, and Oxaliplatin in Treating Patients With Advanced or Metastatic Colorectal Cancer

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 16 participants 3 sites
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Terminated NCT NCT00103103

    Bortezomib, Fluorouracil, and Leucovorin in Treating Patients With Metastatic or Unresectable Stomach Cancer

    Not yet reported California Cancer Consortium Est. completion 2005-08 5 sites
    Other conditions: Gastric Cancer
    View official trial listing →
  • Completed NCT NCT00103259

    Bortezomib With or Without Irinotecan in Treating Patients With Locally Recurrent or Metastatic Squamous Cell Carcinoma of the Head and Neck

    Not yet reported National Cancer Institute (NCI) 71 participants Est. completion 2011-11 1 site Stand-alone
    Other conditions: Recurrent Squamous Cell Carcinoma of the Hypopharynx, Recurrent Squamous Cell Carcinoma of the Larynx, Recurrent Squamous Cell Carcinoma of the Lip and Oral Cavity, Recurrent Squamous Cell Carcinoma of the Nasopharynx, Recurrent Squamous Cell Carcinoma of the Oropharynx, Recurrent Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Recurrent Verrucous Carcinoma of the Larynx, Recurrent Verrucous Carcinoma of the Oral Cavity, Stage IV Squamous Cell Carcinoma of the Hypopharynx, Stage IV Squamous Cell Carcinoma of the Larynx, Stage IV Squamous Cell Carcinoma of the Nasopharynx, Stage IV Verrucous Carcinoma of the Larynx, Stage IVA Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVA Squamous Cell Carcinoma of the Oropharynx, Stage IVA Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVA Verrucous Carcinoma of the Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVB Squamous Cell Carcinoma of the Oropharynx, Stage IVB Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVB Verrucous Carcinoma of the Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Lip and Oral Cavity, Stage IVC Squamous Cell Carcinoma of the Oropharynx, Stage IVC Squamous Cell Carcinoma of the Paranasal Sinus and Nasal Cavity, Stage IVC Verrucous Carcinoma of the Oral Cavity, Tongue Cancer
    View official trial listing →
  • Terminated NCT NCT00103272

    17-N-Allylamino-17-Demethoxygeldanamycin and Bortezomib in Treating Patients With Relapsed or Refractory Hematologic Cancer

    Not yet reported National Cancer Institute (NCI) 74 participants 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Waldenström Macroglobulinemia
    View official trial listing →
  • Terminated NCT NCT00103376

    Bortezomib With or Without Hormone Therapy in Treating Patients With Relapsed Prostate Cancer

    Not yet reported Medical University of South Carolina 23 participants Est. completion 2011-06 4 sites
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00103506

    Study of DOXIL/CAELYX (Pegylated Liposomal Doxorubicin) and VELCADE (Bortezomib) or VELCADE Monotherapy for the Treatment of Relapsed Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 646 participants Est. completion 2014-06 108 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00104871

    Bortezomib in Treating Patients With Metastatic Thyroid Cancer That Did Not Respond to Radioactive Iodine Therapy

    Not yet reported National Cancer Institute (NCI) 24 participants Est. completion 2014-04 9 sites Stand-alone
    Other conditions: Insular Thyroid Cancer, Recurrent Thyroid Cancer, Stage II Follicular Thyroid Cancer, Stage II Papillary Thyroid Cancer, Stage IV Follicular Thyroid Cancer, Stage IV Papillary Thyroid Cancer
    View official trial listing →
  • Terminated NCT NCT00106262

    Study of Velcade and Irinotecan in Advanced Cervical, Vulvar, or Vaginal Cancer

    Not yet reported Women and Infants Hospital of Rhode Island 38 participants Est. completion 2007-03 1 site
    Other conditions: Cervical Cancer
    View official trial listing →
  • Completed NCT NCT00107341

    Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Unresectable, Metastatic Cancer of the Esophagus or Gastroesophageal Junction

    Not yet reported Alliance for Clinical Trials in Oncology 37 participants Est. completion 2008-05 Stand-alone
    Other conditions: Esophageal Cancer
    View official trial listing →
  • Completed NCT NCT00108069

    Tamoxifen and Bortezomib to Treat Recurrent Brain Tumors

    Not yet reported National Cancer Institute (NCI) 43 participants Est. completion 2013-03 1 site Stand-alone
    Other conditions: Glioma
    View official trial listing →
  • Completed NCT NCT00111319

    VELCADE/Melphalan/Prednisone Versus Melphalan/Prednisone in Patients With Previously Untreated Multiple Myeloma

    Not yet reported Millennium Pharmaceuticals, Inc. 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00111748

    UARK 2005-01 Study of Velcade, Thalidomide, and Dexamethasone (VTD) With or Without Adriamycin® in Relapsed/Refractory Patients

    Not yet reported University of Arkansas 180 participants Est. completion 2006-09 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00111813

    Phase 1 Study of Vorinostat and Bortezomib in Multiple Myeloma (MK-0683-015 EXT 1 (AM1))

    Not yet reported Merck Sharp & Dohme LLC 34 participants Est. completion 2011-05 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00114738

    EPOCH-R Chemotherapy Plus Bortezomib to Treat Mantle Cell Lymphoma

    Not yet reported National Cancer Institute (NCI) 53 participants Est. completion 2022-08-11 1 site Stand-alone
    Other conditions: Lymphoma, Mantle Cell, Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00116961

    Velcade, Doxil, and Dexamethasone (VDd) as First Line Therapy for Multiple Myeloma

    Not yet reported University of Michigan Rogel Cancer Center 40 participants Est. completion 2007-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00117351

    VELCADE in Previously Treated Patients With Stage IIIB and IV Bronchioloalveolar Carcinoma (BAC) and Adenocarcinoma With BAC Features

    Not yet reported Millennium Pharmaceuticals, Inc. Est. completion 2007-07 1 site
    Other conditions: Carcinoma, Non-Small-Cell Lung, Adenocarcinoma, Bronchiolo-Alveolar
    View official trial listing →
  • Completed NCT NCT00118144

    Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer

    Not yet reported National Cancer Institute (NCI) 42 participants Est. completion 2010-12 1 site Stand-alone
    Other conditions: Adenocarcinoma of the Lung, Bronchoalveolar Cell Lung Cancer, Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00118183

    Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) 62 participants 1 site Stand-alone
    Other conditions: Adenocarcinoma of the Lung, Adenosquamous Cell Lung Cancer, Large Cell Lung Cancer, Malignant Pleural Effusion, Recurrent Non-small Cell Lung Cancer, Squamous Cell Lung Cancer, Stage IIIB Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT00124579

    S0417 Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported SWOG Cancer Research Network 7 participants Est. completion 2010-06 127 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00128921

    Study of Velcade® and Bone Formation in Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported University of Arkansas 18 participants Est. completion 2008-02 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00129207

    Ketoconazole Administration: How it is Affected by the Body and Broken Down and How it Acts on the Body When Used With Velcade

    Not yet reported Millennium Pharmaceuticals, Inc. 1 site
    Other conditions: Tumors
    View official trial listing →
  • Completed NCT NCT00135187

    Study of Combination Therapy With VELCADE, Doxil, and Dexamethasone (VDd) in Multiple Myeloma

    Not yet reported University of Michigan Rogel Cancer Center 30 participants Est. completion 2007-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00136565

    Study of Bortezomib Combined With ACVBP in Peripheral T-cell Lymphoma

    Not yet reported Lymphoma Study Association 60 participants Est. completion 2011-04-18 5 sites
    Other conditions: Peripheral T-cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT00136591

    A Phase 2 Study of Velcade™ in Subjects With Relapsed or Refractory Follicular B-Cell Lymphoma

    Not yet reported Lymphoma Study Association 87 participants Est. completion 2010-01 4 sites Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00142129

    Bortezomib (Velcade) in Waldenstrom's Macroglobulinemia

    Not yet reported Dana-Farber Cancer Institute 27 participants Est. completion 2007-06 2 sites
    Other conditions: Waldenstrom's Macroglobulinemia, Lymphoplasmacytic Lymphoma
    View official trial listing →
  • Terminated NCT NCT00148018

    Study of Bortezomib (Velcade) in Combination With Dexamethasone to Treat Patients With Relapsed Hodgkin's Lymphoma

    Not yet reported University of Cologne 37 participants 1 site
    Other conditions: Hodgkin Disease
    View official trial listing →
  • Completed NCT NCT00148317

    Phase II Study of Velcade, Decadron, and Doxil Followed by Cyclophosphamide in Multiple Myeloma

    Not yet reported Weill Medical College of Cornell University 38 participants Est. completion 2012-11 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00151320

    Phase I/II Trial of VELCADE + CHOP-Rituximab in Untreated DLCBL or Mantle Cell NHL

    Not yet reported, Not yet reported Weill Medical College of Cornell University 76 participants Est. completion 2013-04-24 4 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00153920

    Bortezomib (Velcade) in Patients With Untreated Multiple Myeloma

    Not yet reported Dana-Farber Cancer Institute 66 participants Est. completion 2008-09 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00153933

    Bortezomib in Combination With CC-5013 in Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported Dana-Farber Cancer Institute 58 participants Est. completion 2014-07 6 sites Stand-alone
    Other conditions: Refractory Multiple Myeloma, Relapsed Multiple Myeloma, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00169468

    Association of Velcade to R-CHOP in the Treatment of B Cell Lymphoma

    Not yet reported Lymphoma Study Association 48 participants Est. completion 2006-01 4 sites
    Other conditions: B Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00182637

    Bortezomib in Treating Patients With Relapsed or Refractory Cutaneous T-Cell Lymphoma

    Not yet reported Jonsson Comprehensive Cancer Center 5 participants Est. completion 2010-09 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT00183937

    Study of Bortezomib and Docetaxel for Patients With Hormone Refractory Prostate Cancer

    Not yet reported University of Southern California 15 participants Est. completion 2012-06-11 1 site Stand-alone
    Other conditions: Prostate Cancer
    View official trial listing →
  • Status unknown NCT NCT00184015

    Bortezomib and Bevacizumab ("BB-mib-mab") in Patients With Advanced or Recurrent Renal Cell Cancer (RCC)

    Not yet reported, Not yet reported University of Southern California 50 participants Est. completion 2018-08-21 1 site Stand-alone
    Other conditions: Renal Cell Cancer
    View official trial listing →
  • Completed NCT NCT00193232

    Weekly Docetaxel and Bortezomib in the Treatment of Advanced Hormone-Refractory Prostate Cancer

    Not yet reported SCRI Development Innovations, LLC 50 participants Est. completion 2007-02
    Other conditions: Prostate Cancer
    View official trial listing →
  • Completed NCT NCT00193557

    Weekly Bortezomib (Velcade) in the Treatment of Patients With Refractory Multiple Myeloma

    Not yet reported SCRI Development Innovations, LLC 40 participants Est. completion 2009-01 2 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00199212

    PS-341 in Combination With Herceptin in Advanced Breast Cancer That Overexpresses HER-2

    Not yet reported Jules Bordet Institute 19 participants Est. completion 2007-12 1 site
    Other conditions: Carcinoma Breast Stage IV
    View official trial listing →
  • Terminated NCT NCT00200382

    Phase II Study of Therapy With PS 341 in Patients With Advanced Stage Non Small Cell Lung Cancer

    Not yet reported Rasim Gucalp 27 participants Est. completion 2007-05 5 sites
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00200681

    IFM 2005-01: Velcade/Dexamethasone Versus Vincristine/Adriamycin (Doxorubicin)/Dexamethasone (VAD) for the Treatment of Patients With Multiple Myeloma

    Not yet reported Nantes University Hospital 493 participants Est. completion 2008-06 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00201877

    Velcade (Bortezomib, PS-341) and Rituximab in Relapsed/Refractory Mantle Cell and Follicular Non-Hodgkin's Lymphoma

    Not yet reported Ohio State University Comprehensive Cancer Center 25 participants Est. completion 2012-03 1 site
    Other conditions: Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00210327

    VELCADE in MALT Lymphoma Pretreated With Prior Systemic Therapy

    Not yet reported International Extranodal Lymphoma Study Group (IELSG) 33 participants Est. completion 2009-04 1 site
    Obstructive sleep apnea
    View official trial listing →
  • Terminated NCT NCT00210392

    VELCADE in MALT Lymphoma Pretreated With More Than One Prior Systemic Therapy

    Not yet reported International Extranodal Lymphoma Study Group (IELSG) 12 participants Est. completion 2007-11 1 site
    Obstructive sleep apnea
    View official trial listing →
  • Completed NCT NCT00216697

    An Extension Study to Provide Bortezomib to Patients With Relapsed or Refractory Multiple Myeloma Who Previously Participated in a Bortezomib Phase I/II Study and Who May Benefit From Re-Treatment With or Continuation of Bortezomib Therapy

    Not yet reported Janssen Pharmaceutical K.K. 13 participants Est. completion 2006-10
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00217503

    Bortezomib and Antiviral Therapy Followed By Effusion Drainage, Bevacizumab, and Combination Chemotherapy in Treating Patients With Primary Effusion Lymphoma

    Not yet reported National Cancer Institute (NCI) 15 participants Est. completion 2007-06 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00227513

    Vorinostat and Bortezomib in Treating Patients With Metastatic or Unresectable Solid Tumors

    Not yet reported National Cancer Institute (NCI) 66 participants 1 site Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00237627

    Doxorubicin Hydrochloride Liposome and Bortezomib in Treating Patients With Refractory Hematologic Cancer or Malignant Solid Tumor or Metastatic Breast Cancer

    Not yet reported, Not yet reported UNC Lineberger Comprehensive Cancer Center 107 participants Est. completion 2010-01 1 site
    Other conditions: Breast Cancer, Leukemia, Lymphoma, Multiple Myeloma and Plasma Cell Neoplasm, Ovarian Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Terminated NCT NCT00243035

    Tipifarnib and Bortezomib in Treating Patients With Relapsed Multiple Myeloma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 64 participants 1 site Stand-alone
    Other conditions: Refractory Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00250926

    Study of the Combination of Bortezomib, Dexamethasone, and Rituximab in Patients With Waldenstroms Macroglobulinemia

    Not yet reported Dana-Farber Cancer Institute 23 participants Est. completion 2009-02 2 sites Stand-alone
    Other conditions: Waldenstrom's Macroglobulinemia
    View official trial listing →
  • Terminated NCT NCT00256776

    MMVAR - Velcade: Study of Velcade for the Treatment of Myeloma Patients After Autologous Transplantation

    Not yet reported European Society for Blood and Marrow Transplantation 269 participants Est. completion 2015-12 81 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00257114

    Evaluation of VELCADE Given as Retreatment to Multiple Myeloma Patients for Efficacy, Safety and Tolerability

    Not yet reported Millennium Pharmaceuticals, Inc. 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00258245

    Arsenic Trioxide and Ascorbic Acid Combined With Bortezomib, Thalidomide, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Plasma Cell Leukemia

    Not yet reported Barbara Ann Karmanos Cancer Institute 5 participants Est. completion 2008-04 1 site Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Status unknown NCT NCT00261612

    Bortezomib, Rituximab and Dexamethasone (BORID) for Relapsed/Refractory Mantle Cell Lymphoma

    Not yet reported Medical University of Vienna 16 participants Est. completion 2007-01 1 site
    Other conditions: Lymphoma, Mantle-Cell
    View official trial listing →
  • Completed NCT NCT00262860

    Bortezomib and Gemcitabine Hydrochloride in Treating Patients With Relapsed or Refractory Hodgkin's Lymphoma

    Not yet reported University of Rochester 18 participants 2 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00262873

    Bortezomib in Treating Patients With Myelodysplastic Syndromes

    Not yet reported University of Rochester 8 participants Est. completion 2010-10 1 site Stand-alone
    Other conditions: Myelodysplastic Syndromes
    View official trial listing →
  • Terminated NCT NCT00265928

    Bortezomib and Rituximab in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma

    Not yet reported University of Virginia 46 participants 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Terminated NCT NCT00271804

    Study of Velcade and Thalidomide in Patients With Myelodysplasia

    Not yet reported Massachusetts General Hospital 28 participants Est. completion 2007-04 3 sites
    Other conditions: Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT00276614

    Bortezomib in Treating Patients With Metastatic Kidney Cancer

    Not yet reported Jonsson Comprehensive Cancer Center 4 participants Est. completion 2009-07 1 site Stand-alone
    Other conditions: Kidney Cancer
    View official trial listing →
  • Completed NCT NCT00280176

    Bortezomib, Fluorouracil, and External-Beam Radiation Therapy in Treating Patients With Stage II, Stage III, or Stage IV Rectal Cancer

    Not yet reported UNC Lineberger Comprehensive Cancer Center 11 participants Est. completion 2010-09 2 sites
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Terminated NCT NCT00283634

    A Study of Tarceva for Use in Patients With Relapsed or Refractory Metastatic Non-Small Cell Lung Cancer

    Not yet reported Millennium Pharmaceuticals, Inc. Est. completion 2007-08 1 site
    Other conditions: NSCLC
    View official trial listing →
  • Completed NCT NCT00287872

    Bortezomib and Thalidomide in Treating Patients With Newly Diagnosed Stage II or Stage III Multiple Myeloma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 30 participants Est. completion 2010-11 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00288028

    Bortezomib in Treating Patients With Multiple Myeloma Who Have Undergone an Autologous Peripheral Blood Stem Cell Transplant

    Not yet reported Barbara Ann Karmanos Cancer Institute 15 participants Est. completion 2012-06 1 site Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00288041

    Bortezomib, Paclitaxel, and Carboplatin in Treating Patients With Metastatic Melanoma

    Not yet reported National Cancer Institute (NCI) 36 participants 1 site Stand-alone
    Other conditions: Ciliary Body and Choroid Melanoma, Medium/Large Size, Extraocular Extension Melanoma, Iris Melanoma, Recurrent Intraocular Melanoma, Recurrent Melanoma, Stage IV Melanoma
    View official trial listing →
  • Completed NCT NCT00290680

    Bortezomib and Celecoxib in Treating Patients With Advanced Solid Tumors

    Not yet reported Medical University of South Carolina 36 participants Est. completion 2009-01 1 site
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Terminated NCT NCT00290706

    A Phase I/II Trial of VELCADE & Gemcitabine for Patients With Relapsed or Refractory Aggressive B- and T-cell Non-Hodgkin's Lymphoma

    Not yet reported, Not yet reported Northwestern University 32 participants Est. completion 2012-09-05 3 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00291538

    Comparison of Pharmacokinetics and Pharmacodynamics of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma

    Not yet reported Nantes University Hospital 20 participants Est. completion 2008-10 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00295932

    Bortezomib, Rituximab, Cyclophosphamide, and Prednisone in Treating Patients With Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma

    Not yet reported, Not yet reported Memorial Sloan Kettering Cancer Center 79 participants Est. completion 2018-03-11 8 sites Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00298766

    Open-Label Phase 1/2 Study of VELCADE for Injection in Patients With Light-chain (AL)-Amyloidosis

    Not yet reported, Not yet reported Millennium Pharmaceuticals, Inc. 70 participants Est. completion 2009-09 4 sites
    Other conditions: Amyloidosis
    View official trial listing →
  • Completed NCT NCT00298779

    Open-Label Study to Assess the Effect of Omeprazole on the Pharmacokinetics of VELCADE in Patients With Either Advanced Solid Tumors or Non-Hodgkin's Lymphoma.

    Not yet reported Millennium Pharmaceuticals, Inc. 20 participants 1 site
    Other conditions: Tumors, Non-Hodgkins's Lymphoma
    View official trial listing →
  • Completed NCT NCT00303797

    Sorafenib and Bortezomib in Treating Patients With Advanced Cancer

    Not yet reported National Cancer Institute (NCI) 50 participants 1 site Stand-alone
    Other conditions: Refractory Chronic Lymphocytic Leukemia, Refractory Multiple Myeloma, Stage III Multiple Myeloma, Stage IV Chronic Lymphocytic Leukemia, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00305734

    Bortezomib and Gemcitabine in Treating Patients With Recurrent or Metastatic Nasopharyngeal Cancer

    Not yet reported National Cancer Institute (NCI) 50 participants 1 site Stand-alone
    Other conditions: Recurrent Nasopharyngeal Cancer, Stage IV Nasopharyngeal Cancer
    View official trial listing →
  • Completed NCT NCT00307086

    Bortezomib Followed by High-Dose Melphalan and Bortezomib as Conditioning Regimen for Tandem Stem Cell Transplants

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 30 participants Est. completion 2012-03 1 site
    Other conditions: Multiple Myeloma, Plasma Cell Leukemia
    View official trial listing →
  • Completed NCT NCT00310024

    Vorinostat and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported National Cancer Institute (NCI) 40 participants 1 site Stand-alone
    Other conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00310037

    Bortezomib After Combination Chemotherapy, Rituximab, and an Autologous Stem Cell Transplant in Treating Patients With Mantle Cell Lymphoma

    Not yet reported Alliance for Clinical Trials in Oncology 151 participants Est. completion 2022-06 48 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00311337

    VELCADE as Maintenance Treatment in Patients With Multiple Myeloma Following Autologous Peripheral Blood Stem Cell Transplantation (PBSCT)

    Not yet reported University of Wuerzburg 61 participants Est. completion 2010-10 8 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00312845

    Study of VELCADE and Rituximab in Patients With Relapsed or Refractory B-cell Non-Hodgkin's Lymphoma

    Not yet reported Millennium Pharmaceuticals, Inc. 676 participants Est. completion 2010-07 206 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT00313690

    Cancer Treatment Followed by Surgery for Early Stage Non-small Cell Lung Cancer

    Not yet reported, Not yet reported University of Southern California
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT00315757

    Study of Mapatumumab in Combination With Bortezomib (Velcade) and Bortezomib Alone in Subjects With Relapsed or Refractory Multiple Myeloma

    Not yet reported Human Genome Sciences Inc. 105 participants Est. completion 2010-10 20 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00316940

    Samarium 153 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Oncotherapeutics 36 participants Est. completion 2011-02 4 sites
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00317811

    Bortezomib, Ascorbic Acid, and Melphalan in Treating Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Oncotherapeutics 35 participants 8 sites
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Status unknown NCT NCT00319865

    PAD Combination Therapy Followed by Thal/Dex for Relapsed or Refractory Multiple Myeloma

    Not yet reported Korean Multiple Myeloma Working Party 47 participants Est. completion 2008-09 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00320476

    VTD Followed By MPT Maintenance As a First Line Treatment For The Patients With MM Who Are Non-Transplant Candidates

    Not yet reported Korean Multiple Myeloma Working Party 35 participants Est. completion 2008-02 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00329589

    A Trial Using Velcade Plus Chemoradiation for Central Nervous System, Head and Neck, and Cervical Cancer Patients

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 54 participants Est. completion 2010-06 1 site Stand-alone
    Other conditions: Brain Cancer, Head and Neck Cancer, Cervix Cancer, Central Nervous System Neoplasms
    View official trial listing →
  • Completed NCT NCT00334438

    Bortezomib, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Relapsed or Refractory Low-Grade, Follicular, or Mantle Cell Non-Hodgkin's Lymphoma

    Not yet reported UNC Lineberger Comprehensive Cancer Center 12 participants Est. completion 2011-10 2 sites
    Other conditions: Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00334932

    Doxorubicin Hydrochloride Liposome, Melphalan, and Bortezomib in Treating Patients With Relapsed or Refractory Stage I, Stage II, or Stage III Multiple Myeloma

    Not yet reported, Not yet reported Herbert Irving Comprehensive Cancer Center 32 participants 2 sites
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00335348

    Bortezomib and Dexamethasone as Treatment and Maintenance for Multiple Myeloma Relapse

    Not yet reported Peter MacCallum Cancer Centre, Australia 101 participants Est. completion 2012-07 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00337506

    Velcade Combined With High-Dose Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Nantes University Hospital 50 participants 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00343720

    Study of Alimta® (Pemetrexed) Plus VELCADE® (Bortezomib) or Alimta Alone or VELCADE Alone in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Failed Prior Therapy

    Not yet reported Millennium Pharmaceuticals, Inc. 1 site
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT00346645

    A Phase II Study of Velcade® in Patients Stage IIIB OR IV Non-Small Cell Lung Cancer

    Not yet reported Gustave Roussy, Cancer Campus, Grand Paris 46 participants Est. completion 2007-12 1 site
    Other conditions: STAGE IIIB OR IV NON-SMALL CELL LUNG CANCER
    View official trial listing →
  • Completed NCT NCT00348985

    PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

    Not yet reported National Cancer Institute (NCI) 55 participants 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Adult Grade III Lymphomatoid Granulomatosis, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Primary Central Nervous System Hodgkin Lymphoma, Primary Central Nervous System Non-Hodgkin Lymphoma, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Hodgkin Lymphoma, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Recurrent Small Lymphocytic Lymphoma, Splenic Marginal Zone Lymphoma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Adult T-cell Leukemia/Lymphoma, Stage III Cutaneous T-cell Non-Hodgkin Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Mycosis Fungoides/Sezary Syndrome, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Adult T-cell Leukemia/Lymphoma, Stage IV Cutaneous T-cell Non-Hodgkin Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Mycosis Fungoides/Sezary Syndrome, Stage IV Small Lymphocytic Lymphoma, Unspecified Adult Solid Tumor, Protocol Specific, Waldenström Macroglobulinemia
    View official trial listing →
  • Terminated NCT NCT00352742

    A Study of ATN-224 and Bortezomib in Patients With Multiple Myeloma

    Not yet reported, Not yet reported Attenuon 46 participants Est. completion 2008-12 10 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00358020

    Melphalan, Prednisone, Thalidomide And Bortezomib In Advanced And Refractory Multiple Myeloma Patients

    Not yet reported University of Turin, Italy 30 participants Est. completion 2008-12 7 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00361088

    A Combination of Zarnestra With Velcade for Patients With Relapsed Multiple Myeloma

    Not yet reported, Not yet reported H. Lee Moffitt Cancer Center and Research Institute 42 participants Est. completion 2007-06 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00361621

    Ph II CHOP+Velcade in Mediastinal LBCL

    Not yet reported Dana-Farber Cancer Institute 3 participants Est. completion 2008-05 1 site
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00362882

    Docetaxel and Bortezomib in Treating Patients With Progressive or Recurrent Non-Small Cell Lung Cancer

    Not yet reported National Cancer Institute (NCI) 81 participants Est. completion 2010-07 1 site Stand-alone
    Other conditions: Non-small Cell Lung Cancer, Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
    View official trial listing →
  • Terminated NCT NCT00366106

    Alternative Schedule of Velcade/Dexamethasone Plus Doxil for Patients With Multiple Myeloma

    Not yet reported Accelerated Community Oncology Research Network 32 participants Est. completion 2011-03 15 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT00367718

    Trial of VELCADE in Patients With Metastatic or Locally Recurrent Nasopharyngeal Carcinoma

    Not yet reported Johns Hopkins University 3 sites
    Other conditions: Nasopharyngeal Carcinoma
    View official trial listing →
  • Completed NCT NCT00369226

    Bortezomib Plus Tacrolimus and Methotrexate to Prevent Graft Versus Host Disease (GVHD) After Mismatched Allogeneic Non-Myeloablative Blood Stem Cell Transplantation

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 45 participants Est. completion 2011-09 2 sites Stand-alone
    Other conditions: Hematologic Malignancies
    View official trial listing →
  • Completed NCT NCT00369707

    Trial of VELCADE and Rituxan as Front-line Tx for Low-grade NHL

    Not yet reported Northwestern University 42 participants Est. completion 2014-10-10 4 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT00372905

    Phase I/II Trial of VELCADE Plus Zevalin in Patients With Relapsed or Refractory Follicular Lymphoma

    Not yet reported, Not yet reported Northwestern University 18 participants Est. completion 2013-07-08 2 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00373906

    Velcade in MALT Lymphoma Patients

    Not yet reported Medical University of Vienna 16 participants
    Other conditions: MALT Lymphoma
    View official trial listing →
  • Completed NCT NCT00374699

    Bortezomib and CHOP in Patients With Advanced Stage Aggressive T Cell or Natural Killer (NK)/T Cell Lymphomas

    Not yet reported, Not yet reported Samsung Medical Center 55 participants Est. completion 2009-10 1 site
    Other conditions: Peripheral T-Cell Lymphomas, Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT00376961

    S0601 Rituximab, Combination Chemotherapy, and Bortezomib Followed by Bortezomib Alone in Treating Patients With Newly Diagnosed Mantle Cell Lymphoma

    Not yet reported SWOG Cancer Research Network 68 participants Est. completion 2017-09 147 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00377052

    Bortezomib and Gemcitabine in Treating Patients With Relapsed Mantle Cell Lymphoma

    Not yet reported NCIC Clinical Trials Group 29 participants Est. completion 2011-06-21 11 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT00378105

    Bortezomib, Lenalidomide and Dexamethasone Combination Therapy in Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 68 participants Est. completion 2026-12 3 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00378209

    Bortezomib, Lenalidomide, and Dexamethasone Combination Therapy for Patients With Relapsed or Relapsed and Refractory Multiple Myeloma

    Not yet reported Dana-Farber Cancer Institute 65 participants Est. completion 2016-10 2 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT00378755

    Sequential VAD and VTD Followed by HDT With ASCT and Velcade Maintenance for NDMM

    Not yet reported Korean Multiple Myeloma Working Party 62 participants Est. completion 2008-07 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00379574

    Bortezomib Plus CHOP Every 2 Weeks for Advanced Stage DLBCL

    Not yet reported, Not yet reported Asan Medical Center 49 participants Est. completion 2011-01 2 sites Stand-alone
    Other conditions: Lymphoma, Large-Cell, Diffuse, Lymphoma, B-Cell
    View official trial listing →
  • Completed NCT NCT00381940

    Bortezomib, Ifosfamide, and Vinorelbine Tartrate in Treating Young Patients With Hodgkin's Lymphoma That is Recurrent or Did Not Respond to Previous Therapy

    Not yet reported National Cancer Institute (NCI) 26 participants Est. completion 2016-12-31 1 site Stand-alone
    Other conditions: Adult Lymphocyte Depletion Hodgkin Lymphoma, Adult Lymphocyte Predominant Hodgkin Lymphoma, Adult Mixed Cellularity Hodgkin Lymphoma, Adult Nodular Lymphocyte Predominant Hodgkin Lymphoma, Adult Nodular Sclerosis Hodgkin Lymphoma, Childhood Lymphocyte Depletion Hodgkin Lymphoma, Childhood Lymphocyte Predominant Hodgkin Lymphoma, Childhood Mixed Cellularity Hodgkin Lymphoma, Childhood Nodular Lymphocyte Predominant Hodgkin Lymphoma, Childhood Nodular Sclerosis Hodgkin Lymphoma, Recurrent Adult Hodgkin Lymphoma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Stage I Adult Hodgkin Lymphoma, Stage I Childhood Hodgkin Lymphoma, Stage II Adult Hodgkin Lymphoma, Stage II Childhood Hodgkin Lymphoma, Stage III Adult Hodgkin Lymphoma, Stage III Childhood Hodgkin Lymphoma, Stage IV Adult Hodgkin Lymphoma, Stage IV Childhood Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT00382954

    Phase I Using Velcade & Idarubicin in Elderly and Relapsed AML

    Not yet reported University of Kentucky 55 participants Est. completion 2008-10 2 sites
    Other conditions: Acute Myelogenous Leukemia
    View official trial listing →
  • Completed NCT NCT00383474

    Tipifarnib and Bortezomib in Treating Patients With Acute Leukemia or Chronic Myelogenous Leukemia in Blast Phase

    Not yet reported National Cancer Institute (NCI) 35 participants Est. completion 2012-06 1 site Stand-alone
    Other conditions: Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia, Adult Acute Megakaryoblastic Leukemia, Adult Acute Monoblastic Leukemia, Adult Acute Monocytic Leukemia, Adult Acute Myeloid Leukemia With Inv(16)(p13.1q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With Maturation, Adult Acute Myeloid Leukemia With Minimal Differentiation, Adult Acute Myeloid Leukemia With t(16;16)(p13.1;q22); CBFB-MYH11, Adult Acute Myeloid Leukemia With t(8;21)(q22;q22); RUNX1-RUNX1T1, Adult Acute Myeloid Leukemia With t(9;11)(p22;q23); MLLT3-MLL, Adult Acute Myeloid Leukemia Without Maturation, Adult Acute Myelomonocytic Leukemia, Adult Erythroleukemia, Adult Pure Erythroid Leukemia, Blastic Phase, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Acute Myeloid Leukemia, Recurrent Disease, Untreated Adult Acute Lymphoblastic Leukemia, Untreated Adult Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00388089

    Bortezomib and Topotecan in Treating Patients With Advanced Solid Tumors

    Not yet reported University of California, Davis 24 participants Est. completion 2008-06 1 site
    Other conditions: Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00388635

    Velcade-Melphalan-Prednisone in Older Untreated Multiple Myeloma Patients.

    Not yet reported, Not yet reported PETHEMA Foundation 60 participants Est. completion 2008-12 19 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT00389701

    Bortezomib and Dexamethasone in Treating Patients With Multiple Myeloma That Has Relapsed or Has Not Responded to Treatment

    Not yet reported Sparrow Regional Cancer Center 30 participants 1 site
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00389805

    Bortezomib and Pemetrexed Disodium in Treating Patients With Advanced Non-Small Cell Lung Cancer or Other Solid Tumors

    Not yet reported, Not yet reported University of California, Davis 27 participants Est. completion 2007-06 1 site
    Other conditions: Lung Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00391157

    VELCADEXA: Velcade and Dexamethasone in Multiple Myeloma

    Not yet reported PETHEMA Foundation 40 participants Est. completion 2008-01 10 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00401011

    Safety & Efficacy Study of Perifosine + Bortezomib +/- Dexamethasone for Multiple Myeloma Patients

    Not yet reported, Not yet reported AEterna Zentaris 84 participants Est. completion 2011-07 Stand-alone
    Other conditions: Multiple Myeloma, Multiple Myeloma in Relapse
    View official trial listing →
  • Completed NCT NCT00401804

    Bortezomib-Dexamethasone-Doxorubicin-Study

    Not yet reported Austrian Forum Against Cancer 72 participants Est. completion 2009-11 9 sites
    Other conditions: Multiple Myeloma, Renal Insuficiency
    View official trial listing →
  • Completed NCT NCT00401843

    A Study of the Safety and Efficacy of CNTO 328 and Bortezomib to Bortezomib Alone in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 307 participants Est. completion 2019-09-24 80 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00407303

    Safety and Efficacy of Obatoclax Mesylate (GX15-070MS) in Combination With Bortezomib for the Treatment of Relapsed or Refractory Mantle Cell Lymphoma (MCL)

    Not yet reported, Not yet reported Gemin X 24 participants Est. completion 2009-11 5 sites Stand-alone
    Other conditions: Mantle-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00408928

    Study on the Safety and Effectiveness of VELCADE® in the Treatment of Graft-Versus-Host Disease

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 11 participants Est. completion 2009-09 1 site Stand-alone
    Other conditions: Graft-versus-Host Disease
    View official trial listing →
  • Completed NCT NCT00410423

    Study of VELCADE® With Mitoxantrone and Etoposide for Leukemias

    Not yet reported, Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 55 participants Est. completion 2014-09 1 site Stand-alone
    Other conditions: Relapsed Acute Leukemia, Refractory Acute Leukemia
    View official trial listing →
  • Withdrawn NCT NCT00411593

    Phase I-II for Patients With Recurrent or Refractory Non-small Cell Lung Cancer (NSCLC)

    Not yet reported, Not yet reported M.D. Anderson Cancer Center Est. completion 2007-05 Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT00411905

    Bortezomib and Low Dose Cytarabine in the Treatment of High-risk Myelodysplastic Syndromes

    Not yet reported, Not yet reported Groupe Francophone des Myelodysplasies 45 participants Est. completion 2011-08-01 15 sites
    Other conditions: Myelodysplastic Syndromes
    View official trial listing →
  • Terminated NCT NCT00413959

    VELCADE,Rituximab,Cyclophosphamide and Decadron

    Not yet reported Oncology Specialists, S.C. 12 participants Est. completion 2011-01 2 sites
    Other conditions: Lymphoma, Non-Hodgkin, Lymphoma, B-Cell
    View official trial listing →
  • Completed NCT NCT00416208

    Consolidation Therapy With Bortezomib in Elderly Patients With Multiple Myeloma

    Not yet reported Janssen-Cilag G.m.b.H 154 participants Est. completion 2013-05 37 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00416273

    A Study of Bortezomib as Consolidation Therapy in Patients With Multiple Myeloma

    Not yet reported Janssen-Cilag G.m.b.H 217 participants Est. completion 2013-05 38 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00416793

    Bortezomib and Carboplatin in Treating Patients With Metastatic Pancreatic Cancer

    Not yet reported National Cancer Institute (NCI) 9 participants Est. completion 2009-12 1 site Stand-alone
    Other conditions: Acinar Cell Adenocarcinoma of the Pancreas, Duct Cell Adenocarcinoma of the Pancreas, Stage IV Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT00417911

    Efficacy of Bortezomib Consolidation After High-dose Melphalan With Stem Cell Support in Myeloma Patients

    Not yet reported Nordic Myeloma Study Group 400 participants Est. completion 2010-05 20 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00422799

    Combination Bortezomib and Rituximab in Patients With Waldenstrom's Macroglobulinemia (WM)

    Not yet reported Dana-Farber Cancer Institute 63 participants Est. completion 2015-10-09 1 site Stand-alone
    Other conditions: Waldenstrom's Macroglobulinemia
    View official trial listing →
  • Terminated NCT NCT00424840

    Phase I/II Study to Evaluate the Efficacy and Safety of a Combination Chemotherapy

    Not yet reported University of Massachusetts, Worcester 12 participants Est. completion 2014-03 1 site Stand-alone
    Other conditions: Lung Cancer
    View official trial listing →
  • Completed NCT NCT00425503

    PS-341 Followed by Removal of Prostate for Those With Prostate Cancer

    Not yet reported Baylor College of Medicine 40 participants Est. completion 2013-12 1 site
    Other conditions: Prostate Neoplasms
    View official trial listing →
  • Completed NCT NCT00425750

    Bortezomib and Docetaxel in Treating Patients With Recurrent or Metastatic Head and Neck Cancer

    Not yet reported Vanderbilt-Ingram Cancer Center 25 participants Est. completion 2009-06 7 sites Stand-alone
    Other conditions: Head and Neck Cancer
    View official trial listing →
  • Completed NCT NCT00426855

    Bendamustine and Bortezomib Combination Therapy in Indolent Non-Hodgkin's Lymphoma(NHL)

    Not yet reported, Not yet reported Peter Moosmann 12 participants Est. completion 2009-06 Stand-alone
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT00428142

    Bortezomib, Combination Chemotherapy, and Rituximab as First-Line Therapy in Treating Patients With Stage III or Stage IV Follicular Non-Hodgkin's Lymphoma

    Not yet reported NCIC Clinical Trials Group 95 participants Est. completion 2012-01-06 19 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00428545

    Bevacizumab and Bortezomib in Patients With Advanced Malignancy

    Not yet reported M.D. Anderson Cancer Center 104 participants Est. completion 2012-11 1 site Stand-alone
    Other conditions: Advanced Malignancy, Lymphoma, Myeloma, Solid Tumors
    View official trial listing →
  • Terminated NCT NCT00431340

    A Phase II Study of Belinostat in Combination With Bortezomib in Patients With Relapsed, Refractory Multiple Myeloma

    Not yet reported Valerio Therapeutics 4 participants Est. completion 2007-06 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00431769

    An Efficacy and Safety Study of Bortezomib Re-treatment in Multiple Myeloma

    Not yet reported Janssen-Cilag International NV 130 participants Est. completion 2010-01 38 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT00431990

    A Phase I/II Trial of Romidepsin (Depsipeptide) and Bortezomib in Patients With Relapsed Myeloma

    Not yet reported, Not yet reported Peter MacCallum Cancer Centre, Australia 40 participants Est. completion 2012-01 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00433537

    Combination Chemotherapy and Rituximab in Treating Patients With Untreated Mantle Cell Lymphoma

    Not yet reported National Cancer Institute (NCI) 77 participants Est. completion 2013-06 1 site Stand-alone
    Other conditions: Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00436059

    The Efficacy of Velcade on Bone Tissue During Myelomatosis (Bone Marrow Cancer)

    Not yet reported Vejle Hospital 20 participants Est. completion 2009-07 2 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00437086

    Bortezomib in Treating Patients With Advanced Myeloproliferative Disorders

    Not yet reported Mayo Clinic 30 participants Est. completion 2008-11 3 sites
    Other conditions: Chronic Myeloproliferative Disorders, Leukemia
    View official trial listing →
  • Status unknown NCT NCT00438841

    Bortezomib, Cyclophosphamide, Dexamethasone, and Thalidomide in Treating Patients With Newly Diagnosed, Previously Untreated Multiple Myeloma

    Not yet reported Fred Hutchinson Cancer Center 43 participants 10 sites
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00439361

    Velcade Plus ICE for Patients With Relapsed Classical Hodgkin Lymphoma

    Not yet reported M.D. Anderson Cancer Center 14 participants Est. completion 2012-06 1 site Stand-alone
    Other conditions: Hodgkin Lymphoma, Lymphoma
    View official trial listing →
  • Completed NCT NCT00439556

    Bortezomib and Chemotherapy in Treating Participants With Lymphoid Malignancies Undergoing Stem Cell Transplant

    Not yet reported M.D. Anderson Cancer Center 40 participants Est. completion 2018-06-07 1 site Stand-alone
    Other conditions: CD20 Positive, Hematopoietic and Lymphoid Cell Neoplasm, Lymphocytic Neoplasm, Lymphoma
    View official trial listing →
  • Terminated NCT NCT00440076

    Velcade in Myelodysplastic Syndrome - Pilot Study

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 28 participants Est. completion 2008-03 4 sites
    Other conditions: MDS
    View official trial listing →
  • Completed NCT NCT00440479

    ADVANCE: An Observational Study To Determine Bortezomib Safety and Effectiveness at First Relapse After Participation In First Line HOVON-49/50 Clinical Studies.

    Janssen-Cilag B.V. 11 participants Est. completion 2011-01 9 sites
    Other conditions: Multiple Myeloma, Hematological Neoplasms
    View official trial listing →
  • Completed NCT NCT00440635

    Expanded Access Protocol (EAP) to Provide Bortezomib to Patients With Multiple Myeloma Who Have Received at Least 2 Previous Lines of Therapy and Are Refractory to or Have Relapsed After Their Last Therapy for Multiple Myeloma

    Janssen-Cilag International NV 641 participants Est. completion 2006-10
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00440726

    Bortezomib With Chemotherapy for Relapsed Pediatric Acute Lymphoblastic Leukemia (ALL)

    Not yet reported, Not yet reported Therapeutic Advances in Childhood Leukemia Consortium 31 participants Est. completion 2011-02-26 24 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT00440765

    VALEO: A Post Authorization Study, Designed to Learn More About the Safety and Effectiveness of the Use of Bortezomib in the Netherlands

    Janssen-Cilag B.V. 331 participants Est. completion 2012-01 44 sites
    Other conditions: Multiple Myeloma, Hematological Neoplasms
    View official trial listing →
  • Terminated NCT NCT00441168

    Velcade (Bortezomib), Adriamycin Dexamethasone (PAD) or Vincristine Adriamycin Dexamethasone in Second Line Treatment of Multiple Myeloma

    Not yet reported Janssen-Cilag International NV 30 participants Est. completion 2008-01 16 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00443235

    GEM05 for Patients With Multiple Myeloma More Than 65 Years Old

    Not yet reported PETHEMA Foundation 260 participants Est. completion 2009-12 77 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00458705

    Bortezomib, Doxorubicin Hydrochloride Liposome, and Dexamethasone Followed by Thalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Multiple Myeloma

    Not yet reported Memorial Sloan Kettering Cancer Center 45 participants Est. completion 2011-04 1 site Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00458822

    Melphalan and Autologous Stem Cell Transplant Followed By Bortezomib and Dexamethasone in Treating Patients With Previously Untreated Systemic Amyloidosis

    Not yet reported Memorial Sloan Kettering Cancer Center 40 participants Est. completion 2015-03 1 site Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00458913

    Bortezomib and Cisplatin as First-Line Therapy in Treating Patients With Malignant Mesothelioma

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC 82 participants Est. completion 2012-03 1 site
    Other conditions: Malignant Mesothelioma
    View official trial listing →
  • Completed NCT NCT00461747

    GEM05 for Patients With Multiple Myeloma Under 65 Years

    Not yet reported PETHEMA Foundation 390 participants Est. completion 2008-12 79 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00464178

    A Phase II Study of Bevacizumab and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported Hackensack Meridian Health 7 participants Est. completion 2009-02 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00469209

    Velcade, Trisenox, Vitamin C and Melphalan for Myeloma Patients

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 60 participants Est. completion 2008-12 1 site
    Other conditions: Myeloma
    View official trial listing →
  • Completed NCT NCT00473590

    A Study of Bevacizumab in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (AMBER)

    Not yet reported Genentech, Inc. 102 participants Est. completion 2009-11 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00477412

    Bortezomib, Rituximab and Combination Chemotherapy in Treating Participants With Mantle Cell Lymphoma

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 107 participants Est. completion 2020-10-28 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00478075

    Samarium Sm 153 Lexidronam Pentasodium and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Mayo Clinic 50 participants Est. completion 2009-06 3 sites
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00479128

    Bortezomib With Gemcitabine/Doxorubicin in Patients With Urothelial Cancer and Other Solid Tumors

    Not yet reported M.D. Anderson Cancer Center 80 participants Est. completion 2026-04-14 1 site Stand-alone
    Other conditions: Solid Tumor, Urethral Cancer
    View official trial listing →
  • Terminated NCT NCT00479167

    A Phase II Trial of Combined Weekly Bortezomib and Tositumomab I-131 in Patients With Relapsed or Refractory Follicular Non-Hodgkin's Lymphoma

    Not yet reported Rush University Medical Center 1 participants Est. completion 2008-09 1 site Stand-alone
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00483262

    Combination CCI-779 (Temsirolimus) and Bortezomib (Velcade) in Relapsed and/or Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 63 participants Est. completion 2012-02 3 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT00492050

    Bortezomib and Rituximab for Patients With Waldenstrom's Macroglobulinemia

    Not yet reported M.D. Anderson Cancer Center 46 participants Est. completion 2026-06-28 1 site Stand-alone
    Other conditions: Waldenstrom's Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00500422

    Doxil, Gemcitabine, and Velcade (PS341) in Advanced Cancer Patients

    Not yet reported M.D. Anderson Cancer Center 134 participants Est. completion 2012-11 1 site
    Other conditions: Solid Tumors
    View official trial listing →
  • Withdrawn NCT NCT00504101

    Bortezomib, Arsenic Trioxide, and Melphalan in Treating Patients Undergoing an Autologous Stem Cell Transplant For Multiple Myeloma

    Not yet reported University of Miami Est. completion 2011-06 1 site
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00504634

    Bortezomib (Velcade) Post Allogenic Peripheral Blood Stem Cell Transplantation for Myeloma

    Not yet reported M.D. Anderson Cancer Center 8 participants Est. completion 2010-05 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00504751

    Phase II Study of "VIPER" Chemotherapy in Rel/Ref DLBCL

    Not yet reported Weill Medical College of Cornell University 15 participants Est. completion 2012-02-17 1 site Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00505700

    VELCADE in Combination With Idarubicin and Cytosine Arabinoside in Patients With Acute Myelogenous Leukemia

    Not yet reported Massachusetts General Hospital 36 participants 3 sites
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT00507416

    Velcade,Thalidomide, and Dexamethasone Versus Velcade and Dexamethasone Versus Velcade, Melphalan, and Prednisone

    Not yet reported Millennium Pharmaceuticals, Inc. 502 participants Est. completion 2013-03 235 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00507442

    Phase 1/2 Study of VELCADE® in Combination With Other Drugs to Treat Previously Untreated Multiple Myeloma Patients

    Not yet reported, Not yet reported Millennium Pharmaceuticals, Inc. 158 participants Est. completion 2010-11 2 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT00508209

    Bortezomib and High-dose Melphalan at Myeloma Relapse

    Not yet reported Nordic Myeloma Study Group 50 participants Est. completion 2010-09 9 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00509379

    Non-randomized Safety Study With Bortezomib/Rituximab in Relapsed/Refractory Indolent Lymphoma

    Not yet reported Gruppo Italiano Multiregionale per lo studio dei Linfomi e delle Leucemie 48 participants Est. completion 2011-01 22 sites
    Other conditions: Lymphoma, Non-Hodgkin Lymphoma
    View official trial listing →
  • Terminated NCT NCT00510887

    Bortezomib (Velcade) With Standard Chemotherapy for Relapsed or Refractory Follicular Lymphoma

    Not yet reported Duke University 14 participants Est. completion 2013-09 1 site Stand-alone
    Other conditions: Lymphoma, Follicular
    View official trial listing →
  • Status unknown NCT NCT00510939

    Study to Assess the Safety, Tolerability, and Efficacy of Tipifarnib Plus Bortezomib in the Treatment of Acute Myeloid Leukemia

    Not yet reported University of Bologna 72 participants 1 site
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00511069

    Velcade (Bortezomib - PS341) in the Treatment of Patients Over 18 Years With Ph+ Leukemia

    Not yet reported University of Bologna 3 participants Est. completion 2008-02 1 site
    Other conditions: Leukemia
    View official trial listing →
  • Terminated NCT NCT00512798

    Bortezomib and Temozolomide in Treating Patients With Advanced Refractory Solid Tumors or Melanoma

    Not yet reported, Not yet reported Vanderbilt-Ingram Cancer Center 47 participants Est. completion 2008-03 1 site
    Other conditions: Brain and Central Nervous System Tumors, Melanoma, Solid Tumor
    View official trial listing →
  • Completed NCT NCT00513877

    Bortezomib in Treating Patients With Malignant Pleural Mesothelioma

    Not yet reported Cancer Trials Ireland 33 participants 13 sites Stand-alone
    Other conditions: Malignant Mesothelioma
    View official trial listing →
  • Completed NCT NCT00513955

    Combination Chemotherapy With or Without Bortezomib in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

    Not yet reported University Hospital Plymouth NHS Trust 50 participants Est. completion 2014-10 25 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00514371

    A Study of Tanespimycin (KOS-953) in Patients With Relapsed-refractory Multiple Myeloma

    Not yet reported, Not yet reported Bristol-Myers Squibb 22 participants Est. completion 2009-02 11 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00515138

    A Pilot Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide (RICE) Plus Bortezomib (Velcade) in a Dose-Escalating Fashion for Patients With Relapsed or Primary Refractory Aggressive B-Cell Non-Hodgkin's Lymphoma Who Are Candidates for Autologous Stem Cell Transplant

    Not yet reported University of California, San Francisco 7 participants Est. completion 2011-11 1 site
    Other conditions: Lymphoma, B-Cell
    View official trial listing →
  • Status unknown NCT NCT00516100

    Bortezomib (Velcade) + Pemetrexed (Alimta) in Advanced NSCLC

    Not yet reported, Not yet reported Aptium Oncology Research Network 62 participants Est. completion 2012-08 4 sites
    Other conditions: Non-small Cell Lung Cancer
    View official trial listing →
  • Withdrawn NCT NCT00516191

    A Phase I/II Study of Liposomal Doxorubicin (Doxil)/Melphalan/Bortezomib (Velcade) in Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported University of California, San Francisco Est. completion 2010-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00520767

    Bortezomib, Melphalan, and Dexamethasone in Treating Patients With Primary Amyloidosis or Light Chain Deposition Disease

    Not yet reported Barbara Ann Karmanos Cancer Institute 35 participants Est. completion 2019-06-06 7 sites Stand-alone
    Other conditions: Primary Systemic Amyloidosis, Light Chain Deposition Disease
    View official trial listing →
  • Terminated NCT NCT00522392

    Bortezomib and Dexamethasone With or Without Lenalidomide in Treating Patients With Multiple Myeloma Previously Treated With Dexamethasone

    Not yet reported National Cancer Institute (NCI) 48 participants Est. completion 2014-07 276 sites Stand-alone
    Other conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00523848

    Bortezomib, Doxorubicin Hydrochloride Liposome, and Thalidomide as First-line Therapy in Treating Patients With Previously Untreated Stage I, II, or III Multiple Myeloma

    Not yet reported Roswell Park Cancer Institute 46 participants Est. completion 2012-10 1 site Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00531453

    A Study to Evaluate Two Different Regimens of VELCADE in Combination With Dexamethasone, Thalidomide and Cyclophosphamide (VDT vs VDTC) in Newly Diagnosed Multiple Myeloma

    Not yet reported Millennium Pharmaceuticals, Inc. 98 participants Est. completion 2009-05 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00532389

    Safety Study of LBH589 When Given in Combination With Bortezomib in Adult Patients With Multiple Myeloma

    Not yet reported Novartis Pharmaceuticals 62 participants Est. completion 2013-10 16 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00536575

    Sorafenib and Bortezomib Treatment for Relapsed or Refractory Multiple Myeloma Patients

    Not yet reported, Not yet reported SCRI Development Innovations, LLC 13 participants Est. completion 2010-08 2 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00538187

    Obatoclax and Bortezomib in Treating Patients With Aggressive Relapsed or Recurrent Non-Hodgkin Lymphoma

    Not yet reported National Cancer Institute (NCI) 18 participants 1 site Stand-alone
    Other conditions: Adult Non-Hodgkin Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT00541359

    Bortezomib and Topotecan Hydrochloride in Treating Patients With Advanced Solid Tumors

    Not yet reported City of Hope Medical Center 54 participants Est. completion 2011-06 2 sites Stand-alone
    Other conditions: Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00544284

    Bortezomib and Temozolomide in Treating Patients With Brain Tumors or Other Solid Tumors That Have Not Responded to Treatment

    Not yet reported City of Hope Medical Center 25 participants Est. completion 2012-01 2 sites Stand-alone
    Other conditions: Brain and Central Nervous System Tumors, Lymphoma, Metastatic Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00546780

    A Study of Tanespimycin (KOS-953) in Patients With Multiple Myeloma in First Relapse

    Not yet reported Bristol-Myers Squibb 31 participants Est. completion 2010-03 19 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00547534

    Pilot Study of Bortezomib, Bendamustine and Rituximab on Non-Hodgkin's Lymphoma

    Not yet reported University of Rochester 31 participants Est. completion 2009-10 3 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Terminated NCT NCT00548717

    Sirolimus, Mycophenolate Mofetil and Bortezomib as Graft-Versus-Host Disease (GVHD) Prophylaxis After Reduced Intensity Conditioning (RIC) Hematopoietic Stem Cell Transplantation

    Not yet reported Dana-Farber Cancer Institute 15 participants Est. completion 2013-09 1 site Stand-alone
    Other conditions: Graft-vs-Host Disease
    View official trial listing →
  • Completed NCT NCT00553644

    Bortezomib and Lenalidomide in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma

    Not yet reported National Cancer Institute (NCI) 53 participants Est. completion 2014-01-21 82 sites Stand-alone
    Other conditions: Recurrent Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00555906

    An Investigational Drug, Palbociclib (PD-0332991), Is Being Studied In Combination With Velcade And Dexamethasone In Patients With Multiple Myeloma. Patients Must Have Received Prior Treatment For Multiple Myeloma.

    Not yet reported Pfizer 53 participants Est. completion 2013-03 19 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00558896

    CC-4047 and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma or Amyloidosis

    Not yet reported Mayo Clinic 378 participants Est. completion 2017-10-25 3 sites Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Terminated NCT NCT00560352

    Safety Study of Dasatinib With Bortezomib (Velcade®) and Dexamethasone for Multiple Myeloma

    Not yet reported Bristol-Myers Squibb 16 participants Est. completion 2011-02 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00561743

    A Study Assessing Safety and Effectiveness of BORTEZOMIB Combination Therapy (Bortezomib + Doxorubicin Hydrochloride + Dexamethasone) in Previously Untreated Multiple Myeloma Patients

    Not yet reported Janssen-Ortho Inc., Canada 50 participants Est. completion 2007-05
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00564200

    MINIALO-VELCADE2005: A Study of Bortezomib (Velcade) Treated Multiple Myeloma Patients Pre and Post Allogeneic Haematopoietic Progenitor Cell Transplant With no Myeloablative Conditioning

    Not yet reported PETHEMA Foundation 30 participants Est. completion 2014-10 10 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00568880

    Hydroxychloroquine and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Abramson Cancer Center at Penn Medicine 25 participants Est. completion 2011-06-22 1 site Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00569868

    UARK 2005-05, Coagulation-Related Effects of Velcade Treatment in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported University of Arkansas 11 participants Est. completion 2008-01 1 site
    Other conditions: MULTIPLE MYELOMA
    View official trial listing →
  • Completed NCT NCT00570180

    Combination Bortezomib-containing Regimens in Newly Diagnosed Patients With t (4; 14) Positive Multiple Myeloma

    Not yet reported University Health Network, Toronto 36 participants Est. completion 2015-09-15 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00571493

    VELCADE®-BEAM and Autologous Hematopoietic Stem Cell Transplantation for Non-Hodgkin's Lymphoma, or Mantle Cell Lymphoma

    Not yet reported, Not yet reported University of Nebraska 42 participants Est. completion 2014-11-01 1 site Stand-alone
    Other conditions: Non-hodgkin's Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT00572169

    UARK 2006-66, Total Therapy 3B: An Extension of UARK 2003-33 Total Therapy

    Not yet reported University of Arkansas 177 participants Est. completion 2027-08 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00573391

    Study of Multiple Myeloma Patients Relapsing or Progressing After Autologous Transplantation on Total Therapy 2

    Not yet reported University of Arkansas 5 participants Est. completion 2008-07 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00574080

    UARK 2006-15: A Study of Tandem Transplants With or Without Bortezomib and Thalidomide

    Not yet reported University of Arkansas 20 participants Est. completion 2011-03 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00574236

    Phase II Trial of Bortezomib and Doxorubicin in Metastatic Breast Cancer

    Not yet reported University of Wisconsin, Madison 4 participants Est. completion 2009-10 1 site Stand-alone
    Other conditions: Metastatic Breast Cancer
    View official trial listing →
  • Withdrawn NCT NCT00577668

    A Pilot Study of the Combination of Melphalan, Bortezomib, Thalidomide and Dexamethasone (MEL-VTD)

    Not yet reported University of Arkansas Est. completion 2009-04 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00580242

    A Phase 1 Dose Escalating Trial of Bortezomib in Combination With Lenalidomide in Patients With Myelodysplasia

    Not yet reported Massachusetts General Hospital 23 participants Est. completion 2012-03 2 sites Stand-alone
    Other conditions: Myelodysplasia
    View official trial listing →
  • Completed NCT NCT00580320

    Safety Study of Dacarbazine and Bortezomib in Melanoma and Soft Tissue Sarcoma

    Not yet reported Virginia Commonwealth University 17 participants Est. completion 2013-11 2 sites Stand-alone
    Other conditions: Melanoma, Soft Tissue Sarcoma, Parathyroid Carcinoma, Small Cell Carcinoma of the Lung, Carcinoid Tumors
    View official trial listing →
  • Completed NCT NCT00581360

    Phase II Trial of Doxorubicin and Bortezomib in Patients With Incurable Adenoid Cystic Carcinoma of the Head and Neck

    Not yet reported University of Pittsburgh 10 participants Est. completion 2011-06 21 sites
    Other conditions: Adenoid Cystic Carcinoma
    View official trial listing →
  • Completed NCT NCT00581776

    Phase II Study of VcR-CVAD With Rituximab Consolidation and Maintenance for Untreated Mantle Cell Lymphoma

    Not yet reported University of Wisconsin, Madison 30 participants Est. completion 2015-05 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00581919

    Ph 2 Bortezomib, Dexamethasone, + Doxorubicin With ALCAR for Previously Treated Multiple Myeloma

    Not yet reported University of Wisconsin, Madison 32 participants Est. completion 2013-07 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00590603

    Trisenox, Ascorbic Acid and Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported Duke University 25 participants Est. completion 2012-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00598169

    Bortezomib, Ifosfamide, Carboplatin, and Etoposide, With or Without Rituximab, in Treating Patients With Relapsed or Refractory AIDS-Related Non-Hodgkin Lymphoma

    Not yet reported AIDS Malignancy Consortium 23 participants Est. completion 2014-11 17 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00602511

    Thalidomide Versus Bortezomib in Melphalan Refractory Myeloma

    Not yet reported Nordic Myeloma Study Group 300 participants Est. completion 2010-12 27 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00608907

    An Open-Label Study to Assess the Effect of CYP3A4 Induction on the Pharmacokinetics of VELCADE (Bortezomib)

    Not yet reported Millennium Pharmaceuticals, Inc. 61 participants Est. completion 2010-04 9 sites Stand-alone
    Other conditions: Multiple Myeloma, Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00609167

    Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Mayo Clinic 63 participants Est. completion 2010-11 2 sites
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Terminated NCT NCT00609817

    Safety and Efficacy Study of GCS-100LE in the Treatment of Multiple Myeloma

    Not yet reported La Jolla Pharmaceutical Company 9 participants Est. completion 2009-04 3 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT00610792

    Phase 2 Study of Twice Weekly VELCADE and CAELYX in Patients With Ovarian Cancer Failing Platinum Containing Regimens

    Not yet reported Millennium Pharmaceuticals, Inc. 91 participants 7 sites Stand-alone
    Other conditions: Ovarian Cancer
    View official trial listing →
  • Completed NCT NCT00611325

    Phase II Avastin + Bortezomib for Patients With Recurrent Malignant Glioma

    Not yet reported Duke University 56 participants Est. completion 2013-10 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Glioblastoma
    View official trial listing →
  • Completed NCT NCT00620295

    Bortezomib and Gemcitabine in Treating Older Patients With Advanced Solid Tumors

    Not yet reported Masonic Cancer Center, University of Minnesota 17 participants Est. completion 2009-10 1 site Stand-alone
    Other conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Sarcoma
    View official trial listing →
  • Completed NCT NCT00622674

    Bortezomib and Cetuximab in Treating Patients With Advanced Solid Tumors

    Not yet reported Masonic Cancer Center, University of Minnesota 37 participants Est. completion 2010-02 1 site Stand-alone
    Other conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Kidney Cancer, Lung Cancer, Pancreatic Cancer, Sarcoma, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00624936

    Azacytidine and Bortezomib in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndromes

    Not yet reported Ohio State University Comprehensive Cancer Center 23 participants Est. completion 2014-06 1 site
    Other conditions: Leukemia, Myelodysplastic Syndromes, Myelodysplastic/Myeloproliferative Neoplasms
    View official trial listing →
  • Completed NCT NCT00629226

    Bortezomib, Cetuximab, and Radiation Therapy With or Without Cisplatin in Treating Patients With Stage IV Head and Neck Cancer

    Not yet reported National Cancer Institute (NCI) 46 participants 2 sites Stand-alone
    Other conditions: Head and Neck Cancer
    View official trial listing →
  • Completed NCT NCT00633594

    Rituximab, Lenalidomide, and Bortezomib in Mantle Cell Lymphoma

    Not yet reported, Not yet reported SCRI Development Innovations, LLC 39 participants Est. completion 2016-11 7 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00634179

    A Phase I/II Trial of VR-CHOP in Lymphoma Patients

    Not yet reported, Not yet reported Emory University 37 participants Est. completion 2015-11 1 site Stand-alone
    Other conditions: Lymphoma, B-Cell, Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00636311

    A Phase II Study of IGEV +/- Bortezomib Before Hign Dose Consolidation in Relapsed/Refractory Hodgkin's Lymphoma

    Not yet reported Istituto Clinico Humanitas 13 participants Est. completion 2010-02 1 site Stand-alone
    Other conditions: Hodgkin Disease
    View official trial listing →
  • Completed NCT NCT00636792

    A Phase II Study of VELCADE (Bortezomib) in Combination With Bendamustine and Rituximab in Subjects With Relapsed or Refractory Follicular Lymphoma

    Not yet reported Millennium Pharmaceuticals, Inc. 73 participants Est. completion 2010-05 2 sites
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00641706

    Vorinostat and Bortezomib in Treating Patients With Progressive, Recurrent Glioblastoma Multiforme

    Not yet reported National Cancer Institute (NCI) 44 participants Est. completion 2010-11 214 sites Stand-alone
    Obstructive sleep apnea Other conditions: Adult Giant Cell Glioblastoma, Adult Glioblastoma, Recurrent Adult Brain Tumor
    View official trial listing →
  • Completed NCT NCT00642395

    Velcade®-Melphalan Association in Autologous Stem-Cell Transplantation (ASCT)

    Not yet reported University Hospital, Toulouse 61 participants Est. completion 2011-07 34 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT00644228

    Lenalidomide and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Multiple Myeloma

    Not yet reported National Cancer Institute (NCI) 525 participants Est. completion 2027-06-10 498 sites Stand-alone
    Other conditions: DS Stage I Multiple Myeloma, DS Stage II Multiple Myeloma, DS Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00644696

    Study of Irinotecan and Bortezomib in Children With Recurrent/Refractory Neuroblastoma

    Not yet reported University of Michigan Rogel Cancer Center 18 participants Est. completion 2012-07 1 site Stand-alone
    Other conditions: Neuroblastoma
    View official trial listing →
  • Completed NCT NCT00651781

    Velcaflagida in Relapsed or Refractary Acute Myeloid Leukemia

    Not yet reported, Not yet reported PETHEMA Foundation 40 participants Est. completion 2013-02 13 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00652041

    Bortezomib/Adriamycine/Melfalan/Prednisone (VAMP)/Thalidomide/Cyclophosphamide/Dexamethasone (TaCyDex) or Bortezomib/Melfalan/Prednisone (V-MP)/TaCyDex) in Refractary or Relapsed Multiple Myeloma

    Not yet reported PETHEMA Foundation 40 participants Est. completion 2010-06 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00657553

    Preemptive Strike With Bortezomib in Multiple Myeloma Patients

    Not yet reported University of Arkansas 10 participants Est. completion 2009-01 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00664898

    A Study of the Safety and Pharmacology of SGN-40 Administered in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Genentech, Inc. 18 participants Est. completion 2010-04-08 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00666588

    Bortezomib and Combination Chemotherapy in Treating Younger Patients With Recurrent, Refractory, or Secondary Acute Myeloid Leukemia

    Not yet reported National Cancer Institute (NCI) 52 participants Est. completion 2012-12 82 sites Stand-alone
    Other conditions: Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myelomonocytic Leukemia (M4), Childhood Acute Basophilic Leukemia, Childhood Acute Eosinophilic Leukemia, Childhood Acute Erythroleukemia (M6), Childhood Acute Megakaryocytic Leukemia (M7), Childhood Acute Minimally Differentiated Myeloid Leukemia (M0), Childhood Acute Monoblastic Leukemia (M5a), Childhood Acute Monocytic Leukemia (M5b), Childhood Acute Myeloblastic Leukemia With Maturation (M2), Childhood Acute Myeloblastic Leukemia Without Maturation (M1), Childhood Acute Myelomonocytic Leukemia (M4), Recurrent Adult Acute Myeloid Leukemia, Recurrent Childhood Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00667641

    Paclitaxel and Bortezomib in Treating Patients With Metastatic or Unresectable Malignant Solid Tumors

    Not yet reported University of Medicine and Dentistry of New Jersey 16 participants Est. completion 2009-02 1 site
    Other conditions: Breast Cancer, Colorectal Cancer, Head and Neck Cancer, Lung Cancer, Melanoma (Skin), Ovarian Cancer, Pancreatic Cancer, Prostate Cancer, Unspecified Adult Solid Tumor, Protocol Specific
    View official trial listing →
  • Completed NCT NCT00670423

    A Study Using Tacrolimus, Sirolimus and Bortezomib as Acute Graft Versus Host Disease (GVHD) Prophylaxis in Allogeneic Peripheral Blood Stem Cell (PBSC) Transplantation

    Not yet reported Jennifer E. Schwartz 27 participants Est. completion 2013-10-16 1 site
    Other conditions: Graft vs Host Disease, Peripheral Blood Stem Cell Transplantation, Transplantation, Homologous
    View official trial listing →
  • Completed NCT NCT00670631

    Tandem Transplantation in Multiple Myeloma (MM) Patients With <12 Months of Prior Treatment

    Not yet reported Guido Tricot 46 participants Est. completion 2014-04 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00671112

    Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma

    Not yet reported Brian Hill, MD, PhD 30 participants 1 site Stand-alone
    Other conditions: 714leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00689507

    A Phase 1 Safety Study of LY2127399 in Combination With Bortezomib

    Not yet reported Applied Molecular Evolution 48 participants Est. completion 2014-05 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00691704

    Celgene High Risk Multiple Myeloma (MM) Revlimid Induction and Maintenance Therapy

    Not yet reported Cristina Gasparetto 18 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00702052

    Safety and Efficacy of RAD001 in Participants With Mantle Cell Lymphoma Who Are Refractory or Intolerant to Velcade® Therapy

    Not yet reported Novartis Pharmaceuticals 58 participants Est. completion 2012-04-20 31 sites
    Other conditions: Lymphoma, Mantle- Cell
    View official trial listing →
  • Completed NCT NCT00703300

    Decitabine and Bortezomib in Treating Patients With Acute Myeloid Leukemia

    Not yet reported National Cancer Institute (NCI) 19 participants Est. completion 2014-10 1 site Stand-alone
    Other conditions: Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia, Untreated Adult Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT00703664

    Bortezomib and Vorinostat in Treating Patients With Recurrent Mantle Cell Lymphoma or Recurrent and/or Refractory Diffuse Large B-Cell Lymphoma

    Not yet reported National Cancer Institute (NCI) 65 participants Est. completion 2017-12-01 12 sites Stand-alone
    Other conditions: Recurrent Mantle Cell Lymphoma, Recurrent Non-Hodgkin Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT00706953

    A Study of Bortezomib and Pegylated Liposomal Doxorubicin in Patients With Relapsed Multiple Myeloma Previously Treated With Bortezomib

    Not yet reported Johnson & Johnson Pharmaceutical Research & Development, L.L.C. Est. completion 2010-06
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00708292

    A Phase I-Ib/II Study to Determine the Maximum Tolerated Dose (MTD) of AUY922 Alone and in Combination With Bortezomib, With or Without Dexamethasone, in Patients With Relapsed or Refractory Multiple Myeloma.

    Not yet reported, Not yet reported Novartis Pharmaceuticals 29 participants Est. completion 2011-01 9 sites Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00711828

    Rituximab, Cyclophosphamide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Low-Grade Follicular Lymphoma, Waldenstrom Macroglobulinemia, or Mantle Cell Lymphoma

    Not yet reported Mayo Clinic 21 participants Est. completion 2018-04-06 2 sites Stand-alone
    Obstructive sleep apnea Other conditions: Nodal Marginal Zone Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Chronic Lymphocytic Leukemia, Splenic Marginal Zone Lymphoma, Waldenstrom Macroglobulinemia
    View official trial listing →
  • Terminated NCT NCT00714246

    Bortezomib (PS-341) in Combination With Carboplatin and Docetaxel for Patients With Advanced Non-Small Cell Lung Cancer

    Not yet reported Milton S. Hershey Medical Center 6 participants Est. completion 2013-05 1 site Stand-alone
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00715208

    Phase 2 Study of VELCADE (Bortezomib) in Patients With Relapsed Follicular Lymphoma

    Not yet reported Millennium Pharmaceuticals, Inc. 55 participants Est. completion 2011-03 43 sites
    Other conditions: Relapsed Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT00718601

    Safety and Dose Study of GRN163L and Velcade to Treat Patients With Refractory or Relapsed Myeloma

    Not yet reported Geron Corporation 40 participants Est. completion 2011-10 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00718640

    An Efficacy and Safety Study of Bortezomib in Participants Previously Treated for Multiple Myeloma With Limited Kidney Function

    Not yet reported Janssen-Ortho Inc., Canada 10 participants Est. completion 2010-01 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00719901

    Obatoclax and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 11 participants Est. completion 2012-06 1 site Stand-alone
    Other conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00720148

    A Phase I Trial of Bortezomib and Sunitinib

    Not yet reported Emory University 30 participants Est. completion 2010-07 1 site
    Other conditions: Solid Tumors
    View official trial listing →
  • Completed NCT NCT00720785

    Natural Killer Cells and Bortezomib to Treat Cancer

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 35 participants Est. completion 2021-04-06 1 site Stand-alone
    Other conditions: Chronic Myeloid Leukemia (CML), Pancreatic Ca, Colon/Rectal Ca, Multiple Myeloma, Carcinoma, Non-Small -Cell Lung
    View official trial listing →
  • Completed NCT NCT00722137

    Study of the Combination of Rituximab, Cyclophosphamide, Doxorubicin, VELCADE, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Mantle Cell Lymphoma

    Not yet reported Millennium Pharmaceuticals, Inc. 487 participants Est. completion 2017-06-17 150 sites
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00722566

    A Study of Subcutaneous and Intravenous VELCADE in Patients With Previously Treated Multiple Myeloma

    Not yet reported Millennium Pharmaceuticals, Inc. 222 participants Est. completion 2010-09 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00722722

    The Impact of Velcade(TM)on Antibody Secreting Cells in Sensitized Renal Allograft Candidates

    Not yet reported Mayo Clinic 18 participants Est. completion 2014-04 1 site
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Withdrawn NCT NCT00723658

    S0629, Observation or Combination Chemotherapy, Bortezomib, Thalidomide, and Rituximab Followed By Two Autologous Peripheral Blood Stem Cell Transplants in Treating Patients With Waldenstrom Macroglobulinemia

    Not yet reported SWOG Cancer Research Network 29 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00724568

    Combination Study of Revlimid®, Velcade® Dexamethasone and Doxil® (RVDD)for Newly Diagnosed Multiple Myeloma

    Not yet reported, Not yet reported University of Michigan Rogel Cancer Center 74 participants Est. completion 2014-09-03 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00726869

    A Phase 1/2, Multi-center, Open-label, Dose-escalation Study of Elotuzumab(Humanized Anti-CS1 Monoclonal IgG1 Antibody) and Bortezomib in Subjects With Multiple Myeloma Following One to Three Prior Therapies.

    Not yet reported Abbott 28 participants Est. completion 2012-03 8 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00731952

    Phase I Study of Induction Therapy With VELCADE and Vorinostat in Patients With Surgically Resectable Non-Small Cell Lung Cancer

    Not yet reported University of Virginia 21 participants Est. completion 2014-03 1 site
    Other conditions: Non Small Cell Lung Cancer
    View official trial listing →
  • Completed NCT NCT00734149

    Bortezomib With Melphalan and Prednisone for Multiple Myeloma

    Not yet reported Duke University 45 participants Est. completion 2008-02 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT00734877

    UARK 2013-13, Total Therapy 4B - Formerly 2008-01 - A Phase III Trial for Low Risk Myeloma

    Not yet reported University of Arkansas 382 participants Est. completion 2028-09 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00737529

    A Study to Determine the Efficacy and Safety of Lenalidomide in Patients With Mantle Cell NHL Who Have Relapsed or Progressed After Treatment With Bortezomib or Are Refractory to Bortezomib. The "EMERGE" Trial

    Not yet reported Celgene 134 participants Est. completion 2017-11-08 70 sites
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00740415

    Rituximab, Bortezomib,Bendamustine , Dexamethasone, Patients With Mantle Cell Lymphoma

    Not yet reported French Innovative Leukemia Organisation 39 participants Est. completion 2015-08 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Status unknown NCT NCT00742404

    Doxorubicin Hydrochloride Liposome, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Oncotherapeutics 35 participants 12 sites
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00742625

    Bortezomib, Daunorubicin, and Cytarabine in Treating Older Patients With Previously Untreated Acute Myeloid Leukemia

    Not yet reported, Not yet reported National Cancer Institute (NCI) 95 participants Est. completion 2012-12 22 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Untreated Adult Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT00744354

    Vorinostat, Bortezomib, and Doxorubicin Hydrochloride Liposome in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported UNC Lineberger Comprehensive Cancer Center 32 participants Est. completion 2015-04 4 sites Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00750815

    Cyclophosphamide, VELCADE, DOXIL, and Dexamethasone, (CVDD) in Newly Diagnosed Patients With Multiple Myeloma (MM)

    Not yet reported, Not yet reported H. Lee Moffitt Cancer Center and Research Institute 58 participants Est. completion 2013-05 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00752518

    A Japan Phase I/II Study of Bortezomib in Relapsed or Refractory Multiple Myeloma Patients

    Not yet reported, Not yet reported Janssen Pharmaceutical K.K. 35 participants Est. completion 2006-01
    Other conditions: Refractory, Multiple Myeloma, Relapse
    View official trial listing →
  • Terminated NCT NCT00765102

    Trial of Romidepsin and Bortezomib for Multiple Myeloma

    Not yet reported Celgene 32 participants Est. completion 2010-03-01 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00770731

    Study of Temsirolimus, Topotecan, and Bortezomib

    Not yet reported M.D. Anderson Cancer Center 80 participants Est. completion 2012-11 1 site Stand-alone
    Other conditions: Advanced Cancer
    View official trial listing →
  • Completed NCT NCT00771875

    Randomized Trial for Mixed Acute Rejection

    Not yet reported University of Cincinnati 30 participants Est. completion 2013-03 2 sites Stand-alone
    Other conditions: Graft Rejection
    View official trial listing →
  • Terminated NCT NCT00772668

    Rituximab, Cyclophosphamide, Bortezomib, and Prednisone in Patients With Stage III/IV FL or MZL

    Not yet reported University of Miami 3 participants Est. completion 2011-02 1 site Stand-alone
    Other conditions: Lymphoma, Follicular Lymphoma, Marginal Zone Lymphoma
    View official trial listing →
  • Completed NCT NCT00773747

    Study of Vorinostat (MK-0683) or Placebo, in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-088 AMN)

    Not yet reported Merck Sharp & Dohme LLC 637 participants Est. completion 2015-06-30 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00773838

    Study of Vorinostat (MK0683), an Histone Deacetylase (HDAC) Inhibitor in Combination With Bortezomib in Patients With Relapsed or Refractory Multiple Myeloma (MK-0683-095)

    Not yet reported Merck Sharp & Dohme LLC 143 participants Est. completion 2012-04-09 Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00777114

    Phase 1 Study of Radiosensitization Using Bortezomib in Relapsed Non-Hodgkin's Lymphoma Patients Receiving Radioimmunotherapy

    Not yet reported Weill Medical College of Cornell University 31 participants Est. completion 2012-12-18 2 sites Stand-alone
    Other conditions: Non-Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT00777738

    Efficacy of Bortezomib (Velcade(R)) in Patients With Advanced Waldenström Macroglobulinemia

    Not yet reported Assistance Publique - Hôpitaux de Paris 34 participants Est. completion 2012-08 1 site Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00782821

    Randomized Trial of Induction Therapies in High Immunological Risk Kidney Transplant Recipients

    Not yet reported University of Cincinnati 40 participants Est. completion 2013-03 2 sites
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT00784823

    Study Combining Bortezomib With High Dose Melphalan to Treat Multiple Myeloma

    Not yet reported, Not yet reported Hackensack Meridian Health 32 participants Est. completion 2013-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00789256

    Low Dose Melphalan and Bortezomib for AML and High-Risk MDS

    Not yet reported Dartmouth-Hitchcock Medical Center 26 participants Est. completion 2008-12 2 sites Stand-alone
    Other conditions: Acute Myelogenous Leukemia, Myelodysplastic Syndromes
    View official trial listing →
  • Completed NCT NCT00790647

    Melphalan, Bortezomib, and Stem Cell Transplant in Treating Patients With Primary Systemic Amyloidosis

    Not yet reported Boston Medical Center 10 participants Est. completion 2014-11 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00791011

    Phase 1b Lymphoma Study of AMG 655 in Combination With Bortezomib or Vorinostat

    Not yet reported Amgen 33 participants Est. completion 2011-08 Stand-alone
    Other conditions: Hodgkin's Lymphoma, Low Grade Lymphoma, Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin's Lymphoma, Diffuse Large Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT00792142

    Bortezomib, Thalidomide, and Dexamethasone After Melphalan and Stem Cell Transplant in Treating Patients With Stage I-III Multiple Myeloma

    Not yet reported City of Hope Medical Center 45 participants Est. completion 2014-04-21 1 site Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm, Neurotoxicity
    View official trial listing →
  • Completed NCT NCT00793572

    Autologous or Syngeneic Stem Cell Transplant Followed by Donor Stem Cell Transplant and Bortezomib in Treating Patients With Newly Diagnosed High-Risk, Relapsed, or Refractory Multiple Myeloma

    Not yet reported Fred Hutchinson Cancer Center 32 participants Est. completion 2016-10 1 site Stand-alone
    Other conditions: Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT00793650

    Combination High Dose Melphalan and Autologous Peripheral Blood Stem Cell (PBSC) Transplant With Bortezomib for Multiple Myeloma: A Dose and Schedule Finding Study

    Not yet reported, Not yet reported Emory University 39 participants Est. completion 2011-09 1 site
    Other conditions: Cancer, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00798720

    Vorinostat and Bortezomib as Third-line Treatment in Advanced Non-small Cell Lung Cancer

    Not yet reported University of Wisconsin, Madison 18 participants Est. completion 2012-10 Stand-alone
    Other conditions: Carcinoma, Non Small Cell Lung
    View official trial listing →
  • No Longer Available NCT NCT00799539

    A Study to Further Assess Safety and Effectiveness Data of the Bortezomib(Velcade)/Melphalan/Prednisone (BMP) Regimen in Previously Untreated and Transplant Ineligible Multiple Myeloma Patients

    Janssen-Ortho Inc., Canada 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00810576

    Combination of Vorinostat and Bortezomib in Relapsed or Refractory T-Cell Non-Hodgkin's Lymphoma

    Not yet reported M.D. Anderson Cancer Center 1 participants Est. completion 2010-04 1 site Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00813150

    Study of Bortezomib and Dexamethasone With or Without Cyclophosphamide in Patients With Relapsed or Not Controllable Multiple Myeloma

    Not yet reported Janssen-Cilag G.m.b.H 96 participants Est. completion 2013-01 40 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00814541

    PAD. ICORG 05-01, V11

    Not yet reported Cancer Trials Ireland 53 participants Est. completion 2012-12 9 sites Stand-alone
    Other conditions: Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT00815919

    Bortezomib Plus Prednisone for Initial Therapy of Chronic Graft Versus Host Disease

    Not yet reported Dana-Farber Cancer Institute 22 participants Est. completion 2013-01 1 site Stand-alone
    Other conditions: Chronic Graft Versus Host Disease
    View official trial listing →
  • Terminated NCT NCT00818649

    Bortezomib and Vorinostat in Treating Patients With High-Risk Myelodysplastic Syndrome or Acute Myeloid Leukemia

    Not yet reported Masonic Cancer Center, University of Minnesota 16 participants Est. completion 2012-05 1 site Stand-alone
    Other conditions: Leukemia, Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT00832234

    Bortezomib, Dexamethasone, and Rituximab in Untreated Waldenstroms Macroglobulinemia

    Not yet reported European Myeloma Network B.V. 59 participants Est. completion 2013-06 1 site Stand-alone
    Other conditions: Waldenstroms Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT00833560

    A Study of Bortezomib, Cyclophosphamide, and Dexamethasone in Patients With Untreated Multiple Myeloma and Planned for a High Dose Chemotherapy

    Not yet reported Janssen-Cilag G.m.b.H 401 participants Est. completion 2009-06 34 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00833833

    MTD, Safety, and Efficacy of Pomalidomide (CC-4047) Alone or With Low-dose Dexamethasone in Patients With Relapsed and Refractory Multiple Myeloma

    Not yet reported, Not yet reported Celgene Corporation 259 participants Est. completion 2015-09 19 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT00837174

    Relapsed and/or Refractory Non-Hodgkin Lymphoma Study

    Not yet reported The Methodist Hospital Research Institute Est. completion 2012-05 Stand-alone
    Other conditions: Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT00839956

    Bortezomib and Vorinostat in Treating Patients With Multiple Myeloma Who Have Undergone Autologous Stem Cell Transplant

    Not yet reported Fred Hutchinson Cancer Center 31 participants Est. completion 2017-03-31 1 site Stand-alone
    Other conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT00849251

    Pegylated Liposomal Doxorubicin Hydrochloride, Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Multiple Myeloma

    Not yet reported, Not yet reported University of Washington 31 participants Est. completion 2015-06 1 site Stand-alone
    Other conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00850499

    Phase 2 Study of VELCADE With Fludarabine in Comparison to Rituximab With Fludarabine in Follicular Lymphoma Patients Previously Treated With Rituximab

    Not yet reported Millennium Pharmaceuticals, Inc. 12 participants Est. completion 2011-10 43 sites
    Other conditions: Follicular Lymphoma
    View official trial listing →
  • Terminated NCT NCT00851552

    Bortezomib, Doxorubicin Hydrochloride Liposome, and Rituximab in Treating Patients With Diffuse Large B-Cell Lymphoma That Has Relapsed or Not Responded to Treatment

    Not yet reported Roswell Park Cancer Institute 9 participants Est. completion 2011-09 1 site
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT00858234

    Phase I Study of MK-0683 in Combination With Bortezomib in Participants With Multiple Myeloma (MK-0683-098)

    Not yet reported Merck Sharp & Dohme LLC 9 participants Est. completion 2012-04-19 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00861250

    Assessment of Molecular Remission by ASO-qPCR After Bortezomib-dexamethasone (Vel/Dex) Followed by ASCT

    Not yet reported, Not yet reported Tampere University Hospital 47 participants Est. completion 2015-07 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00863369

    Bortezomib and Gemcitabine in Treating Patients With Relapsed B-Cell Non-Hodgkin Lymphoma

    Not yet reported, Not yet reported City of Hope Medical Center 33 participants Est. completion 2023-06-20 2 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT00869232

    UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

    Not yet reported University of Arkansas 90 participants Est. completion 2028-10 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00869323

    Bortezomib and Rituximab in Treating Patients With Post-Transplant Lymphoproliferative Disorders

    Not yet reported Masonic Cancer Center, University of Minnesota 3 participants Est. completion 2016-12 2 sites Stand-alone
    Other conditions: Lymphoproliferative Disorder
    View official trial listing →
  • Active, not recruiting NCT NCT00871013

    Trial for Patients Not Qualifying for TT4 and TT5 Protocols Because of Prior Therapy

    Not yet reported University of Arkansas 160 participants Est. completion 2027-12 1 site Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Terminated NCT NCT00871546

    SCH 727965 in Patients With Mantle Cell Lymphoma or B-Cell Chronic Lymphocytic Leukemia (Study P04715)

    Not yet reported Merck Sharp & Dohme LLC 8 participants Est. completion 2010-12 Stand-alone
    Other conditions: Lymphoma, Mantle-Cell, Leukemia, Lymphocytic, Chronic, B-Cell
    View official trial listing →
  • Status unknown NCT NCT00872352

    Evaluation of Bortezomib Induced Peripheral Neuropathy of Multiple Myeloma (MM) Patients

    Not yet reported Wolfson Medical Center 30 participants Est. completion 2009-08 1 site
    Other conditions: Multiple Myeloma, Peripheral Neuropathy
    View official trial listing →
  • Completed NCT NCT00872521

    A Study of Efficacy of Treatment With Bortezomib (in Combination With Doxorubicin and Dexamethasone) in Previously Untreated Patients With Multiple Myeloma

    Not yet reported Janssen-Cilag Pty Ltd 107 participants Est. completion 2011-11 16 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00873093

    Bortezomib and Combination Chemotherapy in Treating Young Patients With Relapsed Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma

    Not yet reported National Cancer Institute (NCI) 148 participants Est. completion 2014-09 171 sites Stand-alone
    Other conditions: B-cell Adult Acute Lymphoblastic Leukemia, B-cell Childhood Acute Lymphoblastic Leukemia, Recurrent Adult Acute Lymphoblastic Leukemia, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Childhood Acute Lymphoblastic Leukemia, Recurrent Childhood Lymphoblastic Lymphoma, T-cell Adult Acute Lymphoblastic Leukemia, T-cell Childhood Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT00884546

    Multiple Ascending Dose (MAD) Combination in Subjects With Multiple Myeloma

    Not yet reported Bristol-Myers Squibb 27 participants Est. completion 2012-03 8 sites
    Other conditions: Advanced Cancer, Various, NOS
    View official trial listing →
  • Completed NCT NCT00889798

    Tumor Registry of Lymphatic Neoplasia

    iOMEDICO AG 3795 participants Est. completion 2019-08-31
    Other conditions: Non-Hodgkin's Lymphoma (NHL), Chronic Lymphocytic Leukemia (CLL), Multiple Myeloma (MM)
    View official trial listing →
  • Terminated NCT NCT00891033

    Panobinostat/Velcade in Multiple Myeloma

    Not yet reported University of Arkansas 12 participants Est. completion 2013-08 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00891618

    Acupuncture for Chemo-Induced Peripheral Neuropathy

    Not yet reported M.D. Anderson Cancer Center 27 participants Est. completion 2013-04 1 site
    Other conditions: Lymphoma, Myeloma, Peripheral Neuropathy
    View official trial listing →
  • Completed NCT NCT00895687

    Study of Erlotinib in Combination With Bortezomib

    Not yet reported M.D. Anderson Cancer Center 24 participants 1 site Stand-alone
    Other conditions: Advanced Cancer
    View official trial listing →
  • Completed NCT NCT00901147

    Study of Bortezomib and Panobinostat in Treating Patients With Relapsed/Refractory Peripheral T-cell Lymphoma or NK/T-cell Lymphoma

    Not yet reported Singapore General Hospital 25 participants Est. completion 2014-01 5 sites Stand-alone
    Other conditions: Peripheral T-cell Lymphoma (Not Otherwise Specified), Angioimmunoblastic T-cell Lymphoma, Extranodal NK/T-cell Lymphoma Nasal Type, Enteropathy- Type T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Anaplastic Large Cell Lymphoma (ALCL) (ALK-1 Negative), Relapsed ALCL (ALK-1 Positive) Post Autologous Transplant
    View official trial listing →
  • Completed NCT NCT00903734

    An Umbrella, Modular Study Based on Epidermal Growth Factor Receptor (EGFR) Mutation Status

    Not yet reported M.D. Anderson Cancer Center 16 participants 1 site
    Other conditions: Advanced Cancers
    View official trial listing →
  • Completed NCT NCT00903968

    Combination Plerixafor (AMD3100)and Bortezomib in Relapsed or Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 58 participants Est. completion 2016-10 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00908232

    Treatment With Velcade (Bortezomib) Plus Dexamethasone (VD) or VD Plus Cyclophosphamide or VD Plus Lenalidomide in Patients With Multiple Myeloma Stabilized After 4 Cycles of VD

    Not yet reported Janssen-Cilag International NV 163 participants Est. completion 2011-08 42 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00908583

    Desensitization in Kidney Transplantation

    Not yet reported University of Cincinnati 44 participants Est. completion 2012-11 2 sites Stand-alone
    Other conditions: HLA Sensitization
    View official trial listing →
  • Status unknown NCT NCT00910897

    Study in Myeloma Patients Newly Diagnosed Treated as an Induction With Velcade-Dex or Velcade (Bortezomib) Thalidomide Dexamethasone (VTD)

    Not yet reported Intergroupe Francophone du Myelome 205 participants 56 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00911859

    A Study to Compare CNTO 328 (Anti-IL-6 Monoclonal Antibody) and VELCADE-Melphalan-Prednisone (VMP) With VMP Alone in Previously Untreated Multiple Myeloma Patients

    Not yet reported Janssen Research & Development, LLC 118 participants Est. completion 2013-04 37 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00920556

    A Clinical Study to Assess the Safety and Activity of SRT501 Alone or in Combination With Bortezomib in Patients With Multiple Myeloma

    Not yet reported Sirtris, a GSK Company 24 participants Est. completion 2010-11-04 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00920855

    Study of Bendamustine Combined With Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported Cephalon 40 participants Est. completion 2011-12 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00923247

    A Targeted Phase I/II Trial of ZD6474 (Vandetanib; ZACTIMA) Plus the Proteasome Inhibitor, Bortezomib (Velcade ), in Adults With Solid Tumors With a Focus on Hereditary or Sporadic, Locally Advanced or Metastatic Medullary Thyroid Cancer (MTC)

    Not yet reported, Not yet reported National Cancer Institute (NCI) 22 participants Est. completion 2016-12-09 1 site Stand-alone
    Other conditions: Medullary Thyroid Carcinoma
    View official trial listing →
  • Completed NCT NCT00931918

    Study to Assess the Effectiveness of RCHOP With or Without VELCADE in Previously Untreated Non-Germinal Center B-Cell-like Diffuse Large B-Cell Lymphoma Patients

    Not yet reported Millennium Pharmaceuticals, Inc. 206 participants Est. completion 2015-08 70 sites Stand-alone
    Other conditions: Non-Germinal B-Cell-like (GCB) Diffuse Large B-cell Lymphoma (DLBCL)
    View official trial listing →
  • Completed NCT NCT00932698

    Study of Oral Ixazomib in Adult Participants With Relapsed and/or Refractory (RR) Multiple Myeloma

    Not yet reported Millennium Pharmaceuticals, Inc. 60 participants Est. completion 2017-05-23 5 sites
    Other conditions: Relapsed and Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00937495

    Vorinostat and Bortezomib in Treating Patients With Advanced Soft Tissue Sarcoma

    Not yet reported National Cancer Institute (NCI) 16 participants Est. completion 2011-06 6 sites Stand-alone
    Other conditions: Recurrent Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
    View official trial listing →
  • Completed NCT NCT00948922

    Melphalan+Bortezomib as a Conditioning Regimen for Autologous and Allogeneic Stem Cell Transplants in Multiple Myeloma

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 124 participants Est. completion 2019-05-14 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00956033

    Skin Biopsies in Chemotherapy-Induced Neuropathy

    Erasmus Medical Center 26 participants Est. completion 2012-02 1 site
    Other conditions: Multiple Myeloma, Peripheral Neuropathy
    View official trial listing →
  • Completed NCT NCT00958256

    Study of Bortezomib in Combination With Cyclophosphamide and Rituximab

    Not yet reported M.D. Anderson Cancer Center 22 participants Est. completion 2014-03 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma, Lymphoma
    View official trial listing →
  • Completed NCT NCT00963274

    Bortezomib and Romidepsin in Patients With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

    Not yet reported Virginia Commonwealth University 18 participants Est. completion 2018-04-13 5 sites Stand-alone
    Other conditions: Leukemia, Lymphoma
    View official trial listing →
  • Completed NCT NCT00963820

    Study Evaluating the Safety and Tolerability of Weekly Dosing of Oral IXAZOMIB in Adult Patients With Relapsed and Refractory Multiple Myeloma

    Not yet reported Millennium Pharmaceuticals, Inc. 60 participants Est. completion 2014-01 6 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00967369

    Combination Chemotherapy With or Without Bortezomib in Treating Patients With Classical Hodgkin Lymphoma That Has Returned or Does Not Respond to Prior Treatment.

    Not yet reported M.D. Anderson Cancer Center 20 participants Est. completion 2018-05-02 1 site Stand-alone
    Other conditions: Recurrent Classic Hodgkin Lymphoma, Refractory Classic Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT00972712

    Protocol of the Combination of Bortezomib and Tipifarnib for Relapsed or Refractory Multiple Myeloma

    Not yet reported Emory University 12 participants Est. completion 2015-03 3 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00972959

    Effect of Combination of Bortezomib/Dexamethasone/Zoledronic Acid on Bone Disease in Patients With Multiple Myeloma Relapsed After 1-3 Prior Lines of Therapy

    Not yet reported University of Athens 17 participants Est. completion 2013-05 3 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00980395

    Bortezomib, Cladribine, and Rituximab in Treating Patients With Advanced Mantle Cell Lymphoma or Indolent Lymphoma

    Not yet reported University of Arizona 24 participants Est. completion 2018-08-14 1 site Stand-alone
    Other conditions: Lymphoma, Mantle Cell Lymphoma, Indolent Lymphoma, SLL
    View official trial listing →
  • Terminated NCT NCT00983346

    Effect of Low Dose Bortezomib on Bone Formation in Smoldering Myeloma Patients

    Not yet reported University of Utah 17 participants Est. completion 2014-09 1 site Stand-alone
    Other conditions: Cancer, Myeloma, Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00984828

    Randomized Study of Velcade-based Regimen With Autologous Stem Cell Transplantation in Newly-diagnosed Myeloma Patients

    Not yet reported, Not yet reported Shanghai Jiao Tong University School of Medicine 23 participants Est. completion 2016-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT00985907

    Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported University of California, San Francisco 13 participants Est. completion 2010-01-12 2 sites Stand-alone
    Other conditions: Multiple Myeloma, Patient Participation
    View official trial listing →
  • Completed NCT NCT00985959

    A Study of JNJ-26866138 (Bortezomib) in Untreated Multiple Myeloma Patients Who Are Not Candidates for Hematopoietic Stem Cell Transplant (HSCT)

    Not yet reported Janssen Pharmaceutical K.K. 101 participants Est. completion 2010-06 28 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT00990652

    Presurgery Bortezomib for Recurrent Malignant Gliomas Followed by Postop Bortezomib & Temozolomide

    Not yet reported Northwestern University 10 participants Est. completion 2012-10 1 site Stand-alone
    Other conditions: Brain and Central Nervous System Tumors
    View official trial listing →
  • Completed NCT NCT00992446

    Bortezomib and Vorinostat as Maintenance Therapy After Autologous Stem Cell Transplant in Treating Patients With Non-Hodgkin Lymphoma

    Not yet reported Fred Hutchinson Cancer Center 27 participants Est. completion 2019-10-29 1 site Stand-alone
    Other conditions: Adult Diffuse Large B-Cell Lymphoma, B-Cell Non-Hodgkin Lymphoma, Follicular Lymphoma, Mantle Cell Lymphoma, Non-Hodgkin Lymphoma, T-Cell Non-Hodgkin Lymphoma
    View official trial listing →
  • Completed NCT NCT00994500

    Vorinostat and Bortezomib in Treating Young Patients With Refractory or Recurrent Solid Tumors, Including Central Nervous System Tumors and Lymphoma

    Not yet reported National Cancer Institute (NCI) 20 participants 6 sites Stand-alone
    Other conditions: Childhood Burkitt Lymphoma, Childhood Central Nervous System Choriocarcinoma, Childhood Central Nervous System Germ Cell Tumor, Childhood Central Nervous System Germinoma, Childhood Central Nervous System Mixed Germ Cell Tumor, Childhood Central Nervous System Teratoma, Childhood Central Nervous System Yolk Sac Tumor, Childhood Choroid Plexus Tumor, Childhood Craniopharyngioma, Childhood Diffuse Large Cell Lymphoma, Childhood Immunoblastic Large Cell Lymphoma, Childhood Medulloepithelioma, Childhood Meningioma, Childhood Mixed Glioma, Childhood Nasal Type Extranodal NK/T-cell Lymphoma, Childhood Oligodendroglioma, Recurrent Childhood Anaplastic Large Cell Lymphoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Central Nervous System Embryonal Tumor, Recurrent Childhood Cerebellar Astrocytoma, Recurrent Childhood Cerebral Astrocytoma, Recurrent Childhood Ependymoma, Recurrent Childhood Grade III Lymphomatoid Granulomatosis, Recurrent Childhood Large Cell Lymphoma, Recurrent Childhood Lymphoblastic Lymphoma, Recurrent Childhood Malignant Germ Cell Tumor, Recurrent Childhood Medulloblastoma, Recurrent Childhood Pineoblastoma, Recurrent Childhood Small Noncleaved Cell Lymphoma, Recurrent Childhood Subependymal Giant Cell Astrocytoma, Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor, Recurrent Childhood Visual Pathway and Hypothalamic Glioma, Recurrent Childhood Visual Pathway Glioma, Recurrent/Refractory Childhood Hodgkin Lymphoma, Unspecified Childhood Solid Tumor, Protocol Specific
    View official trial listing →
  • Withdrawn NCT NCT00995059

    Bortezomib Before Donor Stem Cell Transplant in Treating Patients With Multiple Myeloma

    Not yet reported, Not yet reported Mayo Clinic Stand-alone
    Other conditions: Multiple Myeloma, Refractory Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT00996385

    Velcade and Eloxatin for Patients With Malignant Pleural or Peritoneal Mesothelioma

    Not yet reported Columbia University 29 participants Est. completion 2014-09 1 site Stand-alone
    Other conditions: Mesothelioma
    View official trial listing →
  • Completed NCT NCT00998010

    Bortezomib, Temozolomide, and Regional Radiation Therapy in Treating Patients With Newly Diagnosed Glioblastoma Multiforme or Gliosarcoma

    Not yet reported Jonsson Comprehensive Cancer Center 24 participants Est. completion 2018-04-20 1 site Stand-alone
    Other conditions: Brain and Central Nervous System Tumors
    View official trial listing →
  • Completed NCT NCT01000285

    EPOCH Chemotherapy and Bortezomib for Associated T-Cell Leukemia Lymphoma

    Not yet reported, Not yet reported Washington University School of Medicine 18 participants Est. completion 2016-04 6 sites Stand-alone
    Other conditions: Leukemia-Lymphoma, Adult T-Cell
    View official trial listing →
  • Terminated NCT NCT01002248

    Assessment of Efficacy and Safety of Perifosine, Bortezomib and Dexamethasone in Multiple Myeloma Patients

    Not yet reported AEterna Zentaris 135 participants Est. completion 2013-03 86 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01005628

    Bortezomib (Velcade) - Regulatory Post Marketing Surveillance (PMS)

    Janssen Korea, Ltd., Korea 1121 participants Est. completion 2012-03 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01009840

    IV Busulfan Plus Bortezomib Conditioning Regimen for Second Autologous Stem Cell Transplant in Multiple Myeloma Patients

    Not yet reported Otsuka Pharmaceutical Development & Commercialization, Inc. 30 participants Est. completion 2012-03-01 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01016028

    Chemotherapy-Induced Peripheral Neuropathy Survey

    M.D. Anderson Cancer Center Est. completion 2013-02
    Other conditions: Breast Cancer, Colorectal Cancer, Myeloma, Chemotherapy-induced Peripheral Neuropathy
    View official trial listing →
  • Completed NCT NCT01016730

    Bortezomib in Treating Patients With Relapsed or Refractory AIDS-Related Kaposi Sarcoma

    Not yet reported National Cancer Institute (NCI) 24 participants Est. completion 2015-01-07 9 sites Stand-alone
    Other conditions: AIDS-Related Kaposi Sarcoma, HIV Infection, Recurrent Kaposi Sarcoma
    View official trial listing →
  • Completed NCT NCT01021592

    Quality of Life in Multiple Myeloma Patients Treated With Bortezomib

    Janssen Korea, Ltd., Korea 140 participants Est. completion 2008-07
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01023308

    Panobinostat or Placebo With Bortezomib and Dexamethasone in Patients With Relapsed Multiple Myeloma

    Not yet reported Novartis Pharmaceuticals 767 participants Est. completion 2015-07-30 210 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01026701

    Observational Study of the Effects Intravenous Bortezomib Has on Osteoblast (Cell That is Responsible for Bone Formation) Activity in Multiple Myeloma Patients.

    Janssen Korea, Ltd., Korea 104 participants Est. completion 2009-11
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01029730

    Trial of Bendamustine, Bortezomib, and Rituximab in Patients With Previously Untreated Low Grade Lymphoma

    Not yet reported SCRI Development Innovations, LLC 55 participants Est. completion 2016-07 20 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT01030302

    A Retreatment Study With Bortezomib for Multiple Myeloma

    Janssen Korea, Ltd., Korea 56 participants Est. completion 2010-09
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01034553

    Aurora A Kinase Inhibitor MLN8237 and Bortezomib in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Mayo Clinic 26 participants Est. completion 2014-11 6 sites Stand-alone
    Other conditions: Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01038388

    A Study of the Combination Vorinostat With Lenalidomide, Bortezomib and Dexamethasone for Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Emory University 30 participants Est. completion 2021-08-05 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01040871

    Study of the Combination of VELCADE, Rituximab, Cyclophosphamide, Doxorubicin, and Prednisone or Rituximab, Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone in Patients With Newly Diagnosed Non-Germinal Center B-Cell Subtype of Diffuse Large B-Cell Lymphoma

    Not yet reported Millennium Pharmaceuticals, Inc. 164 participants Est. completion 2012-08 1 site
    Other conditions: Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01045681

    Study of Bendamustine, Velcade and Dexamethasone in the Treatment of Elderly Patients With Multiple Myeloma

    Not yet reported Intergroupe Francophone du Myelome 75 participants Est. completion 2013-03-28 37 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01046006

    Bortezomib, Dexamethasone, and Rituximab in Previously Untreated Patients With Waldenstrom's Macroglobulinemia

    Not yet reported Meletios A. Dimopoulos 59 participants Est. completion 2015-11 4 sites Stand-alone
    Other conditions: Waldenstrom's Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT01053949

    IFM2009-02-Pomalidomide and Dexamethasone Phase 2 Myeloma

    Not yet reported University Hospital, Lille 84 participants Est. completion 2015-04 19 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01055301

    S0833, Bortezomib, Thalidomide, Lenalidomide, Combination Chemotherapy, and Autologous Stem Cell Transplant in Treating Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported SWOG Cancer Research Network Est. completion 2011-07 21 sites Stand-alone
    Other conditions: Multiple Myeloma, Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT01056276

    Study to Evaluate the Combination of Bendamustine, Bortezomib and Dexamethasone (BBD) in the First-Line Treatment of Patients With Multiple Myeloma Who Are Not Candidates for High Dose Chemotherapy

    Not yet reported SCRI Development Innovations, LLC 59 participants Est. completion 2017-02 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01056601

    Panobinostat & Bortezomib in Pancreatic Cancer Progressing on Gemcitabine Therapy

    Not yet reported Masonic Cancer Center, University of Minnesota 7 participants Est. completion 2011-02 1 site Stand-alone
    Other conditions: Pancreatic Cancer
    View official trial listing →
  • Completed NCT NCT01058239

    Bortezomib Plus Rituximab for EBV+ PTLD

    Not yet reported Massachusetts General Hospital 7 participants Est. completion 2017-11 3 sites Stand-alone
    Other conditions: Post-transplant Lymphoproliferative Disease, Solid Organ Transplant, Stem Cell Transplant (Bone Marrow Transplant), Epstein Barr Virus Infections
    View official trial listing →
  • Completed NCT NCT01060202

    Quality of Life of Non-transplant Candidate Multiple Myeloma Patients Treated With Early Bortezomib

    Janssen Korea, Ltd., Korea 60 participants Est. completion 2011-07
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01062230

    Bone Effect of Bortezomib in Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported University of Arkansas 6 participants Est. completion 2013-08 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01063179

    Velcade, Melphalan, Prednisone And Thalidomide Versus Velcade, Melphalan, Prednisone in Multiple Myeloma Patients

    Not yet reported Fondazione EMN Italy Onlus 511 participants Est. completion 2014-07 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01063907

    A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Kyowa Kirin Co., Ltd. 95 participants Est. completion 2013-11 26 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01072773

    Bortezomib, Cyclophosphamide, and Dexamethasone in Treating Patients With Primary Systemic Light Chain Amyloidosis

    Not yet reported Mayo Clinic 2 participants Est. completion 2012-06 1 site Stand-alone
    Other conditions: Primary Systemic Amyloidosis
    View official trial listing →
  • Completed NCT NCT01074411

    Intraperitoneal Bortezomib and Carboplatin in Treating Patients With Persistent or Recurrent Ovarian Epithelial Cancer, Fallopian Tube Cancer, or Primary Peritoneal Cancer

    Not yet reported National Cancer Institute (NCI) 33 participants Est. completion 2018-01-27 14 sites Stand-alone
    Other conditions: Fallopian Tube Clear Cell Adenocarcinoma, Fallopian Tube Endometrioid Adenocarcinoma, Fallopian Tube Mucinous Adenocarcinoma, Fallopian Tube Serous Adenocarcinoma, Fallopian Tube Transitional Cell Carcinoma, Ovarian Brenner Tumor, Ovarian Clear Cell Adenocarcinoma, Ovarian Clear Cell Cystadenocarcinoma, Ovarian Endometrioid Adenocarcinoma, Ovarian Mucinous Adenocarcinoma, Ovarian Mucinous Cystadenocarcinoma, Ovarian Seromucinous Carcinoma, Ovarian Serous Adenocarcinoma, Ovarian Serous Cystadenocarcinoma, Ovarian Transitional Cell Carcinoma, Recurrent Fallopian Tube Carcinoma, Recurrent Ovarian Carcinoma, Recurrent Primary Peritoneal Carcinoma, Undifferentiated Fallopian Tube Carcinoma, Undifferentiated Ovarian Carcinoma
    View official trial listing →
  • Completed NCT NCT01075425

    Belinostat and Bortezomib in Treating Patients With Relapsed or Refractory Acute Leukemia or Myelodysplastic Syndrome

    Not yet reported Virginia Commonwealth University 41 participants Est. completion 2015-02 2 sites Stand-alone
    Other conditions: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Myelodysplastic Syndrome, Chronic Myelogenous Leukemia
    View official trial listing →
  • Terminated NCT NCT01078441

    Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant

    Not yet reported National Cancer Institute (NCI) 2 participants Est. completion 2014-03 130 sites Stand-alone
    Other conditions: Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01078454

    Melphalan and Dexamethasone With or Without Bortezomib in Treating Patients With Previously Untreated Systemic Light-Chain Amyloidosis

    Not yet reported National Cancer Institute (NCI) 11 participants Est. completion 2012-11-27 209 sites Stand-alone
    Other conditions: Light Chain Deposition Disease, Primary Systemic Amyloidosis
    View official trial listing →
  • Completed NCT NCT01078961

    An Expanded Cohort Trial of Bortezomib and Sorafenib in Advanced Malignant Melanoma

    Not yet reported Massachusetts General Hospital 11 participants Est. completion 2016-06 3 sites Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Completed NCT NCT01083316

    Bortezomib and Dexamethasone Followed by High-Dose Melphalan and Stem Cell Transplantation for Primary (AL) Amyloidosis

    Not yet reported Boston Medical Center 35 participants Est. completion 2020-09-04 1 site Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Completed NCT NCT01083602

    Efficacy of Panobinostat in Patients With Relapsed and Bortezomib-refractory Multiple Myeloma

    Not yet reported Novartis Pharmaceuticals 55 participants Est. completion 2014-02 13 sites Stand-alone
    Other conditions: Relapsed and Bortezomib Refractory Multiple Myeloma, Refractory Multiple Myeloma, Multiple Myeloma in Relapse
    View official trial listing →
  • Completed NCT NCT01084837

    Study of Induction Treatment With Velcade and Dexamethasone for Previously Untreated Patients With Multiple Myeloma and Renal Failure

    Not yet reported PETHEMA Foundation 60 participants Est. completion 2013-12 11 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01088048

    Study to Investigate Idelalisib in Combination With Chemotherapeutic Agents, Immunomodulatory Agents and Anti-CD20 Monoclonal Antibody (mAb) in Participants With Relapsed or Refractory Indolent B-cell Non-Hodgkin's Lymphoma, Mantle Cell Lymphoma or Chronic Lymphocytic Leukemia

    Not yet reported Gilead Sciences 241 participants Est. completion 2015-04-28 11 sites Stand-alone
    Other conditions: Indolent Non-Hodgkin's Lymphoma, Chronic Lymphocytic Leukemia, Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01090921

    Safety and Efficacy Study of Single Weekly Bortezomib in Newly Diagnosed Multiple Myeloma

    Not yet reported Boston VA Research Institute, Inc. 50 participants Est. completion 2015-03 11 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01100242

    Velcade and Sorafenib in Unresected or Metastatic Renal Cell Carcinoma

    Not yet reported New Mexico Cancer Research Alliance 17 participants Est. completion 2015-02 3 sites Stand-alone
    Other conditions: Metastatic Renal Cell Carcinoma
    View official trial listing →
  • Completed NCT NCT01103778

    Pilot Study of Velcade® in IgA Nephropathy

    Not yet reported The Rogosin Institute 11 participants Est. completion 2017-04-17 1 site Stand-alone
    Chronic kidney disease Other conditions: IgA Nephropathy
    View official trial listing →
  • Completed NCT NCT01109004

    Stem Cell Transplant With Lenalidomide Maintenance in Patients With Multiple Myeloma (BMT CTN 0702)

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 758 participants Est. completion 2018-03-03 54 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01111188

    Trial of PD 0332991 Plus Bortezomib in Patients With Relapsed Mantle Cell Lymphoma

    Not yet reported Weill Medical College of Cornell University 20 participants Est. completion 2019-04-12 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT01114048

    Early Response-adapted Intensification of Induction Chemotherapy in Patients With Newly Diagnosed Multiple Myeloma (MM)

    Not yet reported Chonnam National University Hospital 78 participants 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01114282

    Phase I Bortezomib (VELCADE) in Combo With Pralatrexate in Relapsed/Refractory MM

    Not yet reported Stanford University 11 participants 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01119794

    Ofatumumab and Bortezomib for Patients With Low-grade B-cell Non-hodgkin Lymphoma That Relapse After Rituximab

    Not yet reported Brown University 10 participants Est. completion 2015-07 3 sites Stand-alone
    Other conditions: Lymphoma, Non-Hodgkins
    View official trial listing →
  • Terminated NCT NCT01125293

    Everolimus, Bortezomib and/or Rituximab in Patients With Relapsed/Refractory Waldenstrom's Macroglobulinemia

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 46 participants Est. completion 2014-08 1 site Stand-alone
    Other conditions: Waldenstrom's Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT01127009

    Bortezomib, Mitoxantrone, Etoposide, and Cytarabine in Relapsed or Refractory Acute Myeloid Leukemia

    Not yet reported Case Comprehensive Cancer Center 3 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a), Adult Acute Monocytic Leukemia (M5b), Adult Acute Myeloblastic Leukemia With Maturation (M2), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Adult Acute Myelomonocytic Leukemia (M4), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Recurrent Adult Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01129180

    Bortezomib and Azacitidine in Treating Patients With Relapsed or Refractory T-Cell Lymphoma

    Not yet reported Pierluigi Porcu 8 participants Est. completion 2012-12 1 site Stand-alone
    Other conditions: Adult Nasal Type Extranodal NK/T-cell Lymphoma, Anaplastic Large Cell Lymphoma, Angioimmunoblastic T-cell Lymphoma, Hepatosplenic T-cell Lymphoma, Peripheral T-cell Lymphoma, Post-transplant Lymphoproliferative Disorder, Prolymphocytic Leukemia, Recurrent Adult T-cell Leukemia/Lymphoma, Recurrent Cutaneous T-cell Non-Hodgkin Lymphoma, Recurrent Mycosis Fungoides/Sezary Syndrome, Small Intestine Lymphoma, T-cell Large Granular Lymphocyte Leukemia
    View official trial listing →
  • Completed NCT NCT01132911

    A Phase I Study of Vorinostat and Bortezomib in Children With Refractory of Recurrent Solid Tumors, Including CNS Tumors and Lymphomas

    Not yet reported National Cancer Institute (NCI) 5 participants Est. completion 2011-04-13 1 site
    Other conditions: Lymphoma, Sarcoma, WilmsTumor, Neuroblastoma
    View official trial listing →
  • Status unknown NCT NCT01134484

    VELCADE-Thalidomide-Dexamethasone (VTD) vs Thalidomide-Dexamethasone (TD) Incorporated Into Double Autotransplantation for Untreated Multiple Myeloma (MM)

    Not yet reported Michele Cavo 480 participants Est. completion 2015-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01142401

    Fulvestrant With or Without Bortezomib in Patients With Inoperable Locally Advanced or Metastatic Estrogen Receptor Positive Breast Cancer

    Not yet reported National Cancer Institute (NCI) 118 participants Est. completion 2021-01-08 21 sites Stand-alone
    Other conditions: Metastatic Breast Carcinoma, Stage IIIB Breast Cancer AJCC v7, Stage IIIC Breast Cancer AJCC v7, Stage IV Breast Cancer AJCC v6 and v7
    View official trial listing →
  • Completed NCT NCT01143779

    FLT-PET as an Imaging Biomarker With Temsirolimus, Topotecan, and Bortezomib

    Not yet reported M.D. Anderson Cancer Center 3 participants Est. completion 2021-12-27 1 site
    Other conditions: Advanced Cancer
    View official trial listing →
  • Completed NCT NCT01146834

    Trial of Three Stem Cell Mobilization Regimens for Multiple Myeloma

    Not yet reported Weill Medical College of Cornell University 47 participants Est. completion 2019-02-04 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT01158105

    Bortezomib for the Treatment of Refractory Chronic Graft-vs-Host Disease(cGVHD)

    Not yet reported Baylor Research Institute 25 participants Est. completion 2017-01 1 site Stand-alone
    Other conditions: Chronic Graft-versus-host Disease
    View official trial listing →
  • Completed NCT NCT01160484

    Pegylated Liposomal Doxorubicin, Bortezomib, Dexamethasone and Lenalidomide for Relapsed/Refractory Multiple Myeloma

    Not yet reported Oncotherapeutics 40 participants Est. completion 2012-09 8 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01162031

    Phase II Study of VELCADE for Relapsed or Refractory T-cell Prolymphocytic Leukemia

    Not yet reported Stanford University Est. completion 2011-07 1 site
    Other conditions: Leukemia, Acute Lymphocytic Leukemia
    View official trial listing →
  • Completed NCT NCT01163357

    Bortezomib, Total Marrow Irradiation, Fludarabine Phosphate, and Melphalan in Treating Patients Undergoing Donor Peripheral Blood Stem Cell Transplant For High-Risk Stage I or II Multiple Myeloma

    Not yet reported City of Hope Medical Center 18 participants Est. completion 2024-05-20 1 site Stand-alone
    Other conditions: Autologous Hematopoietic Stem Cell Transplant Recipient, Loss of Chromosome 17p, Plasma Cell Leukemia, Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT01163786

    A Proposal to Test the Efficacy and Tolerability of Bortezomib in Pulmonary Chronic GVHD

    Not yet reported Northwestern University 17 participants Est. completion 2015-09-09 1 site Stand-alone
    Other conditions: Bronchiolitis Obliterans
    View official trial listing →
  • Completed NCT NCT01164709

    Nelfinavir Mesylate and Bortezomib in Treating Patients With Relapsed or Progressive Advanced Hematologic Cancer

    Not yet reported Swiss Cancer Institute 18 participants Est. completion 2013-11 4 sites Stand-alone
    Other conditions: Leukemia, Lymphoma, Mature T-cell and Nk-cell Neoplasms, Multiple Myeloma and Plasma Cell Neoplasm
    View official trial listing →
  • Completed NCT NCT01168804

    Bendamustine Plus Bortezomib Plus Dexamethasone in Relapsed or Refractory Multiple Myeloma

    Not yet reported Austrian Forum Against Cancer 79 participants Est. completion 2013-05 8 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01169857

    Velcade for Proliferative Lupus Nephritis

    Not yet reported The Rogosin Institute Est. completion 2012-12 1 site
    Other conditions: Lupus Nephritis, Proteinuria, Hematuria
    View official trial listing →
  • Completed NCT NCT01171092

    A Safety Study Looking at the Combination of Velcade and G-CSF in Patients With Myeloma or Lymphoma

    Not yet reported University of Kansas Medical Center 21 participants Est. completion 2014-12 2 sites Stand-alone
    Other conditions: Malignant Lymphoma, Stem Cell Type, Autologous Transplant
    View official trial listing →
  • Status unknown NCT NCT01171443

    The Pathophysiology of Bortezomib Induced Peripheral Neuropathy

    Wolfson Medical Center 30 participants Est. completion 2011-08 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01174888

    Phase I Combination of Midostaurin, Bortezomib, and Chemo in Relapsed/Refractory Acute Myeloid Leukemia

    Not yet reported Alison Walker 34 participants Est. completion 2016-05 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia With Multilineage Dysplasia Following, Myelodysplastic Syndrome, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With Inv(16)(p13;q22), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Myeloid Leukemia With t(8;21)(q22;q22), Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT01177683

    Bendamustine in Combination With Bortezomib and Pegylated Liposomal Doxorubicin for Multiple Myeloma

    Not yet reported, Not yet reported Sherif Farag, MB, BS 32 participants Est. completion 2017-12 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01183949

    Effect of AT7519M Alone and AT7519M Plus Bortezomib in Patients With Previously Treated Multiple Myeloma

    Not yet reported, Not yet reported Astex Pharmaceuticals, Inc. 18 participants Est. completion 2015-03 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01186458

    Fludarabine, Velcade and Rituximab for Relapsed or Refractory Follicular Non-Hodgkin Lymphoma

    Not yet reported Hoosier Cancer Research Network 4 participants Est. completion 2013-10 11 sites
    Other conditions: Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT01190787

    Subcutaneous Velcade Plus Oral Melphalan and Prednisone or Plus Cycloposphamide and Prednisone or Plus Prednisone

    Not yet reported European Myeloma Network B.V. 150 participants Est. completion 2024-01-18 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01191060

    Study Comparing Conventional Dose Combination RVD to High-Dose Treatment With ASCT in the Initial Myeloma up to 65 Years

    Not yet reported University Hospital, Toulouse 700 participants Est. completion 2018-11-30 68 sites Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Completed NCT NCT01206205

    Frontline Therapy in de Novo Multiple Myeloma Patients Under 65

    Not yet reported University Hospital, Toulouse 31 participants Est. completion 2012-10 9 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT01208662

    Randomized Trial of Lenalidomide, Bortezomib, Dexamethasone vs High-Dose Treatment With SCT in MM Patients up to Age 65

    Not yet reported Paul Richardson, MD 729 participants Est. completion 2026-12 46 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01208766

    Study to Compare VMP With HDM Followed by VRD Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Stichting Hemato-Oncologie voor Volwassenen Nederland 1503 participants Est. completion 2025-01 208 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01208818

    Studies in Patients With Multiple Myeloma and Renal Failure Due to Myeloma Cast Nephropathy

    Not yet reported Assistance Publique - Hôpitaux de Paris 284 participants Est. completion 2017-12 1 site Stand-alone
    Other conditions: Chronic Renal Failure With Uremic Nephropathy
    View official trial listing →
  • Completed NCT NCT01212952

    Pomalidomide, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported Mayo Clinic 50 participants Est. completion 2018-03-22 3 sites Stand-alone
    Other conditions: Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01215344

    First Autologous Transplant on Minimal Residual Disease Markers in Previously Untreated Myeloma Undergoing Initial Treatment With Velcade

    Not yet reported Vanderbilt-Ingram Cancer Center 36 participants Est. completion 2018-03 2 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01216683

    Bendamustine Hydrochloride and Rituximab With or Without Bortezomib Followed by Rituximab With or Without Lenalidomide in Treating Patients With High-Risk Stage II, Stage III, or Stage IV Follicular Lymphoma

    Not yet reported ECOG-ACRIN Cancer Research Group 289 participants Est. completion 2019-12-02 227 sites Stand-alone
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT01226849

    Feasibility Study Of Adding Bortezomib to R-ICE Chemotherapy To Treat Relapsed/ Refractory Diffuse Large B-Cell Lymphoma

    Not yet reported Singapore General Hospital 6 participants Est. completion 2014-11 1 site Stand-alone
    Other conditions: Diffuse Large B-Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01233895

    Study of AVE1642 Anti-IGF1R Monoclonal Antibody in Patients With Advanced Multiple Myeloma

    Not yet reported Sanofi 26 participants Est. completion 2008-09 4 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01236391

    Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)

    Not yet reported Pharmacyclics LLC. 115 participants Est. completion 2014-01 18 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01237249

    Study of Treatment for Newly Diagnosed Multiple Myeloma Patients Older Than 65 Years With Sequential Melphalan/Prednisone/Velcade (MPV) Followed by Revlimid/Low Dose Dexamethasone (Rd) Versus Alternating Velcade/Melphalan/Prednisone (MPV) With Revlimid/Low Dose Dexamethasone

    Not yet reported PETHEMA Foundation 250 participants Est. completion 2016-05 63 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01241708

    Tandem Auto Stem Cell Transplant With Melphalan Followed by Melphalan and Bortezomib in Patients With Multiple Myeloma

    Not yet reported Hackensack Meridian Health 148 participants Est. completion 2023-07-15 1 site Stand-alone
    Other conditions: Multiple Myeloma, Auto Stem Cell Transplant
    View official trial listing →
  • Completed NCT NCT01242267

    Escalating Doses of Thalidomide in Conjunction With Bortezomib and HIgh Dose Melphalan for BSCT

    Not yet reported, Not yet reported Hackensack Meridian Health 29 participants Est. completion 2016-01-20 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01248923

    A Study of ARRY-520 and Bortezomib Plus Dexamethasone in Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported Array Biopharma, now a wholly owned subsidiary of Pfizer 55 participants 13 sites Stand-alone
    Other conditions: Multiple Myeloma, Plasma Cell Leukemia
    View official trial listing →
  • Status unknown NCT NCT01249690

    Efficacy Study of PAD and TAD in Newly Diagnosed Multiple Myeloma

    Not yet reported Second Military Medical University 100 participants Est. completion 2014-06 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Available NCT NCT01250808

    Technology Platform and System Construction of Clinical Evaluation Studies on New Drugs of Hematological Malignancy

    Peking University 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01255514

    Sequential High-dose Dexamethasone and Response Adopted PAD or VAD Induction Chemotherapy Followed by High-dose Chemotherapy With Autologous Stem Cell Transplantation for Newly Diagnosed Multiple Myeloma

    Not yet reported Yonsei University 30 participants Est. completion 2014-12-31 8 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT01255527

    Evaluating the Efficacy and Safety of the Lower Dose of Bortezomib Plus Busulfan and Melphalan as a Conditioning Regimen in Patients With Multiple Myeloma Undergoing Autologous Peripheral Blood Stem Cell Transplantation- KMM103 Study

    Not yet reported, Not yet reported Yonsei University 53 participants Est. completion 2014-12 8 sites
    Other conditions: Multiple Myeloma Patients Who Candidate for Autologous Peripheral Blood Stem Cell Transplantation
    View official trial listing →
  • Withdrawn NCT NCT01266811

    A Phase 3 Study of Siltuximab or Placebo in Combination With Velcade and Dexamethasone in Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported Centocor, Inc. Est. completion 2014-12 48 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01267812

    Bortezomib and Rituximab in Treating Patients With Mantle Cell Lymphoma Who Have Previously Undergone Stem Cell Transplantation

    Not yet reported City of Hope Medical Center 23 participants Est. completion 2020-11-02 2 sites Stand-alone
    Other conditions: Contiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Recurrent Mantle Cell Lymphoma, Stage I Mantle Cell Lymphoma, Stage III Mantle Cell Lymphoma, Stage IV Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01272466

    Vaccination With Peptides From Anti-apoptotic Proteins in Relapsed Multiple Myeloma

    Not yet reported, Not yet reported Herlev Hospital 40 participants Est. completion 2015-01-01 1 site Stand-alone
    Other conditions: Relapsed Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01273844

    Study of Bortezomib +HSCT in Primary Systemic Amyloidosis (AL)

    Not yet reported Zhi-Hong Liu, M.D. 21 participants Est. completion 2016-05-12 1 site Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Completed NCT NCT01277016

    A Trial for Systemic Light-chain (AL) Amyloidosis

    Not yet reported European Myeloma Network B.V. 110 participants Est. completion 2016-07-31 1 site Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Completed NCT NCT01281917

    Study of Velcade and Temsirolimus for Relapsed or Refractory Non-Hodgkin Lymphoma

    Not yet reported University of Wisconsin, Madison 40 participants Est. completion 2014-06 18 sites
    Other conditions: Non-Hodgkins Lymphoma
    View official trial listing →
  • Completed NCT NCT01283997

    Prevention of Treatment Induced Neuropathy in Multiple Myeloma

    Not yet reported M.D. Anderson Cancer Center 79 participants Est. completion 2022-08-22 1 site
    Other conditions: Myeloma
    View official trial listing →
  • Completed NCT NCT01286077

    Velcade Consolidation Bone Study

    Not yet reported Janssen-Cilag International NV 106 participants Est. completion 2014-04 21 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01286272

    Ofatumumab and Bendamustine Hydrochloride With or Without Bortezomib in Treating Patients With Untreated Follicular Non-Hodgkin Lymphoma

    Not yet reported National Cancer Institute (NCI) 135 participants Est. completion 2025-09-02 96 sites Stand-alone
    Other conditions: Ann Arbor Stage III Grade 1 Follicular Lymphoma, Ann Arbor Stage III Grade 2 Follicular Lymphoma, Ann Arbor Stage III Grade 3 Follicular Lymphoma, Ann Arbor Stage IV Grade 1 Follicular Lymphoma, Ann Arbor Stage IV Grade 2 Follicular Lymphoma, Ann Arbor Stage IV Grade 3 Follicular Lymphoma, Grade 3a Follicular Lymphoma
    View official trial listing →
  • Terminated NCT NCT01300793

    Study of Standard-Dose Rituximab, Ifosfamide, Carboplatin and Etoposide

    Not yet reported University of California, San Francisco 6 participants Est. completion 2012-04 1 site
    Other conditions: Non-Hodgkin's Lymphoma, B-cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT01309412

    A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Pharmaceutical K.K. 9 participants Est. completion 2012-12 5 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01311687

    A Phase 3, Multicenter, Randomized, Open-Label Study to Compare the Efficacy and Safety of Pomalidomide in Combination With Low-Dose Dexamethasone Versus High-Dose Dexamethasone in Subjects With Refractory Multiple Myeloma or Relapsed and Refractory Multiple Myeloma and Companion Study

    Not yet reported Celgene 455 participants Est. completion 2017-08-29 94 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01312818

    Bortezomib, Vorinostat and Dexamethasone for Relapsed/Refractory Acute Lymphoblastic Leukemia (ALL)

    Not yet reported Masonic Cancer Center, University of Minnesota 2 participants Est. completion 2013-01 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT01313897

    UARK 2010-35, A Study of Expanded Natural Killer Cell Therapy for Multiple Myeloma

    Not yet reported University of Arkansas 10 participants Est. completion 2016-10 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT01314625

    A Study Evaluating Hypotension and Autonomic Nervous System Dysfunction in Multiple Myeloma (MM) Patients

    University of Arkansas 10 participants Est. completion 2012-08 2 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01315873

    Bortezomib and Bendamustine to Treat Relapsed/Refractory Myeloma

    Not yet reported NYU Langone Health 24 participants Est. completion 2015-09 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT01322776

    Combination of Bortezomib, Fludarabine and Cyclophosphamide Treat Recurrent Mantle Cell Lymphoma

    Not yet reported, Not yet reported Sun Yat-sen University 40 participants Est. completion 2013-10 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma Recurrent
    View official trial listing →
  • Completed NCT NCT01323751

    Study of ACY-1215 Alone and in Combination With Bortezomib and Dexamethasone in Multiple Myeloma

    Not yet reported, Not yet reported Celgene 120 participants Est. completion 2016-12-03 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01323920

    Bortezomib-based GVHD Prophylaxis After Allogeneic Transplant for Patients Without Matched Related Donors

    Not yet reported Dana-Farber Cancer Institute 35 participants Est. completion 2013-11 1 site Stand-alone
    Other conditions: Leukemia, Lymphoma, Myelodysplastic Syndrome
    View official trial listing →
  • Completed NCT NCT01324596

    A Randomised Evaluation of Molecular Guided Therapy for Diffuse Large B-cell Lymphoma With Bortezomib

    Not yet reported University Hospital Southampton NHS Foundation Trust 1132 participants Est. completion 2015-06 109 sites Stand-alone
    Other conditions: Lymphoma, Large B-Cell, Diffuse
    View official trial listing →
  • Completed NCT NCT01324947

    Study to Evaluate the Safety and Efficacy of Pomalidomide Monotherapy in Subjects With Refractory or Relapsed Refractory Multiple Myeloma

    Not yet reported Celgene 74 participants Est. completion 2014-07-31 91 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT01328236

    Bortezomib in Combination With Liposomal Doxorubicin and Dexamethasone to Treat Plasma Cell Leukemia

    Not yet reported Clinical Service, China 20 participants Est. completion 2015-09 1 site Stand-alone
    Other conditions: Plasma Cell Leukemia, Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01329289

    SOM230 LAR With Bortezomib and Dexamethasone for Refractory or Relapsed Multiple Myeloma

    Not yet reported University of Pittsburgh Est. completion 2012-02 1 site Stand-alone
    Other conditions: Multiple Myeloma in Relapse, Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01332617

    Phase II Study of Simvastatin for Relapsed/Refractory Myeloma

    Not yet reported University of Louisville Est. completion 2019-02 Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Completed NCT NCT01337752

    Study in Patients With Untreated Multiple Myeloma and Renal Insufficiency

    Not yet reported Novartis Pharmaceuticals 9 participants Est. completion 2013-05 8 sites Stand-alone
    Other conditions: Multiple Myeloma, Renal Insufficiency
    View official trial listing →
  • Terminated NCT NCT01349595

    Impact of Proteasome Inhibition on Anti-Donor HLA Antibody Production After Kidney Transplantation

    Not yet reported Mark Stegall 4 participants Est. completion 2015-03 1 site Stand-alone
    Other conditions: Disorder of Transplanted Kidney
    View official trial listing →
  • Terminated NCT NCT01350232

    Treatment of Sickle Cell Anemia With Stem Cell Transplant

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 2 participants Est. completion 2011-08 1 site Stand-alone
    Other conditions: Sickle Cell Anemia, Sickle Cell-hemoglobin C Disease, Sickle Cell-β0-thalassemia
    View official trial listing →
  • Completed NCT NCT01359657

    Anti-CXCR4 (BMS-936564) Alone and in Combination With Lenalidomide/Dexamethasone or Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

    Not yet reported Bristol-Myers Squibb 46 participants Est. completion 2016-03 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01365559

    Study of Carfilzomib for Multiple Myeloma Patients Who Are Relapsed/Refractory to Bortezomib-containing Treatments

    Not yet reported, Not yet reported Oncotherapeutics 39 participants Est. completion 2016-03-01 9 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01370434

    Two Cycles of PAD Combination by AHCT in MM

    Not yet reported Cooperative Study Group A for Hematology 43 participants Est. completion 2009-01 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01371227

    A Study of JNS002 (Doxorubicin Hydrochloride Liposome Injection) in Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Pharmaceutical K.K. 3 participants Est. completion 2012-05 2 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01371981

    Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia

    Not yet reported National Cancer Institute (NCI) 1645 participants Est. completion 2026-03-31 220 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Leukemia Cutis, Myeloid Neoplasm, Myeloid Sarcoma
    View official trial listing →
  • Completed NCT NCT01376401

    Bendamustine, Bortezomib (Velcade ®) and Prednisone (BVP) in Patients Newly Diagnosed Multiple Myeloma

    Not yet reported PETHEMA Foundation 60 participants Est. completion 2015-12 14 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01381692

    Bortezomib, Rituximab, and Dexamethasone With or Without Temsirolimus in Treating Patients With Untreated or Relapsed Waldenstrom Macroglobulinemia or Relapsed or Refractory Mantle Cell or Follicular Lymphoma

    Not yet reported, Not yet reported National Cancer Institute (NCI) 9 participants Est. completion 2021-09-01 11 sites Stand-alone
    Other conditions: Recurrent Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Non-Hodgkin Lymphoma, Recurrent Small Lymphocytic Lymphoma, Recurrent Waldenstrom Macroglobulinemia, Refractory Follicular Lymphoma, Refractory Mantle Cell Lymphoma, Refractory Marginal Zone Lymphoma, Refractory Non-Hodgkin Lymphoma, Refractory Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT01383759

    Bortezomib/Dexamethasone (BD), Followed By Autologous Stem Cell Transplantation and Maintenance Bortezomib/Dexamethasone For the Initial Treatment of Monoclonal Immunoglobulin Deposition Disease (MIDD) Associated With Multiple Myeloma and AL Amyloidosis

    Not yet reported Memorial Sloan Kettering Cancer Center 20 participants Est. completion 2019-04-30 5 sites Stand-alone
    Other conditions: Light Chain Deposition Disease (LCDD or MIDD), Light Chain and Heavy Chain Deposition Disease (LHCDD or MIDD), Monoclonal Immunoglobulin Deposition Disease (MIDD), Amyloidosis
    View official trial listing →
  • Withdrawn NCT NCT01386398

    Vorinostat With or Without Bortezomib in Treating Patients With Refractory or Recurrent Stage IIB, Stage III, or Stage IV Cutaneous T-Cell Lymphoma

    Not yet reported European Organisation for Research and Treatment of Cancer - EORTC
    Other conditions: Lymphoma
    View official trial listing →
  • Completed NCT NCT01394354

    Vorinostat in Combination With Bortezomib, Doxorubicin and Dexamethasone (VBDD) in Patients With Refractory or Relapsed Multiple Myeloma (MM)

    Not yet reported, Not yet reported University Hospital Freiburg 34 participants Est. completion 2015-12 1 site Stand-alone
    Other conditions: Multiple Myeloma in Relapse
    View official trial listing →
  • Terminated NCT NCT01397591

    Ofatumumab and Bortezomib in Subjects With Relapsed CD20+Diffuse Large B Cell, Follicular, or Mantle Cell Lymphoma

    Not yet reported OHSU Knight Cancer Institute 3 participants Est. completion 2013-07 1 site Stand-alone
    Other conditions: Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT01408797

    Clonal Deletion on Living-Relative Donor Kidney Transplantation

    Not yet reported, Not yet reported Fuzhou General Hospital 15 participants Est. completion 2013-03 1 site Stand-alone
    Other conditions: Renal Transplantation, Uremia
    View official trial listing →
  • Active, not recruiting NCT NCT01415752

    Rituximab, Bendamustine Hydrochloride, and Bortezomib Followed by Rituximab and Lenalidomide in Treating Older Patients With Previously Untreated Mantle Cell Lymphoma

    Not yet reported Eastern Cooperative Oncology Group 373 participants Est. completion 2031-09 418 sites Stand-alone
    Other conditions: Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01415882

    Ixazomib Citrate in Treating Patients With Relapsed Multiple Myeloma That Is Not Refractory to Bortezomib

    Not yet reported Mayo Clinic 165 participants Est. completion 2025-04-30 3 sites
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT01420926

    Decitabine With or Without Bortezomib in Treating Older Patients With Acute Myeloid Leukemia

    Not yet reported National Cancer Institute (NCI) 165 participants Est. completion 2021-04-01 53 sites Stand-alone
    Other conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Therapy-Related Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT01428492

    Ph 1b Study to Evaluate GSK2110183 in Combination With Bortezomib and Dexamethasone in Subjects With Multiple Myeloma

    Not yet reported Novartis 90 participants Est. completion 2015-10 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01435395

    Trial of Temozolomide, Bevacizumab Plus Bortezomib for Recurrent Glioblastoma Multiforme

    Not yet reported Emory University 12 participants Est. completion 2016-04 2 sites Stand-alone
    Other conditions: Glioblastoma Multiforme
    View official trial listing →
  • Terminated NCT NCT01438177

    Chloroquine in Combination With VELCADE and Cyclophosphamide for Relapsed and Refractory Multiple Myeloma

    Not yet reported NYU Langone Health 11 participants Est. completion 2014-02 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT01439750

    Bortezomib (VELCADE), Cladribine and Rituximab (VCR) in Mantle Cell Lymphoma (PSHCI 10-011)

    Not yet reported Milton S. Hershey Medical Center 13 participants Est. completion 2020-08 2 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01440582

    Combination Therapy of Lenalidomide/Bortezomib/Dexamethasone and Panobinostat in Transplant Eligible New Diagnosed Multiple Myeloma (MM) Patients

    Not yet reported M.D. Anderson Cancer Center 77 participants Est. completion 2019-02-28 1 site Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Completed NCT NCT01445405

    Radiation Therapy and Bortezomib and Cetuximab With or Without Cisplatin to Treat Head and Neck Cancer

    Not yet reported National Cancer Institute (NCI) 3 participants Est. completion 2010-08-27 1 site
    Other conditions: Carcinoma, Squamous, Head and Neck Cancer, Oral Cancer, Laryngeal Cancer, Pharyngeal Cancer
    View official trial listing →
  • Withdrawn NCT NCT01445587

    A Study of GSK2110183 in Subjects With Proteasome Inhibitor Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline Est. completion 2011-11 1 site Stand-alone
    Other conditions: Cancer
    View official trial listing →
  • Status unknown NCT NCT01449344

    Efficacy and Safety of R-HAD Alone or in Combination With Bortezomib in Patients With Relapsed or Refractory MCL

    Not yet reported Prof. Dr. M. Dreyling (co-chairman) 128 participants Est. completion 2018-12 54 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT01453088

    Auto Transplant High Dose Melphalan vs High Dose Melphalan+Bortezomib in Pts With Multiple Myeloma Age 65 Years or Older

    Not yet reported Hackensack Meridian Health 63 participants Est. completion 2022-05-01 2 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01453101

    Allogeneic Hematopoietic Stem Cell Transplantation for Multiple Myeloma

    Not yet reported Hackensack Meridian Health 54 participants Est. completion 2020-06-11 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01457144

    Study of Mantle Cell Lymphoma Treatment by RiBVD

    Not yet reported French Innovative Leukemia Organisation 76 participants Est. completion 2016-03 1 site
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01460420

    Sequential Trial on Reduced Intensity Conditioning (RIC) Allogeneic Transplantation

    Not yet reported, Not yet reported European Myeloma Network B.V. 49 participants Est. completion 2017-06-29 10 sites Stand-alone
    Other conditions: Hematologic Malignancies, Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01460602

    Velcade, Nipent, Rituxan (VNR) in Subjects With Relapsed Follicular, Marginal Zone, and Mantle Cell Lymphoma

    Not yet reported, Not yet reported Louisiana State University Health Sciences Center Shreveport Est. completion 2014-10 1 site
    Other conditions: Follicular Lymphoma, Marginal Zone Lymphoma, Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01462773

    Study of Patients With Stage IV Malignant Melanoma Using PS-341 (Bortezomib, Velcade) and Interferon-alpha-2b in Malignant Melanoma

    Not yet reported Ohio State University Comprehensive Cancer Center 16 participants Est. completion 2013-04 1 site Stand-alone
    Other conditions: Melanoma
    View official trial listing →
  • Completed NCT NCT01464112

    A Dose Escalation Study of the Histone Deacetylase Inhibitor (HDACi) JNJ 26481585 in Combination With VELCADE (Bortezomib) and Dexamethasone for Patients With Relapsed Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 18 participants Est. completion 2013-11-19 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01465386

    Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission

    Not yet reported Fred Hutchinson Cancer Center 6 participants Est. completion 2015-03-02 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Myeloblastic Leukemia Without Maturation (M1), Adult Acute Myeloid Leukemia in Remission, Adult Acute Myeloid Leukemia With 11q23 (MLL) Abnormalities, Adult Acute Myeloid Leukemia With Del(5q), Adult Acute Myeloid Leukemia With t(15;17)(q22;q12), Adult Acute Myeloid Leukemia With t(16;16)(p13;q22), Adult Acute Promyelocytic Leukemia (M3), Adult Erythroleukemia (M6a), Adult Pure Erythroid Leukemia (M6b), Secondary Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT01470131

    A Phase 3 Study to Evaluate Efficacy and Safety of Masitinib in Patients With Relapse or Refractory Multiple Myeloma

    Not yet reported AB Science 147 participants Est. completion 2017-02-01 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01472627

    Effects of Bortezomib-Based Therapy on Cellular Immunity and Response to DC/Myeloma Fusion Vaccines in Vitro

    Dana-Farber Cancer Institute 11 participants Est. completion 2018-01 2 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01478048

    Study of Bortezomib and Dexamethasone With or Without Elotuzumab to Treat Relapsed or Refractory Multiple Myeloma

    Not yet reported Bristol-Myers Squibb 185 participants Est. completion 2017-04-21 77 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01481194

    ACVDL Treatment for Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Vejle Hospital 35 participants Est. completion 2018-08-28 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01484626

    Bendamustine, Wkly Bortezomib, Lenalidomide and Dexamethasone for Multiple Myeloma

    Not yet reported, Not yet reported Loyola University 3 participants Est. completion 2014-06-18 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01485835

    A Phase I Study of Ganetespib +/- Bortezomib in Patients With Relapsed and/or Refractory Multiple Myeloma

    Not yet reported Emory University 8 participants Est. completion 2015-09 8 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01492881

    Study of Vorinostat With Doxil and Bortezomib for Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported UNC Lineberger Comprehensive Cancer Center Est. completion 2017-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01495351

    Study of ABT-888 in Combination With Bortezomib and Dexamethasone in Patients With Relapsed Refractory Myeloma

    Not yet reported AHS Cancer Control Alberta 19 participants Est. completion 2015-02-10 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01497093

    Study to Determine the Maximum Tolerated Dose for the Combination of Pomalidomide, Bortezomib and Low-Dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

    Not yet reported Celgene 34 participants Est. completion 2019-07-23 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01497275

    Zevalin and Velcade in Relapsed/Refractory Mantle Cell Lymphoma

    Not yet reported Duke University 5 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Mantle-Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT01497626

    Lapatinib and Bortezomib in Patients With Advanced Malignancies

    Not yet reported Georgetown University 15 participants Est. completion 2015-12 1 site Stand-alone
    Other conditions: Advanced Solid Tumors
    View official trial listing →
  • Status unknown NCT NCT01502267

    Desensitization Protocol for Highly Sensitized Patients on the Waiting List for Kidney Transplant

    Not yet reported Seoul National University Hospital 2 participants Est. completion 2016-01 1 site Stand-alone
    Other conditions: End Stage Renal Disease
    View official trial listing →
  • Terminated NCT NCT01504477

    Panitumumab and Bortezomib for Patients With Advanced Colorectal Cancer

    Not yet reported, Not yet reported Georgetown University 6 participants Est. completion 2014-02 1 site Stand-alone
    Other conditions: Colorectal Cancer
    View official trial listing →
  • Completed NCT NCT01504776

    Phase I Study of Panobinostat + Bortezomib for Relapsed and/or Refractory Mantle Cell Lymphoma (MCL)

    Not yet reported Anand Jillella 3 participants Est. completion 2014-09 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01517724

    Bortezomib Consolidation Trial

    Not yet reported University College, London 40 participants Est. completion 2019-01-24 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01521533

    NOX-A12 in Combination With Bortezomib and Dexamethasone in Relapsed Multiple Myeloma

    Not yet reported TME Pharma AG 28 participants Est. completion 2015-09 10 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT01522872

    Open-label Study of TH-302 and Dexamethasone With or Without Bortezomib or Pomalidomide in Subjects With Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported Threshold Pharmaceuticals 98 participants Est. completion 2017-09 10 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01524445

    Retrospective Survey of Re-treatment With Bortezomib

    Janssen Pharmaceutica N.V., Belgium 35 participants Est. completion 2011-10 4 sites
    Other conditions: Hematological Cancer, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01526694

    Phase II Trial Designed to Determine Efficacy and Safety of Bendamustine+Dexamethasone+Thalidomide in R/R MM

    Not yet reported Azienda Ospedaliera di Bolzano 30 participants Est. completion 2017-04-08 19 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01530594

    Lenalidomide and Low Dose Dexamethasone Versus Bortezomib, Lenalidomide and Low Dose Dexamethasone for Induction, in Patients With Previously Untreated Multiple Myeloma

    Not yet reported King Faisal Specialist Hospital & Research Center 440 participants Est. completion 2013-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01531998

    Lenalidomide/Bortezomib/Dexamethasone & CNTO 328 in Transplant Eligible Newly Diagnosed Multiple Myeloma (MM)

    Not yet reported, Not yet reported M.D. Anderson Cancer Center 14 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Terminated NCT NCT01534143

    High Dose Busulfan and Bortezomib in Treating Patients With High Risk Multiple Myeloma Undergoing Stem Cell Transplant

    Not yet reported Barbara Ann Karmanos Cancer Institute 1 participants Est. completion 2013-05 1 site Stand-alone
    Other conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01534260

    Phase I/II Study of Combination of Sorafenib, Vorinostat, and Bortezomib for the Treatment of Acute Myeloid Leukemia With Complex- or Poor-risk (Monosomy 5/7) Cytogenetics or FLT3-ITD Positive Genotype

    Not yet reported, Not yet reported Hamid Sayar 37 participants Est. completion 2017-02-13 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT01536067

    Ofatumumab and Bortezomib in Treating Patients With Previously Untreated Waldenstrom Macroglobulinemia

    Not yet reported Roswell Park Cancer Institute 3 participants 2 sites Stand-alone
    Other conditions: Waldenström Macroglobulinemia
    View official trial listing →
  • Terminated NCT NCT01537861

    Filgrastim in Treating Patients With Bortezomib-, Carfilzomib-, or IMID-Refractory Multiple Myeloma

    Not yet reported Washington University School of Medicine 7 participants Est. completion 2014-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01539083

    Velcade (Bortezomib) Consolidation After Transplant

    Not yet reported Janssen Scientific Affairs, LLC 256 participants Est. completion 2018-01-09 23 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01541644

    1068GCC Evaluate Efficacy & Explore Mechanism of Acupuncture in Treating Bortezomib-induced Peripheral Neuropathy (BIPN) in Multiple Myeloma

    Not yet reported University of Maryland, Baltimore 27 participants Est. completion 2014-12 1 site
    Other conditions: Peripheral Neuropathies, Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01548573

    Tandem Auto Transplantation in Myeloma Patients With <12 Months of Prior Treatment

    Not yet reported University of Iowa 19 participants Est. completion 2014-08 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01553357

    Lenalidomide and Dexamethasone in Primary Plasma Cell Leukemia

    Not yet reported IRCCS Centro di Riferimento Oncologico della Basilicata 23 participants Est. completion 2011-09 1 site
    Other conditions: Primary Plasma Cell Leukemia
    View official trial listing →
  • Status unknown NCT NCT01554852

    Use of Thalidomide, Lenalidomide, Carfilzomib, Bortezomib and Vorinostat in the Initial Treatment of Newly Diagnosed Multiple Myeloma Patients

    Not yet reported University of Leeds 4420 participants Est. completion 2022-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01556347

    Multi-Drug Desensitization Protocol for Heart Transplant Candidates

    Not yet reported Providence Health & Services 2 participants Est. completion 2016-05 1 site Stand-alone
    Other conditions: Heart Transplantation
    View official trial listing →
  • Completed NCT NCT01556438

    Study of Tabalumab (LY2127399) in Japanese Participants With Relapsed or Refactory Multiple Myeloma

    Not yet reported Eli Lilly and Company 16 participants Est. completion 2015-08 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01568866

    Phase 3 Study With Carfilzomib and Dexamethasone Versus Bortezomib and Dexamethasone for Relapsed Multiple Myeloma Patients

    Not yet reported Amgen 929 participants Est. completion 2018-02-05 241 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01592981

    Randomised Trial in Waldenstrom's Macroglobulinaemia

    Not yet reported University College, London 60 participants Est. completion 2020-08-02 30 sites Stand-alone
    Other conditions: Waldenstrom's Macroglobulinaemia
    View official trial listing →
  • Completed NCT NCT01594242

    Autophagy Induction After Bortezomib for Myeloma

    Not yet reported Abramson Cancer Center at Penn Medicine 11 participants Est. completion 2015-03-02 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01599949

    A Study to Evaluate the Efficacy and Safety of Ibrutinib, in Patients With Mantle Cell Lymphoma Who Progress After Bortezomib Therapy

    Not yet reported Janssen Research & Development, LLC 120 participants Est. completion 2015-05 56 sites
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01602224

    A Study of Tabalumab (LY2127399) in Participants With Previously Treated Multiple Myeloma (MM)

    Not yet reported Eli Lilly and Company 220 participants Est. completion 2014-07 57 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01605032

    Busulfan, Melphalan, and Bortezomib Before First-Line Stem Cell Transplant in Treating Patients With Multiple Myeloma

    Not yet reported Albert Einstein College of Medicine 19 participants Est. completion 2018-03 4 sites Stand-alone
    Other conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT01633281

    Acupuncture for Peripheral Neuropathy

    Not yet reported Singapore General Hospital 8 participants Est. completion 2014-06 1 site
    Other conditions: Peripheral Neuropathy Grade 2 or Greater
    View official trial listing →
  • Completed NCT NCT01633645

    Bortezomib in Combination With Gemcitabine and Cisplatin in Advanced or Metastatic Non-Small Cell Lung Cancer

    Not yet reported University Hospital of Crete 53 participants Est. completion 2013-04 5 sites Stand-alone
    Other conditions: Non Small Cell Lung Cancer, Metastatic
    View official trial listing →
  • Withdrawn NCT NCT01647165

    Phase II Study of Subcutaneous (SC) Bortezomib, Lenalidomide and Dexamethasone for Relapsed and/or Refractory Multiple Myeloma; Followed by SC Bortezomib Maintenance

    Not yet reported National Cancer Institute (NCI) Est. completion 2015-06-26
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01653418

    Phase II Study of V-BEAM Conditioning Regimen Prior to Second Autologous Stem Cell Transplantation

    Not yet reported Washington University School of Medicine 10 participants Est. completion 2013-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01668719

    S1211 Bortezomib, Dexamethasone, and Lenalidomide With or Without Elotuzumab in Treating Patients With Newly Diagnosed High-Risk Multiple Myeloma

    Not yet reported, Not yet reported SWOG Cancer Research Network 142 participants Est. completion 2025-09-22 417 sites Stand-alone
    Other conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT01672229

    Bortezomib in Patients With Chronic Graft Versus Host Disease

    Not yet reported Mehrdad Abedi, MD 16 participants Est. completion 2018-04-09 1 site Stand-alone
    Other conditions: Graft Versus Host Disease
    View official trial listing →
  • Terminated NCT NCT01672736

    A Trial of ASP7487 (OSI-906) in Combination With Bortezomib for the Treatment of Relapsed Multiple Myeloma

    Not yet reported, Not yet reported University Health Network, Toronto 19 participants Est. completion 2017-12-27 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01675245

    An Observational Study of Chinese Multiple Myeloma Patients Treated With Velcade

    Xian-Janssen Pharmaceutical Ltd. 532 participants Est. completion 2010-05
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT01680796

    Dovitinib Combined With Bortezomib and Dexamethasone for Relapsed/Refractory Multiple Myeloma

    Not yet reported University of Florida Est. completion 2013-02 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT01685814

    Lenalidomide, Adriamycin, Dexamethasone (RAD) Versus Lenalidomide, Bortezomib, Dexamethasone (VRD) for Induction in Newly Diagnosed Multiple Myeloma Followed by Response-adapted Consolidation and Lenalidomide Maintenance

    Not yet reported Wuerzburg University Hospital 406 participants Est. completion 2023-12 32 sites Stand-alone
    Other conditions: Previously Untreated Symptomatic Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01695330

    Subcutaneous (SC) Bortezomib-Regimens for Patients With RR MM Failing Prior IV Bortezomib-Containing Regimens

    Not yet reported Oncotherapeutics 5 participants Est. completion 2015-10 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT01695941

    Alisertib, Bortezomib, and Rituximab in Treating Patients With Relapsed or Refractory Mantle Cell Lymphoma or B-cell Low Grade Non-Hodgkin Lymphoma

    Not yet reported National Cancer Institute (NCI) 24 participants Est. completion 2027-03-03 4 sites Stand-alone
    Other conditions: Recurrent B-Cell Non-Hodgkin Lymphoma, Recurrent Mantle Cell Lymphoma, Refractory B-Cell Non-Hodgkin Lymphoma, Refractory Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01696474

    Short Course of Bortezomib in Anemic Patients With Refractory Cold Agglutinin Disease

    Not yet reported Gruppo Italiano Malattie EMatologiche dell'Adulto 21 participants Est. completion 2017-03-27 8 sites Stand-alone
    Other conditions: Refractory Cold Agglutinin Disease
    View official trial listing →
  • Completed NCT NCT01697839

    Serum Vitamin D Levels and Peripheral Neuropathy Among Multiple Myeloma Patients

    Oncotherapeutics 110 participants Est. completion 2015-08 3 sites
    Other conditions: Multiple Myeloma, Peripheral Neuropathy
    View official trial listing →
  • Completed NCT NCT01702831

    Busulfan & Melphalan Conditioning for Autologous Stem Cell Transplant (ASCT) and Lenalidomide Maintenance

    Not yet reported University Health Network, Toronto 78 participants Est. completion 2022-07-31 10 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01706666

    Bortezomib Based Consolidation in Multiple Myeloma Patients Completing Stem Cell Transplant

    Not yet reported Mayo Clinic 3 participants Est. completion 2016-05-17 4 sites Stand-alone
    Other conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01711528

    Dinaciclib, Bortezomib, and Dexamethasone in Treating Patients With Relapsed Multiple Myeloma

    Not yet reported National Cancer Institute (NCI) 41 participants Est. completion 2016-11-22 6 sites Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT01720043

    Hemostatic Effects of VELCADE®* Treatment in Multiple Myeloma Patients

    Not yet reported University of Utah 8 participants Est. completion 2017-07 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01720875

    Vorinostat, Bortezomib and Dexamethasone in Multiple Myeloma (MUKFour)

    Not yet reported University of Leeds 16 participants Est. completion 2018-08-29 2 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01728259

    First-line Pomalidomide, Bortezomib, and Dexamethasone For AL Amyloidosis or LCDD

    Not yet reported Barbara Ann Karmanos Cancer Institute 18 participants Est. completion 2018-10-31 5 sites Stand-alone
    Other conditions: Light Chain Deposition Disease, Primary Systemic Amyloidosis
    View official trial listing →
  • Terminated NCT NCT01729338

    Velcade + Cyclophosphamide in Newly Diagnosed Multiple Myeloma

    Not yet reported Duke University 17 participants Est. completion 2016-12-31 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01734928

    Safety and Efficacy of Pomalidomide, Bortezomib and Low-dose Dexamethasone in Subjects With Relapsed or Refractory Multiple Myeloma

    Not yet reported Celgene 559 participants Est. completion 2022-05-13 321 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01736943

    Bortezomib and Doxil for the Treatment of Patients With Acute Myelogenous Leukemia

    Not yet reported Joseph Tuscano 25 participants Est. completion 2019-05-20 1 site Stand-alone
    Other conditions: Acute Myelogenous Leukemia
    View official trial listing →
  • Completed NCT NCT01754389

    Standard of Care vs. Bortezomib in Graft-Versus Host Disease After Hematopoietic Stem Cell Transplant

    Not yet reported Dana-Farber Cancer Institute 138 participants Est. completion 2016-11 4 sites Stand-alone
    Other conditions: Graft Versus Host Disease
    View official trial listing →
  • Completed NCT NCT01769209

    Bortezomib and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Lymphoblastic Leukemia

    Not yet reported Stanford University 18 participants Est. completion 2017-07-04 1 site Stand-alone
    Other conditions: B-cell Adult Acute Lymphoblastic Leukemia (ALL), Ph-positive Adult Acute Lymphoblastic Leukemia (ALL), Recurrent Adult Acute Lymphoblastic Leukemia (ALL), T-cell Adult Acute Lymphoblastic Leukemia (ALL)
    View official trial listing →
  • Terminated NCT NCT01769443

    Safety and Efficacy of Desensitization Therapy in Sensitized Participants Awaiting Heart Transplantation

    Not yet reported National Institute of Allergy and Infectious Diseases (NIAID) 2 participants Est. completion 2014-07 14 sites Stand-alone
    Other conditions: Primary Heart Transplant, Heart Transplantation, Heart Transplant
    View official trial listing →
  • Completed NCT NCT01782963

    Lenalidomide/Bortezomib/Dexamethasone for Multiple Myeloma (MM)

    Not yet reported Massachusetts General Hospital 50 participants Est. completion 2017-12 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT01783522

    Glutamine in Preventing Peripheral Neuropathy in Patients With Multiple Myeloma Receiving Bortezomib

    Not yet reported Beth Faiman 9 participants Est. completion 2013-11 1 site
    Other conditions: Chemotherapeutic Agent Toxicity, Multiple Myeloma, Peripheral Neuropathy
    View official trial listing →
  • Completed NCT NCT01788020

    Efficacy of First Line DRC +/- Bortezomib for Patients With Waldenström's Macroglobulinemia

    Not yet reported University of Ulm 202 participants Est. completion 2024-04 1 site Stand-alone
    Other conditions: Waldenström's Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT01794507

    A Study Evaluating ABT-199 in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

    Not yet reported AbbVie 66 participants Est. completion 2019-07-16 9 sites Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01801436

    A Post-Approval Pharmacokinetic Study of Bortezomib in Participants With Multiple Myeloma

    Not yet reported Johnson & Johnson Taiwan Ltd 14 participants Est. completion 2008-04 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01805557

    Phase II Randomized Study With R-DHAP +/- Bortezomib as Induction Therapy in Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL) Patients Eligible to Transplantation. BR-DHAP Versus R-DHAP.

    Not yet reported, Not yet reported Fondazione Italiana Linfomi - ETS 108 participants Est. completion 2020-11-20 24 sites Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma Refractory, Diffuse Large B-cell Lymphoma Recurrent
    View official trial listing →
  • Status unknown NCT NCT01812096

    Study of Subcutaneous Versus Intravenous Administration of Bortezomib in Patients With Multiple Myeloma in China

    Not yet reported, Not yet reported The First Affiliated Hospital of Soochow University 20 participants Est. completion 2017-06 1 site Stand-alone
    Other conditions: Multiple Myeloma Proved by Laboratory Tests
    View official trial listing →
  • Completed NCT NCT01818752

    Phase 3 Study of Carfilzomib, Melphalan, Prednisone vs Bortezomib, Melphalan, Prednisone in Newly Diagnosed Multiple Myeloma

    Not yet reported Amgen 955 participants Est. completion 2016-11-04 213 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01827137

    WT1 Vaccine Treatment of Patients With Multiple Myeloma After Autologous Stem Cell Transplantation

    Not yet reported, Not yet reported Sellas Life Sciences Group 20 participants Est. completion 2017-11-06 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01830465

    VELCADE® Plus Rituximab in Non Hodgkin's Follicular Lymphoma

    Not yet reported Gruppo Italiano Studio Linfomi 45 participants Est. completion 2011-05 1 site Stand-alone
    Other conditions: Non Hodgkin's Follicular Lymphoma
    View official trial listing →
  • Completed NCT NCT01833143

    Bortezomib in KRAS-Mutant Non-Small Cell Lung Cancer in Never Smokers or Those With KRAS G12D

    Not yet reported Memorial Sloan Kettering Cancer Center 17 participants Est. completion 2019-08-28 5 sites Stand-alone
    Other conditions: Non-Small Cell Lung Cancer
    View official trial listing →
  • Status unknown NCT NCT01842074

    Desensitization With Bortezomib Before a Living Kidney Donation

    Not yet reported Assistance Publique - Hôpitaux de Paris 10 participants Est. completion 2018-03 1 site Stand-alone
    Other conditions: Patients Awaiting a Living Kidney Donation
    View official trial listing →
  • Completed NCT NCT01848132

    Efficacy/Safety Study of R-CHOP vs Bortezomib-R-CAP for Young Patients With Diffuse Large B-cell Lymphoma With Poor IPI.

    Not yet reported Grupo Español de Linfomas y Transplante Autólogo de Médula Ósea 121 participants Est. completion 2018-08 21 sites Stand-alone
    Other conditions: Diffuse, Large B-Cell, Lymphoma
    View official trial listing →
  • Completed NCT NCT01849783

    Autologous Stem Cell Transplant Followed By Maintenance Therapy in Treating Elderly Patients With Multiple Myeloma

    Not yet reported Margarida Magalhaes-Silverman 41 participants Est. completion 2020-09-30 1 site Stand-alone
    Other conditions: Extramedullary Plasmacytoma, Isolated Plasmacytoma of Bone, Light Chain Deposition Disease, Primary Systemic Amyloidosis, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01852799

    A Study of PAD Followed by Autologous Stem Cell Transplantation (ASCT) to Treat Newly Diagnosed Multiple Myeloma

    Not yet reported Shanghai Changzheng Hospital 18 participants Est. completion 2017-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01860170

    Post-Transplant Bortezomib and High Dose Cyclophosphamide as Graft-Versus-Host Disease (GVHD) Prophylaxis

    Not yet reported, Not yet reported Corewell Health West 28 participants Est. completion 2018-03 1 site
    Other conditions: Hematological Malignancy
    View official trial listing →
  • Active, not recruiting NCT NCT01861314

    Bortezomib, Sorafenib Tosylate, and Decitabine in Treating Patients With Acute Myeloid Leukemia

    Not yet reported National Cancer Institute (NCI) 15 participants Est. completion 2027-03-19 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia, Acute Myeloid Leukemia Post Cytotoxic Therapy, Recurrent Adult Acute Myeloid Leukemia, Secondary Acute Myeloid Leukemia
    View official trial listing →
  • Terminated NCT NCT01863004

    Proteasomal Inhibition for Patients With Mis-sense Mutated Dysferlin

    Not yet reported University Hospital, Basel, Switzerland 3 participants Est. completion 2017-09-15 1 site Stand-alone
    Other conditions: Dysferlinopathy
    View official trial listing →
  • Active, not recruiting NCT NCT01863550

    Bortezomib or Carfilzomib With Lenalidomide and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported ECOG-ACRIN Cancer Research Group 1087 participants Est. completion 2034-02-05 920 sites Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Status unknown NCT NCT01868828

    A Study of PAD Versus Velcade, Cyclophosphamide and Dexamethasone (VCD) Treatment in Subjects With Multiple Myeloma

    Not yet reported Peking University People's Hospital 50 participants Est. completion 2017-05 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01873157

    Bortezomib in Late Antibody-mediated Kidney Transplant Rejection

    Not yet reported Medical University of Vienna 44 participants Est. completion 2017-02-28 1 site
    Other conditions: Late Rejection of Renal Transplant, Antibody-mediated Rejection
    View official trial listing →
  • Completed NCT NCT01891968

    Bortezomib for Low or Intermediate-1 Myelodysplastic Syndrome (MDS) With p65 Activation

    Not yet reported M.D. Anderson Cancer Center 15 participants Est. completion 2017-01-18 1 site Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Terminated NCT NCT01902862

    An Efficacy and Tolerability Study of Bortezomib in Combination With Rituximab Standard Therapy in Participants With Relapsed or Refractory Follicular Lymphoma

    Not yet reported Janssen-Cilag G.m.b.H 7 participants Est. completion 2007-08 3 sites Stand-alone
    Other conditions: Lymphoma, Follicular
    View official trial listing →
  • Completed NCT NCT01910987

    Study to Evaluate Optimized Retreatment and Prolonged Therapy With Bortezomib

    Not yet reported Janssen-Cilag International NV 80 participants Est. completion 2016-02 54 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01913730

    Maintenance Therapy With Subcutaneous Bortezomib

    Not yet reported European Myeloma Network B.V. 63 participants Est. completion 2023-09-07 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01916252

    Bortezomib (Velcade®), Lenalidomide (Revlimid®) and IV Busulfan (Busilvex®) in Patients Under 65 Years Old

    Not yet reported PETHEMA Foundation 460 participants Est. completion 2016-11-16 74 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01919086

    Response Adapted Therapy With Bortezomib/Dexamethasone Followed by Addition of Lenalidomide in Non Responders as Initial Treatment for Patients With Multiple Myeloma

    Not yet reported Memorial Sloan Kettering Cancer Center 30 participants Est. completion 2024-05-16 7 sites Stand-alone
    Other conditions: Multiple Myeloma (MM)
    View official trial listing →
  • Completed NCT NCT01926899

    A Multicenter Phase I Study Evaluating the Addition of Bortezomib to an Established Acute Graft Versus Host Disease Prophylaxis Regimen in Pediatric Allogeneic Hematopoietic Stem Cell Transplant Patients

    Not yet reported Indiana University 15 participants Est. completion 2018-03-15 2 sites Stand-alone
    Other conditions: Hematopoetic Stem Cell Transplant
    View official trial listing →
  • Completed NCT NCT01929980

    Bortezomib to Treat Significant Complication of HSCT

    Not yet reported Children's Hospital Medical Center, Cincinnati 4 participants Est. completion 2014-05 1 site Stand-alone
    Other conditions: Allogeneic Stem Cell Transplantation, Refractory Autoimmune Cytopenia(s)
    View official trial listing →
  • Completed NCT NCT01936090

    Bortezomib, Melphalan, and Total-Body Irradiation Before Stem Cell Transplant in Treating Patients With Multiple Myeloma

    Not yet reported Mayo Clinic 11 participants Est. completion 2018-02-16 1 site Stand-alone
    Other conditions: DS Stage I Plasma Cell Myeloma, DS Stage II Plasma Cell Myeloma, DS Stage III Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Status unknown NCT NCT01950611

    Proteasome Inhibition in Acute Promyelocytic Leukemia

    Not yet reported Christian Medical College, Vellore, India 30 participants Est. completion 2018-05 1 site Stand-alone
    Other conditions: Relapsed Acute Promyelocytic Leukemia
    View official trial listing →
  • Terminated NCT NCT01954784

    Lenalidomide After Donor Stem Cell Transplant and Bortezomib in Treating Patients With High Risk Multiple Myeloma

    Not yet reported Case Comprehensive Cancer Center 8 participants Est. completion 2017-01-30 1 site Stand-alone
    Other conditions: Refractory Multiple Myeloma, Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01965353

    A Phase I Study Of Panobinostat/Lenalidomide/Bortezomib/Dex for Relapsed And Relapsed/Refractory Multiple Myeloma

    Not yet reported Dana-Farber Cancer Institute 21 participants Est. completion 2021-09 4 sites Stand-alone
    Other conditions: Multiple Myeloma in Relapse
    View official trial listing →
  • Status unknown NCT NCT01965977

    Bortezomib Maintenance in High Risk DLBCL

    Not yet reported Samsung Medical Center 59 participants Est. completion 2021-10-30 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT01971658

    Efficacy Study Comparing Velcade Dexamethasone Thalidomide Versus Velcade Cyclophosphamide Dexamethasone as Induction Treatment in the Initial Management of Multiple Myeloma (IFM2013-04)

    Not yet reported Nantes University Hospital 358 participants Est. completion 2015-08 62 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT01998503

    Bortezomib and Dexamethasone Followed by ASCT Compared With ASCT Alone in Treating Patients With AL Amyloidosis

    Not yet reported Nanjing University School of Medicine 56 participants Est. completion 2013-08 1 site
    Other conditions: Amyloidosis
    View official trial listing →
  • Completed NCT NCT01998971

    A Study of JNJ-54767414 (HuMax CD38) (Anti-CD38 Monoclonal Antibody) in Combination With Backbone Treatments for the Treatment of Patients With Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 240 participants Est. completion 2024-01-11 22 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02026505

    Evaluation of Cardiotoxic Effects of Bortezomib

    Oregon Health and Science University 11 participants Est. completion 2019-03-01
    Heart failure Other conditions: Multiple Myeloma, Cardiotoxins
    View official trial listing →
  • Status unknown NCT NCT02027220

    Combination of G-CSF, Bortezomib, Cyclophosphamide and Dexamethasone in Patients With Multiple Myeloma

    Not yet reported Second Affiliated Hospital of Soochow University 60 participants Est. completion 2015-12 1 site Stand-alone
    Other conditions: Myeloma, Bortezomib, Cyclophosphamide, Dexamethasone, Granulocyte Colony-Stimulating Factor
    View official trial listing →
  • Completed NCT NCT02037256

    Bortezomib and Filgrastim to Promote Stem Cell Mobilization in Patients With Non-Hodgkin Lymphoma or Multiple Myeloma

    Not yet reported Barbara Ann Karmanos Cancer Institute 23 participants Est. completion 2015-01-21 1 site Stand-alone
    Obstructive sleep apnea Other conditions: Adult Grade III Lymphomatoid Granulomatosis, B-cell Chronic Lymphocytic Leukemia, Contiguous Stage II Adult Burkitt Lymphoma, Contiguous Stage II Adult Diffuse Large Cell Lymphoma, Contiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Contiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Contiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Contiguous Stage II Adult Lymphoblastic Lymphoma, Contiguous Stage II Grade 1 Follicular Lymphoma, Contiguous Stage II Grade 2 Follicular Lymphoma, Contiguous Stage II Grade 3 Follicular Lymphoma, Contiguous Stage II Mantle Cell Lymphoma, Contiguous Stage II Marginal Zone Lymphoma, Contiguous Stage II Small Lymphocytic Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Intraocular Lymphoma, Nodal Marginal Zone B-cell Lymphoma, Noncontiguous Stage II Adult Burkitt Lymphoma, Noncontiguous Stage II Adult Diffuse Large Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Mixed Cell Lymphoma, Noncontiguous Stage II Adult Diffuse Small Cleaved Cell Lymphoma, Noncontiguous Stage II Adult Immunoblastic Large Cell Lymphoma, Noncontiguous Stage II Adult Lymphoblastic Lymphoma, Noncontiguous Stage II Grade 1 Follicular Lymphoma, Noncontiguous Stage II Grade 2 Follicular Lymphoma, Noncontiguous Stage II Grade 3 Follicular Lymphoma, Noncontiguous Stage II Mantle Cell Lymphoma, Noncontiguous Stage II Marginal Zone Lymphoma, Noncontiguous Stage II Small Lymphocytic Lymphoma, Progressive Hairy Cell Leukemia, Initial Treatment, Recurrent Adult Burkitt Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma, Recurrent Adult Diffuse Mixed Cell Lymphoma, Recurrent Adult Diffuse Small Cleaved Cell Lymphoma, Recurrent Adult Grade III Lymphomatoid Granulomatosis, Recurrent Adult Immunoblastic Large Cell Lymphoma, Recurrent Adult Lymphoblastic Lymphoma, Recurrent Grade 1 Follicular Lymphoma, Recurrent Grade 2 Follicular Lymphoma, Recurrent Grade 3 Follicular Lymphoma, Recurrent Mantle Cell Lymphoma, Recurrent Marginal Zone Lymphoma, Recurrent Small Lymphocytic Lymphoma, Refractory Hairy Cell Leukemia, Refractory Multiple Myeloma, Small Intestine Lymphoma, Splenic Marginal Zone Lymphoma, Stage I Adult Burkitt Lymphoma, Stage I Adult Diffuse Large Cell Lymphoma, Stage I Adult Diffuse Mixed Cell Lymphoma, Stage I Adult Diffuse Small Cleaved Cell Lymphoma, Stage I Adult Immunoblastic Large Cell Lymphoma, Stage I Adult Lymphoblastic Lymphoma, Stage I Grade 1 Follicular Lymphoma, Stage I Grade 2 Follicular Lymphoma, Stage I Grade 3 Follicular Lymphoma, Stage I Mantle Cell Lymphoma, Stage I Marginal Zone Lymphoma, Stage I Multiple Myeloma, Stage I Small Lymphocytic Lymphoma, Stage II Multiple Myeloma, Stage III Adult Burkitt Lymphoma, Stage III Adult Diffuse Large Cell Lymphoma, Stage III Adult Diffuse Mixed Cell Lymphoma, Stage III Adult Diffuse Small Cleaved Cell Lymphoma, Stage III Adult Immunoblastic Large Cell Lymphoma, Stage III Adult Lymphoblastic Lymphoma, Stage III Grade 1 Follicular Lymphoma, Stage III Grade 2 Follicular Lymphoma, Stage III Grade 3 Follicular Lymphoma, Stage III Mantle Cell Lymphoma, Stage III Marginal Zone Lymphoma, Stage III Multiple Myeloma, Stage III Small Lymphocytic Lymphoma, Stage IV Adult Burkitt Lymphoma, Stage IV Adult Diffuse Large Cell Lymphoma, Stage IV Adult Diffuse Mixed Cell Lymphoma, Stage IV Adult Diffuse Small Cleaved Cell Lymphoma, Stage IV Adult Immunoblastic Large Cell Lymphoma, Stage IV Adult Lymphoblastic Lymphoma, Stage IV Grade 1 Follicular Lymphoma, Stage IV Grade 2 Follicular Lymphoma, Stage IV Grade 3 Follicular Lymphoma, Stage IV Mantle Cell Lymphoma, Stage IV Marginal Zone Lymphoma, Stage IV Small Lymphocytic Lymphoma, Untreated Hairy Cell Leukemia, Waldenström Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT02057380

    A Rollover Study for Subjects That Have Participated in an Astellas Sponsored Linsitinib Trial

    Not yet reported Astellas Pharma Global Development, Inc. 13 participants Est. completion 2016-12-21 12 sites Stand-alone
    Other conditions: Advanced Solid Tumors
    View official trial listing →
  • Withdrawn NCT NCT02082405

    Bortezomib, Dexamethasone, and Cyclophosphamide in Treating Older Patients With Multiple Myeloma

    Not yet reported Case Comprehensive Cancer Center Stand-alone
    Other conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02086942

    Tolerability and Efficacy of Modified VCD Regimens in Previously Untreated Multiple Myeloma.

    Not yet reported Yongping Zhai 94 participants Est. completion 2017-08 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02093910

    Efficacy of Monosialotetrahexosylganglioside in the Prophylactic Treatment of Bortezomib-induced Peripheral Neuropathy

    Not yet reported Sun Yat-sen University 100 participants Est. completion 2018-04 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02100657

    Study of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Patients With Multiple Myeloma

    Not yet reported PharmaMar 39 participants Est. completion 2018-06 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02102594

    Therapy of Antibody-mediated Autoimmune Diseases by Bortezomib (TAVAB)

    Not yet reported Charite University, Berlin, Germany 11 participants Est. completion 2019-08-30 2 sites Stand-alone
    Other conditions: Myasthenia Gravis, Systemic Lupus Erythematosus, Rheumatoid Arthritis
    View official trial listing →
  • Status unknown NCT NCT02109861

    Microdose Study of Melphalan, Bortezomib and Dexamethasone

    Not yet reported Henrik Gregersen 6 participants Est. completion 2015-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02112175

    Lenalidomide vs Placebo Maintenance Therapy Following Melphalan Prednisone Velcade® Induction Therapy in NDMM

    Not yet reported Celgene 46 participants Est. completion 2020-10-12 73 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT02112916

    Combination Chemotherapy With or Without Bortezomib in Treating Younger Patients With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia or Stage II-IV T-Cell Lymphoblastic Lymphoma

    Not yet reported National Cancer Institute (NCI) 847 participants Est. completion 2026-09-16 212 sites Stand-alone
    Other conditions: Adult T Acute Lymphoblastic Leukemia, Ann Arbor Stage II Adult Lymphoblastic Lymphoma, Ann Arbor Stage II Childhood Lymphoblastic Lymphoma, Ann Arbor Stage III Adult Lymphoblastic Lymphoma, Ann Arbor Stage III Childhood Lymphoblastic Lymphoma, Ann Arbor Stage IV Adult Lymphoblastic Lymphoma, Ann Arbor Stage IV Childhood Lymphoblastic Lymphoma, Childhood T Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT02136134

    Addition of Daratumumab to Combination of Bortezomib and Dexamethasone in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 498 participants Est. completion 2024-01-10 105 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02139397

    Study of Difluoromethylornithine (DFMO) in Combination With Bortezomib for Relapsed or Refractory Neuroblastoma

    Not yet reported, Not yet reported Giselle Sholler 16 participants Est. completion 2024-01-19 6 sites Stand-alone
    Other conditions: Neuroblastoma Recurrent
    View official trial listing →
  • Terminated NCT NCT02145598

    Treatment Optimization in Patients With Untreated Multiple Myeloma

    Not yet reported, Not yet reported Dr. med. Lars-Olof Muegge 85 participants Est. completion 2018-12-31 19 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02145715

    Velcade, Thalidomide, Dexamethasone and Panobinostat Treatment and Panobinostat Maintenance in Multiple Myeloma

    Not yet reported, Not yet reported Prof Jamie Cavenagh 54 participants Est. completion 2016-01 5 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02158702

    Efficacy and Toxicity Study of Pomalidomide and Dexamethasone in Patients Who Have Relapsed After Exposure to Lenalidomide and Bortezomib

    Not yet reported National University Hospital, Singapore 100 participants Est. completion 2018-11 2 sites
    Other conditions: Multiple Myeloma, Relapse After Use of Lenalidomide and Bortezomib
    View official trial listing →
  • Completed NCT NCT02164955

    A Post Authorisation Registry of IMNOVID (Pomalidomide) for Patients With Relapsed and Refractory Multiple Myeloma.

    Celgene 775 participants Est. completion 2022-10-10 122 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02178579

    Prospective Observation of Cardiac Safety With Proteasome Inhibition

    Vanderbilt University Medical Center 95 participants Est. completion 2019-07-15 2 sites
    Heart failure Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02188368

    Pomalidomide for Lenalidomide for Relapsed or Refractory Multiple Myeloma Patients

    Not yet reported Oncotherapeutics 45 participants Est. completion 2020-10-23 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02188537

    Nelfinavir as Bortezomib-sensitizing Drug in Patients With Proteasome Inhibitor-nonresponsive Myeloma

    Not yet reported Swiss Cancer Institute 34 participants Est. completion 2018-04-17 12 sites Stand-alone
    Other conditions: Myeloma
    View official trial listing →
  • Completed NCT NCT02195479

    A Study of Combination of Daratumumab and Velcade (Bortezomib) Melphalan-Prednisone (DVMP) Compared to Velcade Melphalan-Prednisone (VMP) in Participants With Previously Untreated Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 706 participants Est. completion 2024-08-07 160 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02197221

    Bortezomib-Melphalan Conditioning Regimen vs Melphalan for Frontline Transplant Eligible Patients With Multiple Myeloma

    Not yet reported University Hospital, Toulouse 300 participants Est. completion 2018-12-31 46 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02201576

    Bortezomib in Rejection of Kidney Transplants

    Not yet reported Assistance Publique - Hôpitaux de Paris 60 participants Est. completion 2020-07-16 1 site Stand-alone
    Other conditions: Chronic Antibody-mediated Transplant Rejection
    View official trial listing →
  • No Longer Available NCT NCT02204553

    Expanded Treatment Prot of Panobinostat in Combo w/ Bortez and Dex in Pts w/ Relapsed and/or Refractory Multiple Myeloma

    Novartis Pharmaceuticals 27 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02206425

    Ixazomib as a Replacement for Carfilzomib and Bortezomib for Multiple Myeloma Patients

    Not yet reported, Not yet reported Oncotherapeutics 45 participants Est. completion 2018-03-06 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02208037

    Novel Approaches for Graft-versus-Host Disease Prevention Compared to Contemporary Controls (BMT CTN 1203)

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 279 participants Est. completion 2017-10 30 sites Stand-alone
    Other conditions: Acute Leukemia, Chronic Myelogenous Leukemia, Myelodysplasia, Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Lymphoma, B-Cell, Lymphoma, Follicular, Lymphoma, Large B-Cell, Diffuse, Hodgkin's Lymphoma
    View official trial listing →
  • Completed NCT NCT02211755

    Trial of the Combination of Bortezomib and Clofarabine in Adults With Relapsed Solid Tumors

    Not yet reported National Cancer Institute (NCI) 28 participants Est. completion 2025-08-15 1 site Stand-alone
    Other conditions: Neoplasms, Myelodysplastic Syndromes, Lymphomas
    View official trial listing →
  • Completed NCT NCT02219178

    Study of the Efficacy and Safety of RsqVD Combination Therapy for Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Cancer Trials Ireland 42 participants Est. completion 2020-04 8 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02220049

    Dose Escalation of Velcade Daily Dose in Patients With Solid Tumors

    Not yet reported Gustave Roussy, Cancer Campus, Grand Paris 18 participants Est. completion 2013-11 1 site Stand-alone
    Other conditions: Advanced or Metastatic Solid Tumors
    View official trial listing →
  • Completed NCT NCT02220608

    Phase I Study of Bortezomib With G-CSF for Stem Cell Mobilization in Patients With Multiple Myeloma

    Not yet reported Washington University School of Medicine 10 participants Est. completion 2016-11-30 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02224729

    Bendamustine Hydrochloride, Bortezomib, and Dexamethasone in Treating Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University 24 participants Est. completion 2018-11-17 1 site Stand-alone
    Other conditions: Stage I Multiple Myeloma, Stage II Multiple Myeloma, Stage III Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02237261

    Bendamustine, Prednisone and Velcade® for First-line Treatment of Patients With Symptomatic Multiple Myeloma

    Not yet reported University Hospital Heidelberg 46 participants Est. completion 2018-10 15 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02254551

    Safety/Efficacy Study of LDE225 (Sonidegib) Plus Bortezomib in Patients With Relapsed or Relapsed/Refractory Multiple Myeloma

    Not yet reported SCRI Development Innovations, LLC 7 participants Est. completion 2015-10 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02265510

    An Open-Label Study of a Novel JAK-inhibitor, INCB052793, Given to Patients With Advanced Malignancies

    Not yet reported, Not yet reported Incyte Corporation 83 participants Est. completion 2019-02-27 14 sites Stand-alone
    Other conditions: Solid Tumors, Advanced Malignancies, Metastatic Cancer
    View official trial listing →
  • Completed NCT NCT02268890

    A Pharmacokinetic Study of Bortezomib in Taiwanese Participants With Multiple Myeloma

    Not yet reported Johnson & Johnson Taiwan Ltd 18 participants Est. completion 2015-07 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02290431

    Study of Panobinostat in Combination With Bortezomib and Dexamethasone in Japanese Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported Novartis Pharmaceuticals 31 participants Est. completion 2018-12-25 20 sites Stand-alone
    Other conditions: Relapse/Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02308280

    Nonmyeloablative Allogeneic Stem Cell Transplant Followed by Bortezomib in High-risk Multiple Myeloma Patients

    Not yet reported Maisonneuve-Rosemont Hospital 40 participants Est. completion 2023-09-27 1 site Stand-alone
    Other conditions: Multiple Myeloma, High-Risk Cancer
    View official trial listing →
  • Completed NCT NCT02312102

    Velcade and Lenalidomide in Patients With Relapsed AML and MDS After Allogeneic Stem Cell Transplantation

    Not yet reported Massachusetts General Hospital 22 participants Est. completion 2024-10-07 2 sites Stand-alone
    Other conditions: Myelodysplastic Syndrome, Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT02322320

    Continued, Long-Term Follow-Up and Lenalidomide Maintenance Therapy for Patients on BMT CTN 0702 Protocol (BMT CTN 07LT)

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 273 participants Est. completion 2019-06-07 42 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02336386

    CDD Plus Bortezomib or CDDin Relapsed or Refractory Multiple Myeloma With Extramedullary Plasmacytoma

    Not yet reported Beijing Chao Yang Hospital 100 participants Est. completion 2016-12 1 site Stand-alone
    Other conditions: Extramedullary Plasmacytoma
    View official trial listing →
  • Completed NCT NCT02336815

    Selinexor Treatment of Refractory Myeloma

    Not yet reported Karyopharm Therapeutics Inc 202 participants Est. completion 2019-07-26 61 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02351427

    Bortezomib With Steroid Pulse Therapy for Acute Cellular Rejection in Kidney Transplantation

    Not yet reported Asan Medical Center 30 participants Est. completion 2015-12 1 site
    Other conditions: Kidney Transplantation
    View official trial listing →
  • Completed NCT NCT02352558

    A Study of BBI608 in Adult Patients With Advanced, Refractory Hematologic Malignancies

    Not yet reported Sumitomo Pharma America, Inc. 15 participants Est. completion 2019-05-16 8 sites Stand-alone
    Other conditions: Hematologic Malignancy
    View official trial listing →
  • Terminated NCT NCT02353468

    Bortezomib, Lenalidomide, and Dexamethasone in Treating Patients With Multiple Myeloma Undergoing Stem Cell Transplant

    Not yet reported University of Colorado, Denver 3 participants Est. completion 2011-10 1 site Stand-alone
    Other conditions: Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT02353572

    Melphalan and Bortezomib Prior to Autologous Stem Cell Transplant in Treating Patients With Multiple Myeloma

    Not yet reported, Not yet reported University of Colorado, Denver 3 participants Est. completion 2011-09 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma, Plasmacytosis, Recurrent Plasma Cell Myeloma, Smoldering Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT02356458

    Combination of Ibrutinib and Bortezomib to Treat Patients With Mantle Cell Lymphoma

    Not yet reported, Not yet reported Swiss Cancer Institute 58 participants Est. completion 2021-03-30 19 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT02362165

    CyBorD vs. PAD in the Treatment of Newly Diagnosed Multiple Myeloma

    Not yet reported Sun Yat-sen University 236 participants Est. completion 2018-05 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02370693

    Comparing and Combining Bortezomib and Mycophenolate in SSc Pulmonary Fibrosis

    Not yet reported Northwestern University 9 participants Est. completion 2020-01-01 1 site
    Other conditions: Lung Diseases, Interstitial, Systemic Sclerosis, Scleroderma
    View official trial listing →
  • Completed NCT NCT02371148

    Fase II Study With BRB for Non-Hodgkin Lymphoplasmacytic Lymphoma/Waldenstrom Macroglobulinemia's

    Not yet reported Fondazione Italiana Linfomi - ETS 38 participants Est. completion 2020-07-22 23 sites Stand-alone
    Other conditions: Waldenstrom's Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT02375555

    Study of Bortezomib,Lenalidomide,Dexamethasone & Elotuzumab in Newly Diagnosed MM

    Not yet reported Dana-Farber Cancer Institute 40 participants Est. completion 2024-01-26 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02419755

    Bortezomib and Vorinostat in Younger Patients With Refractory or Relapsed MLL Rearranged Hematologic Malignancies

    Not yet reported St. Jude Children's Research Hospital 12 participants Est. completion 2016-12-31 1 site Stand-alone
    Other conditions: Mixed Lineage Acute Leukemia, Acute Myeloid Leukemia, Acute Lymphoid Leukemia
    View official trial listing →
  • Completed NCT NCT02424851

    Optimising Renal Outcome in Myeloma Renal Failure

    Not yet reported Oxford University Hospitals NHS Trust 31 participants Est. completion 2020-04-20 9 sites
    Chronic kidney disease Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02440464

    Allogeneic Hematopoietic Stem Cell Transplantation With Ixazomib for High Risk Multiple Myeloma (BMT CTN 1302)

    Not yet reported National Heart, Lung, and Blood Institute (NHLBI) 57 participants Est. completion 2020-10-01 15 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02441686

    Phase II Study of Efficacy and Safety of Lenalidomide, Subcutaneous Bortezomib and Dexamethasone Therapy for Newly Diagnosed Multiple Myeloma

    Not yet reported Dana-Farber Cancer Institute 46 participants Est. completion 2025-10 8 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02461888

    Phase II Randomised Trial of Cyclophosphamide & Dexamethasone in Combination With Ixazomib in Relapsed or Refractory Multiple Myeloma.

    Not yet reported University of Leeds 112 participants Est. completion 2025-01-19 18 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02467010

    Relapse Myeloma; Cyclofosfamide; Bortezomib; Maintenance

    Not yet reported University Medical Center Groningen 73 participants Est. completion 2013-07 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02474563

    Observational Study to Evaluate the Efficacy and Safety of Bortezomib, Melphalan, Prednisone (VMP) in Participants With Multiple Myeloma

    Janssen Korea, Ltd., Korea 171 participants Est. completion 2014-05 18 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02481934

    Clinical Trial of Expanded and Activated Autologous NK Cells to Treat Multiple Myeloma

    Not yet reported Joaquín Martínez López, MD, PhD 5 participants Est. completion 2016-10 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02484261

    Monitoring and Treatment of Relapsed Leukemia Following Allogeneic Hematopoietic Stem Cell Transplantation in Children

    Not yet reported Reuven Schore 10 participants 1 site Stand-alone
    Other conditions: Leukemia
    View official trial listing →
  • Completed NCT NCT02485613

    Bortezomib for Immunoglobulin Light Chain(AL) Amyloidosis

    Zhi-Hong Liu, M.D. 72 participants Est. completion 2015-03
    Other conditions: Amyloidosis
    View official trial listing →
  • Terminated NCT NCT02489500

    Trial of High Dose Melphalan/Stem Cell Transplant With or Without Bortezomib

    Not yet reported Boston Medical Center 3 participants Est. completion 2017-04-28 1 site Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Completed NCT NCT02495922

    A Phase III Trial on the Effect of Elotuzumab in VRD Induction /Consolidation and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma

    Not yet reported University of Heidelberg Medical Center 564 participants Est. completion 2021-06-24 68 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02497378

    A Study of JNJ-54767414 (Daratumumab) in Combination With Bortezomib and Dexamethasone (D-Vd) in Japanese Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Pharmaceutical K.K. 8 participants Est. completion 2018-03-06 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02500251

    Belimumab Impacting Transplant Eligibility

    Not yet reported, Not yet reported E. Steve Woodle 11 participants Est. completion 2018-08 2 sites Stand-alone
    Other conditions: Renal Transplant Rejection
    View official trial listing →
  • Completed NCT NCT02513186

    Study of Isatuximab Combined With Bortezomib + Cyclophosphamide + Dexamethasone (VCD) and Bortezomib + Lenalidomide + Dexamethasone (VRD) in Newly Diagnosed Multiple Myeloma (MM) Non Eligible for Transplant or No Intent for Immediate Transplantation

    Not yet reported Sanofi 90 participants Est. completion 2024-01-22 12 sites Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT02514382

    Wild-Type Reovirus, Bortezomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported University of Southern California 14 participants Est. completion 2022-04-19 1 site Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT02518750

    Re-Induction Therapy for Relapsed Pediatric T-Cell Acute Lymphoblastic Leukemia or Lymphoma

    Not yet reported St. Jude Children's Research Hospital 3 participants Est. completion 2018-03-11 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Lymphoma, Non-Hodgkin's, Leukemia, T-Cell, Leukemia, B-Cell
    View official trial listing →
  • Status unknown NCT NCT02522572

    Quantitating the Impact of Plerixafor

    Not yet reported, Not yet reported E. Steve Woodle 12 participants Est. completion 2020-10 2 sites Stand-alone
    Other conditions: Transplants and Implants
    View official trial listing →
  • Status unknown NCT NCT02525172

    Immune Modulation Therapy for Pompe Disease

    Not yet reported National Taiwan University Hospital 8 participants Est. completion 2020-07 1 site Stand-alone
    Other conditions: Pompe Disease
    View official trial listing →
  • Terminated NCT NCT02535806

    Four Drug Reinduction With Bortezomib for Relapsed or Refractory ALL or LL in Children and Young Adults

    Not yet reported Children's Mercy Hospital Kansas City 2 participants Est. completion 2017-05-25 1 site
    Other conditions: Acute Lymphoblastic Leukemia, Lymphoblastic Lymphoma
    View official trial listing →
  • Completed NCT NCT02541383

    A Study to Evaluate Daratumumab in Transplant Eligible Participants With Previously Untreated Multiple Myeloma

    Not yet reported Intergroupe Francophone du Myelome 1085 participants Est. completion 2023-09-01 107 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02542111

    A Study of Bortezomib Plus GDP in the Treatment of Refractory and Relapsed Non-GCB DLBCL

    Not yet reported Ruijin Hospital 30 participants Est. completion 2018-05 1 site Stand-alone
    Other conditions: Diffuse Large B-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02551718

    High Throughput Drug Sensitivity Assay and Genomics- Guided Treatment of Patients With Relapsed or Refractory Acute Leukemia

    Not yet reported University of Washington 34 participants Est. completion 2021-05-13 1 site Stand-alone
    Other conditions: Recurrent Acute Leukemia of Ambiguous Lineage, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Acute Leukemia of Ambiguous Lineage
    View official trial listing →
  • Active, not recruiting NCT NCT02553460

    Total Therapy for Infants With Acute Lymphoblastic Leukemia (ALL) I

    Not yet reported, Not yet reported St. Jude Children's Research Hospital 50 participants Est. completion 2031-10 15 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia
    View official trial listing →
  • Completed NCT NCT02555839

    Treatment of Relapsed/Refractory Multiple Myeloma (rrMM) With Pomalidomide in Clinical Practice

    Celgene 127 participants Est. completion 2023-06-30 13 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02559154

    Modified Bortezomib-based Combination Therapy for Multiple Myeloma

    Not yet reported Shanghai General Hospital, Shanghai Jiao Tong University School of Medicine 80 participants Est. completion 2018-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02563340

    Effect of BM-MSCs on Chronic AMR After Kidney Transplantation

    Not yet reported, Not yet reported First Affiliated Hospital, Sun Yat-Sen University 60 participants Est. completion 2017-11 1 site Stand-alone
    Other conditions: Kidney Transplantation
    View official trial listing →
  • No Longer Available NCT NCT02568943

    An Expanded Treatment Protocol of Panobinostat in Combination Therapy for Relapsed, and Relapsed and Refractory Multiple Myeloma

    Novartis Pharmaceuticals 40 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02573935

    Clarithromycin in Multiple Myeloma Induction Therapy

    Not yet reported Henrik Gregersen 58 participants Est. completion 2016-09 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02577783

    PDD vs PAD to Treat Initially Diagnosed MM

    Not yet reported The First Affiliated Hospital of Soochow University 64 participants Est. completion 2021-12 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT02605356

    Phase 1b/2 Study Testing Radium-223 Dichloride/Bortezomib/Dexamethasone Combination in Relapsed Multiple Myeloma

    Not yet reported, Not yet reported Bayer Est. completion 2021-07 58 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02613598

    Dose Escalation Study to Determine the Maximum Tolerated Dose of the Combination of Ruxolitinib and Bortezomib in Patients With Relapsed or Refractory Lymphoma

    Not yet reported University of Michigan Rogel Cancer Center 15 participants Est. completion 2021-06-07 1 site Stand-alone
    Other conditions: Hodgkin's Lymphoma, Lymphoma, Non-Hodgkin
    View official trial listing →
  • Completed NCT NCT02626481

    Study of Daratumumab in Combination With Dexamethasone in Resistant or Refractory Multiple Myeloma

    Not yet reported University Hospital, Lille 64 participants Est. completion 2020-03-09 41 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02654990

    Panobinostat/Bortezomib/Dexamethasone in Relapsed or Relapsed-and-refractory Multiple Myeloma

    Not yet reported pharmaand GmbH 248 participants Est. completion 2022-08-15 80 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT02658396

    GO-203-2C + Bortezomib For Relapsed Or Refractory MM

    Not yet reported Dana-Farber Cancer Institute Est. completion 2022-01 2 sites Stand-alone
    Other conditions: Multiple Myeloma, Multiple Myeloma in Relapse, Refractory Multiple Myeloma
    View official trial listing →
  • No Longer Available NCT NCT02666209

    Early Patient Access Single Named Patient Program for the Use of Ulocuplumab for the Treatment of Multiple Myeloma

    Dana-Farber Cancer Institute 1 site
    Other conditions: Multiple Myeloma in Relapse, Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02703779

    Exploratory Trial to Estimate Proportion of Patients With Tumor Cell Contaminated Leukapheresis Products With and Without Bortezomib With In-vivo Purging - Multiple Myeloma (MM)

    Not yet reported Siddhartha Ganguly 101 participants Est. completion 2020-04-08 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT02718833

    A Study of Elotuzumab With Pomalidomide, Bortezomib, and Dexamethasone in Relapsed Multiple Myeloma

    Not yet reported Massachusetts General Hospital 52 participants Est. completion 2027-12 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02719613

    Continuing Treatment for Participants Who Have Participated in a Prior Protocol Investigating Elotuzumab

    Not yet reported Bristol-Myers Squibb 67 participants Est. completion 2026-02-23 41 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02720510

    A Trial Evaluating Efficacy & Safety of RVD +/- Panobinostat in Transplant Eligible, Newly Diagnosed Multiple Myeloma (NDMM)

    Not yet reported Novartis Pharmaceuticals 6 participants Est. completion 2017-05-22 5 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02755597

    A Study Evaluating Venetoclax (ABT-199) in Multiple Myeloma Subjects Who Are Receiving Bortezomib and Dexamethasone as Standard Therapy

    Not yet reported AbbVie 291 participants Est. completion 2022-08-15 97 sites Stand-alone
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT02773030

    A Study to Determine Dose, Safety, Tolerability and Efficacy of CC-220 Monotherapy, and in Combination With Other Treatments in Subjects With Multiple Myeloma

    Not yet reported, Not yet reported Celgene 466 participants Est. completion 2028-07-28 162 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02773550

    Treatment With a Scheme With Low Doses of Bortezomib / Melphalan / Prednisone (MPV) in Patients With Multiple Myeloma

    Not yet reported Basque Health Service 24 participants Est. completion 2018-07 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02783625

    Trial of Duvelisib in Combination With Either Romidepsin or Bortezomib in Relapsed/Refractory T-cell Lymphomas

    Not yet reported Memorial Sloan Kettering Cancer Center 114 participants Est. completion 2026-04-21 11 sites Stand-alone
    Other conditions: Lymphoma, Relapsed/Refractory T-cell Lymphomas
    View official trial listing →
  • Completed NCT NCT02788201

    Genomic Based Assignment of Therapy in Advanced Urothelial Carcinoma

    Not yet reported National Cancer Institute (NCI) 8 participants Est. completion 2019-10-23 1 site Stand-alone
    Other conditions: Urothelial Carcinoma, Bladder Cancer, Urinary Bladder Neoplasms
    View official trial listing →
  • Status unknown NCT NCT02797041

    Bortezomib as First Salvage Therapy for Myeloma Patients Previously Exposed to Bortezomib as Initial Treatment.

    IRCCS Centro di Riferimento Oncologico della Basilicata 100 participants Est. completion 2016-06
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02808091

    Bortezomib With Combination of Gemcitabine, Ifosfamide and Oxaliplatin in Untreated NK/T Cell Lymphoma

    Not yet reported National Cancer Centre, Singapore 7 participants Est. completion 2014-03 1 site Stand-alone
    Other conditions: Extranodal NK-T-CELL LYMPHOMA
    View official trial listing →
  • Completed NCT NCT02811822

    A Study to Determine the Efficacy, Safety and Pharmacokinetics of GMI-1271 as Adjunct to Standard of Care for the Treatment of Multiple Myeloma

    Not yet reported GlycoMimetics Incorporated 10 participants Est. completion 2019-04 8 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02811978

    Study of Subcutaneous and Intravenous Velcade in Combination With Dexamethasone in Chinese Subjects With Relapsed and Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 81 participants Est. completion 2018-11-10 10 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02840539

    Trial of Bortezomib, Cytarabine, and Dexamethasone in Mantle Cell Lymphoma

    Not yet reported Seoul National University Hospital 19 participants Est. completion 2022-12-31 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Completed NCT NCT02844322

    The Comparison of RCD Versus BCD in Newly Diagnosed Waldenström Macroglobulinemia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 35 participants Est. completion 2023-05 1 site Stand-alone
    Other conditions: Waldenström Macroglobulinemia
    View official trial listing →
  • Completed NCT NCT02858999

    Treatment of Primary Plasma Cell Leukaemia in Subjects Under the Age of 70

    Not yet reported Centre Hospitalier Universitaire, Amiens 40 participants Est. completion 2016-09 18 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02874742

    Study Comparing Daratumumab, Lenalidomide, Bortezomib, and Dexamethasone (D-RVd) Versus Lenalidomide, Bortezomib, and Dexamethasone (RVd) in Subjects With Newly Diagnosed Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 224 participants Est. completion 2022-04-08 36 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02877082

    Tacrolimus, Bortezomib, & Thymoglobulin in Preventing Low Toxicity GVHD in Donor Blood Stem Cell Transplant Patients

    Not yet reported Emory University 5 participants Est. completion 2017-07 1 site Stand-alone
    Other conditions: Acute Leukemia, Chronic Lymphocytic Leukemia, Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Diffuse Large B-Cell Lymphoma, Follicular Lymphoma, Graft Versus Host Disease, Mantle Cell Lymphoma, Marginal Zone Lymphoma, Myelodysplastic Syndrome, Myelofibrosis, Myeloproliferative Neoplasm, Small Lymphocytic Lymphoma
    View official trial listing →
  • Completed NCT NCT02893111

    Efficacy and Safety of Bortezomib as add-on Treatment in Relapsing Neuromyelitis Optica Spectrum Disorder

    Not yet reported Tianjin Medical University General Hospital 5 participants Est. completion 2017-01-31 1 site Stand-alone
    Other conditions: Neuromyelitis Optica Spectrum Disorder
    View official trial listing →
  • Completed NCT NCT02902965

    Study of Ibrutinib in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed/Relapsed and Refractory Multiple Myeloma

    Not yet reported Pharmacyclics Switzerland GmbH 74 participants Est. completion 2018-10-26 33 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT02928029

    Study Testing Radium-223 Dichloride in Relapsed Multiple Myeloma

    Not yet reported, Not yet reported Bayer 7 participants Est. completion 2019-03-20 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT02951819

    A Study to Evaluate Dara-CyBorD in Previously Untreated and Relapsed Subjects With Multiple Myeloma

    Not yet reported Janssen Scientific Affairs, LLC 101 participants Est. completion 2020-08-17 26 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02955810

    Cyclophosphamide-Bortezomib-Dexamethasone (CyBorD) With Daratumumab (DARA)

    Not yet reported National University of Ireland, Galway, Ireland 18 participants Est. completion 2020-11 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02971982

    PCD Versus RCD for the Treatment of Patients With Waldenstrom's Macroglobulinemia

    Not yet reported, Not yet reported The First Affiliated Hospital of Soochow University 40 participants Est. completion 2018-12 1 site
    Other conditions: Treatment
    View official trial listing →
  • Status unknown NCT NCT02976272

    Neurotoxic Effect of Bortezomib Treatment in Patient With Myeloma Multiple

    University Hospital, Clermont-Ferrand 60 participants Est. completion 2021-01-31 1 site
    Other conditions: Multiple Myeloma, Bortezomib Regimen, Adult
    View official trial listing →
  • Completed NCT NCT02977494

    Daratumumab in Combination With Bortezomib and Dexamethasone in Subjects With Relapsed or Relapsed and Refractory Multiple Myeloma and Severe Renal Impairment

    Not yet reported Universitätsklinikum Hamburg-Eppendorf 22 participants Est. completion 2021-06 10 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT02981199

    Microtransplantation Versus Auto-SCT in ≥PR Multiple Myeloma Patients

    Not yet reported Chen Wenming 80 participants Est. completion 2019-12 1 site
    Other conditions: Microtransplantation, Autologous Stem Cell Transplantation, Multiple Myeloma in Relapse
    View official trial listing →
  • Withdrawn NCT NCT03000634

    2015-09: a Phase II Randomized, Open-label Study of Anti-signaling Lymphocytic Activation Molecule Monoclonal Antibody During Maintenance Therapy

    Not yet reported University of Arkansas Est. completion 2017-04-01 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03001804

    Use Lenalidomide (Revlimid®) in Combination With Dexamethasone in Clinical Practice for the Treatment of Newly Diagnosed Multiple Myeloma (MM) Transplant Ineligible Patients

    Celgene 29 participants Est. completion 2022-12-16 12 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03004287

    2015-12: A Study Exploring the Use of Early and Late Consolidation/Maintenance Therapy

    Not yet reported University of Arkansas 50 participants Est. completion 2028-10 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03013114

    A Single-center Clinical Trial of Bortezomib in Management of Immune Thrombocytopenia (ITP)

    Not yet reported Shandong University 20 participants Est. completion 2017-12 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia
    View official trial listing →
  • Status unknown NCT NCT03016988

    The Efficacy and Safety of Bortezomib Combined With Fludarabine and Cytarabine Treatment for Mantle Cell Lymphoma

    Not yet reported Tingbo Liu 50 participants Est. completion 2020-12
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Terminated NCT NCT03044353

    Multiple Treatment Session Study to Assess GSK2398852 Administered Following and Along With GSK2315698

    Not yet reported GlaxoSmithKline 7 participants Est. completion 2019-01-03 3 sites Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Status unknown NCT NCT03051841

    CKD-581 + Bortezomib + Dexamethasone in Patients With Previously Treated Multiple Myeloma

    Not yet reported Chong Kun Dang Pharmaceutical 18 participants Est. completion 2022-11 1 site Stand-alone
    Other conditions: Myeloma, Multiple
    View official trial listing →
  • Completed NCT NCT03053024

    Study of Bortezomib (BTZ) Treatment on Mantle Cell Lymphoma (MCL) in Chinese Participants

    Xian-Janssen Pharmaceutical Ltd. 54 participants Est. completion 2019-09-30 9 sites
    Other conditions: Lymphoma, Mantle-Cell
    View official trial listing →
  • Completed NCT NCT03056599

    Precise Local Injection of Anti-cancer Drugs Using Presage's CIVO Device in Soft Tissue Sarcoma

    Not yet reported Presage Biosciences 23 participants Est. completion 2021-09-22 3 sites
    Other conditions: Soft Tissue Sarcoma Adult
    View official trial listing →
  • Status unknown NCT NCT03089411

    Collection of Additional Data Followed the Study IFM 2013-04

    Nantes University Hospital 340 participants Est. completion 2017-07-15 63 sites
    Other conditions: Myeloma Multiple
    View official trial listing →
  • Status unknown NCT NCT03103555

    Treatment of Adult-Onset Immunodeficiency With Bortezomib

    Not yet reported Mahidol University 5 participants Est. completion 2019-11-01 1 site Stand-alone
    Other conditions: Adult-onset Immunodeficiency
    View official trial listing →
  • Completed NCT NCT03110562

    Bortezomib, Selinexor, and Dexamethasone in Patients With Multiple Myeloma

    Not yet reported Karyopharm Therapeutics Inc 402 participants Est. completion 2022-05-12 157 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT03117361

    Trial of Plitidepsin (Aplidin®) in Combination With Bortezomib and Dexamethasone in Multiple Myeloma Patients Double Refractory to Bortezomib and Lenalidomide

    Not yet reported PharmaMar 10 participants Est. completion 2018-07-30 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03117751

    Total Therapy XVII for Newly Diagnosed Patients With Acute Lymphoblastic Leukemia and Lymphoma

    Not yet reported, Not yet reported St. Jude Children's Research Hospital 790 participants Est. completion 2028-09-30 8 sites Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Acute Lymphoblastic Lymphoma
    View official trial listing →
  • Completed NCT NCT03129828

    Ibrutinib, Bortezomib and Rituximab-CHOP for the Treatment of Elderly Patients With CD20+ DLBCL, IPI ≥ 2

    Not yet reported, Not yet reported Prof. Dr. Clemens Schmitt 38 participants Est. completion 2024-11-12 1 site Stand-alone
    Other conditions: Diffuse Large B Cell Lymphoma
    View official trial listing →
  • Withdrawn NCT NCT03130348

    Ibrutinib With or Without Bortezomib and Dexamethasone in Treating Patients With Relapsed or Refractory Immunoglobulin Light Chain Amyloidosis

    Not yet reported Mayo Clinic Est. completion 2022-04 Stand-alone
    Other conditions: Amyloidosis, Immunoglobulin Light Chain Deposition
    View official trial listing →
  • Completed NCT NCT03136653

    A Phase 2 Trial of MP0250 Plus Bortezomib + Dexamethasone in Patients With Multiple Myeloma

    Not yet reported, Not yet reported Molecular Partners AG 33 participants Est. completion 2021-01-13 24 sites Stand-alone
    Other conditions: Multiple Myeloma in Relapse
    View official trial listing →
  • Withdrawn NCT NCT03168100

    2017-03: A Single-Arm, Open-label Study of Anti-Signaling Lymphocytic Activation Molecule F7 (Anti-SLAMF7) Monoclonal Antibody (mAb) Therapy After Autologous Stem Cell Transplant in Patients With Multiple Myeloma

    Not yet reported University of Arkansas Est. completion 2019-01-24 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT03173092

    A Study of Ixazomib (NINLARO®) in Combination With Lenalidomide and Dexamethasone (IRD) for the Treatment of Participants With Multiple Myeloma (MM)

    Not yet reported Takeda 141 participants Est. completion 2026-03-30 21 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03188172

    MUK Nine b: OPTIMUM Treatment Protocol

    Not yet reported University of Leeds 95 participants Est. completion 2026-05-31 21 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03201965

    A Study to Evaluate the Efficacy and Safety of Daratumumab in Combination With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared to CyBorD Alone in Newly Diagnosed Systemic Amyloid Light-chain (AL) Amyloidosis

    Not yet reported Janssen Research & Development, LLC 416 participants Est. completion 2024-11-19 140 sites Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Status unknown NCT NCT03210753

    Study of Risk Factors and Genetic Association With Bortezomib-induced Peripheral Neuropathy in Multiple Myeloma

    National Taiwan University Hospital 400 participants Est. completion 2020-07 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03217812

    A Study of VELCADE (Bortezomib) Melphalan-Prednisone (VMP) Compared to Daratumumab in Combination With VMP (D-VMP), in Participants With Previously Untreated Multiple Myeloma Who Are Ineligible for High-Dose Therapy (Asia Pacific Region)

    Not yet reported Janssen Research & Development, LLC 220 participants Est. completion 2024-03-08 44 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03234972

    A Study to Compare Daratumumab, Bortezomib, and Dexamethasone (DVd) vs Bortezomib and Dexamethasone (Vd) in Chinese Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 213 participants Est. completion 2024-02-27 27 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03242460

    The Safety and Efficacy of Pomalidomide in Combination With Cyclophosphamide and Dexamethasone (PCD) in the Transplant-ineligible Patients With Relapsed and/or Refractory Multiple Myeloma (MM)

    Not yet reported Kosin University Gospel Hospital 55 participants Est. completion 2019-05-02 1 site
    Other conditions: Relapsed and/or refractorY Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03314181

    A Study of Combination Therapy With Venetoclax, Daratumumab and Dexamethasone (With and Without Bortezomib) in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported AbbVie 156 participants Est. completion 2031-05 40 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03319667

    A Study to Investigate the Clinical Benefit of Isatuximab in Combination With Bortezomib, Lenalidomide and Dexamethasone in Adults With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

    Not yet reported Sanofi 475 participants Est. completion 2027-06-30 104 sites Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Status unknown NCT NCT03335098

    Study of VTD in Waldenstrom's Macroglobulinemia

    Not yet reported Seoul National University Hospital 15 participants Est. completion 2020-12 2 sites Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia, Lymphoplasmacytic Lymphoma
    View official trial listing →
  • Completed NCT NCT03344328

    Prevalence, Intensity and Consequences of Bortezomib-induced Neuropathic Disorders.

    University Hospital, Clermont-Ferrand 67 participants Est. completion 2020-01-31 1 site
    Other conditions: Chemotherapy Induced Peripheral Neuropathy, Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03345303

    Bortezomib in Intrahepatic Cholangiocellular Carcinoma

    Not yet reported Zhengang Yuan 50 participants Est. completion 2022-12 1 site Stand-alone
    Other conditions: Intrahepatic Cholangiocarcinoma
    View official trial listing →
  • Status unknown NCT NCT03390387

    Childhood Acute Lymphoblastic Leukemia Treatment Protocol Moscow-Berlin 2015 (ALL-MB 2015)

    Not yet reported Federal Research Institute of Pediatric Hematology, Oncology and Immunology 4000 participants Est. completion 2025-11 58 sites Stand-alone
    Other conditions: Childhood Acute Lymphoblastic Leukemia
    View official trial listing →
  • Withdrawn NCT NCT03393273

    Elotuzumab in Patients With Multiple Myeloma Before and After Peripheral Stem Cell Autologous Graft

    Not yet reported Assistance Publique - Hôpitaux de Paris Est. completion 2019-01-15 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03401372

    BCD With or Without Doxycycline in Mayo Stage II-III Light Chain Amyloidosis Patients

    Not yet reported Jian Li 140 participants Est. completion 2020-12-31 1 site Stand-alone
    Other conditions: Amyloidosis; Systemic
    View official trial listing →
  • Completed NCT NCT03402295

    Superiority of VCD Versus CTD in Patients With Newly Diagnose Multiple Myeloma Eligible for Transplantation

    Not yet reported Grupo de Estudos Multicentricos em Onco-Hematologia 311 participants Est. completion 2017-10-15
    Other conditions: Multiple Myeloma, Effects of Chemotherapy
    View official trial listing →
  • Completed NCT NCT03412565

    A Study to Evaluate Subcutaneous Daratumumab in Combination With Standard Multiple Myeloma Treatment Regimens

    Not yet reported Janssen Research & Development, LLC 265 participants Est. completion 2024-04-18 64 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03416374

    A Study to Evaluate the Efficacy and Safety of Ixazomib in Combination With Lenalidomide and Dexamethasone in Patients With Relapsed and/or Refractory Multiple Myeloma Initially Treated With an Injection of Proteasome Inhibitor-Based Therapy

    Not yet reported Takeda 45 participants Est. completion 2021-05-28 23 sites Stand-alone
    Other conditions: Relapsed and/or Refractory Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT03422874

    Dose Escalation Study of Nelfinavir Plus MLN9708 in Patients With Advanced Solid Tumors or Lymphoma

    Not yet reported Dartmouth-Hitchcock Medical Center Est. completion 2017-08-04 1 site Stand-alone
    Other conditions: Neoplasms, Lymphoma
    View official trial listing →
  • Status unknown NCT NCT03443570

    Rituximab Combining Bortezomib Versus Rituximab in Management of ITP

    Not yet reported Shandong University 200 participants Est. completion 2021-03-01 1 site Stand-alone
    Other conditions: Immune Thrombocytopenia, Purpura, Thrombocytopenic, Idiopathic
    View official trial listing →
  • Terminated NCT NCT03474458

    A Trial of Doxycycline vs. Standard Supportive Therapy in Newly-diagnosed Cardiac AL Amyloidosis Patients Undergoing Bortezomib-based Therapy

    Not yet reported, Not yet reported Fondazione IRCCS Policlinico San Matteo di Pavia 19 participants Est. completion 2022-05-30 8 sites
    Other conditions: Cardiac AL Amyloidosis
    View official trial listing →
  • Terminated NCT NCT03481556

    Study of Melphalan Flufenamide (Melflufen) + Dex With Bortezomib or Daratumumab in Patients With RRMM

    Not yet reported, Not yet reported Oncopeptides AB 56 participants Est. completion 2022-02-02 16 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03487133

    Bortezomib/Dexamethasone Therapy in Patients With Relapsed and/or Refractory Cutaneous T-cell Lymphoma

    Not yet reported Samsung Medical Center 32 participants Est. completion 2020-09-30 1 site Stand-alone
    Other conditions: Relapsed and/or Refractory Cutaneous T-cell Lymphoma
    View official trial listing →
  • Completed NCT NCT03493737

    Cost-Utility Analysis Hospital Versus Home in Multiple Myeloma

    Central Hospital, Nancy, France 43 participants Est. completion 2020-02-15 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03509246

    Bortezomib and Pegylated Liposomal Doxorubicin in BRCA Wild-type Platinum-resistant Recurrent Ovarian Cancer Patients

    Not yet reported Seoul National University Hospital 44 participants Est. completion 2022-03 1 site Stand-alone
    Other conditions: Ovarian Neoplasm Epithelial, High Grade Serous Carcinoma
    View official trial listing →
  • Terminated NCT NCT03515200

    Treatment With Combination Chemotherapy for Relapsed or Refractory Acute Lymphoblastic Leukemia

    Not yet reported St. Jude Children's Research Hospital 12 participants Est. completion 2020-07-29 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, in Relapse, Acute Lymphoblastic Leukemia With Failed Remission
    View official trial listing →
  • Completed NCT NCT03544281

    To Evaluate Safety, Tolerability, and Clinical Activity of the Antibody-drug Conjugate, GSK2857916 Administered in Combination With Lenalidomide Plus Dexamethasone (Arm A), or in Combination With Bortezomib Plus Dexamethasone (Arm B) in Participants With Relapsed/Refractory Multiple Myeloma (RRMM)

    Not yet reported, Not yet reported GlaxoSmithKline 153 participants Est. completion 2024-02-28 26 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03589222

    SELIBORDARA: Selinexor, Bortezomib and Daratumumab in Multiple Myeloma

    Not yet reported PETHEMA Foundation 62 participants Est. completion 2026-08 15 sites Stand-alone
    Other conditions: Refractory Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT03591744

    Daratumumab, Bortezomib, Dexamethasone, Pegylated Liposomal Doxorubicin Hydrochloride, and Lenalidomide in Treating Participants With Plasma Cell Leukemia

    Not yet reported City of Hope Medical Center Est. completion 2019-10-25 5 sites Stand-alone
    Other conditions: Plasma Cell Leukemia
    View official trial listing →
  • Status unknown NCT NCT03607643

    A Study of the Efficacy of Cannabidiol in Patients With Multiple Myeloma, Glioblastoma Multiforme, and GI Malignancies

    Not yet reported, Not yet reported Leaf Vertical Inc. 160 participants Est. completion 2020-12-15 1 site Stand-alone
    Other conditions: Cancer of Pancreas, Cancer of Liver, Cancer of Rectum, Cancer of Colon, Cancer, Gall Bladder, Myeloma Multiple, Glioblastoma Multiforme
    View official trial listing →
  • Withdrawn NCT NCT03617484

    Bortezomib in Combination With Ibrutinib in Ibrutinib Relapsed Mantle Cell Lymphoma

    Not yet reported University of Michigan Rogel Cancer Center Est. completion 2030-07 1 site Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT03617731

    Trial on the Effect of Isatuximab to Lenalidomide/Bortezomib/Dexamethasone (RVd) Induction and Lenalidomide Maintenance in Patients With Newly Diagnosed Myeloma (GMMG HD7)

    Not yet reported University of Heidelberg Medical Center 662 participants Est. completion 2028-06 72 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03619252

    Pneumococcal Vaccination of Multiple Myeloma Patients on Novel Agents

    Not yet reported Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology 36 participants Est. completion 2021-06-30 1 site Stand-alone
    Other conditions: Multiple Myeloma, Pneumococcal Infection, Febrile Neutropenia, Pneumococcal Pneumonia
    View official trial listing →
  • Active, not recruiting NCT NCT03620903

    Efficacy of First Line B-RI for Treatment Naive Waldenström's Macroglobulinemia

    Not yet reported Christian Buske 53 participants Est. completion 2027-02 12 sites Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia
    View official trial listing →
  • Status unknown NCT NCT03641456

    VRD as Induction Followed by VR Maintenance in Patients With Newly Diagnosed High Risk Multiple Myeloma

    Not yet reported Sun Yat-sen University 50 participants Est. completion 2025-12-30 1 site Stand-alone
    Other conditions: Myeloma, Newly Diagnosed, High Risk
    View official trial listing →
  • Completed NCT NCT03651128

    Efficacy and Safety Study of bb2121 Versus Standard Regimens in Subjects With Relapsed and Refractory Multiple Myeloma (RRMM)

    Not yet reported Celgene 386 participants Est. completion 2026-04-13 62 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03652064

    A Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Participants With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant is Not Planned as Initial Therapy

    Not yet reported Janssen Research & Development, LLC 395 participants Est. completion 2026-04-21 114 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03670173

    Safety and Efficacy Assessments of Osalmid in Multiple Myeloma

    Not yet reported, Not yet reported Shanghai 10th People's Hospital 20 participants Est. completion 2021-05-18 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03695744

    Daratumumab in Combination With Bortezomib and Dexamethasone in Newly Diagnosed Transplant Ineligible Multiple Myeloma

    Not yet reported Singapore General Hospital 27 participants Est. completion 2024-04 2 sites Stand-alone
    Other conditions: Multiple Myeloma, Myeloma
    View official trial listing →
  • Status unknown NCT NCT03697356

    R-VRD Followed by Lenalidomide Maintenance in Patients With Waldenstrom's Macroglobulinemia

    Not yet reported Kosin University Gospel Hospital 54 participants Est. completion 2026-06-30 1 site Stand-alone
    Other conditions: Waldenström's Macroglobulinemia
    View official trial listing →
  • Status unknown NCT NCT03700229

    Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A

    Not yet reported Peking Union Medical College Hospital 22 participants Est. completion 2020-04-15 1 site Stand-alone
    Other conditions: Acquired Hemophilia A
    View official trial listing →
  • Withdrawn NCT NCT03701321

    Daratumumab, Bortezomib, and Dexamethasone With or Without Venetoclax in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported, Not yet reported National Cancer Institute (NCI) Est. completion 2020-05-28 3 sites Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03710603

    Daratumumab, VELCADE (Bortezomib), Lenalidomide and Dexamethasone Compared to VELCADE, Lenalidomide and Dexamethasone in Subjects With Previously Untreated Multiple Myeloma

    Not yet reported Stichting European Myeloma Network 709 participants Est. completion 2029-11 13 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03729804

    Carfilzomib, Lenalidomide, and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone (KRd vs. VRd) in Patients With Newly Diagnosed Multiple Myeloma (COBRA)

    Not yet reported University of Chicago 250 participants Est. completion 2026-12-28 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03737136

    Comparison Between Bortezomib and Rituximab Plus Plasmapheresis in AMR

    Not yet reported Shahid Beheshti University of Medical Sciences 20 participants Est. completion 2025-09-01 1 site
    Other conditions: Antibody-mediated Rejection
    View official trial listing →
  • Active, not recruiting NCT NCT03742297

    Treatment for Elderly Fit Newly Diagnosed Multiple Myeloma Patients Aged Between 65 and 80 Years

    Not yet reported PETHEMA Foundation 462 participants Est. completion 2031-01 58 sites
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03759093

    CURATE.AI Optimized Modulation for Multiple Myeloma

    Not yet reported, Not yet reported National University Hospital, Singapore 20 participants Est. completion 2025-09-10 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03763162

    Daratumumab, Bortezomib, and Dexamethasone Followed by Daratumumab, Ixazomib, and Dexamethasone in Treating Patients With Relapsed or Refractory Multiple Myeloma

    Not yet reported M.D. Anderson Cancer Center 40 participants Est. completion 2027-10-30 1 site Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Available NCT NCT03763370

    Managed Access Program for Combination Treatment With Belantamab Mafodotin in Multiple Myeloma

    GlaxoSmithKline
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03828292

    An Open-label, Dose Escalation Study in Japanese Participants With Relapsed/Refractory Multiple Myeloma Who Have Failed Prior Anti Myeloma Treatments

    Not yet reported GlaxoSmithKline 15 participants Est. completion 2024-09-05 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT03829020

    Metformin, Nelfinavir, and Bortezomib in Treating Patients With Relapsed and/or Refractory Multiple Myeloma

    Not yet reported Mayo Clinic 9 participants Est. completion 2023-11-24 2 sites Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03829371

    STUDY COMPARING TWO STANDARD TREATMENTS IN AUTOLOGOUS STEM CELL TRANSPLANTATION INELIGIBLE POPULATION AFFECTED BY MULTIPLE MYELOMA

    Not yet reported University of Turin, Italy 450 participants Est. completion 2030-01-03 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT03870451

    Cryocompression Therapy for Peripheral Neuropathy in Patients With Multiple Myeloma

    Not yet reported Wake Forest University Health Sciences 18 participants Est. completion 2023-02-10 1 site Stand-alone
    Other conditions: Chemotherapy-induced Peripheral Neuropathy, Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT03878524

    Serial Measurements of Molecular and Architectural Responses to Therapy (SMMART) PRIME Trial

    Not yet reported OHSU Knight Cancer Institute 2 participants Est. completion 2020-12-10 1 site Stand-alone
    Other conditions: Accelerated Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Anatomic Stage IV Breast Cancer AJCC v8, Anemia, Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Non-Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Non-Hodgkin Lymphoma, Atypical Chronic Myeloid Leukemia, BCR-ABL1 Negative, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Castration-Resistant Prostate Carcinoma, Chronic Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Hematopoietic and Lymphoid System Neoplasm, Locally Advanced Pancreatic Adenocarcinoma, Metastatic Breast Carcinoma, Metastatic Malignant Solid Neoplasm, Metastatic Pancreatic Adenocarcinoma, Myelodysplastic/Myeloproliferative Neoplasm With Ring Sideroblasts and Thrombocytosis, Myelodysplastic/Myeloproliferative Neoplasm, Unclassifiable, Primary Myelofibrosis, Recurrent Acute Lymphoblastic Leukemia, Recurrent Acute Myeloid Leukemia, Recurrent Chronic Lymphocytic Leukemia, Recurrent Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Hematologic Malignancy, Recurrent Hodgkin Lymphoma, Recurrent Myelodysplastic Syndrome, Recurrent Myelodysplastic/Myeloproliferative Neoplasm, Recurrent Myeloproliferative Neoplasm, Recurrent Non-Hodgkin Lymphoma, Recurrent Plasma Cell Myeloma, Recurrent Small Lymphocytic Lymphoma, Refractory Acute Lymphoblastic Leukemia, Refractory Acute Myeloid Leukemia, Refractory Chronic Lymphocytic Leukemia, Refractory Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Refractory Chronic Myelomonocytic Leukemia, Refractory Hematologic Malignancy, Refractory Hodgkin Lymphoma, Refractory Malignant Solid Neoplasm, Refractory Myelodysplastic Syndrome, Refractory Myelodysplastic/Myeloproliferative Neoplasm, Refractory Non-Hodgkin Lymphoma, Refractory Plasma Cell Myeloma, Refractory Primary Myelofibrosis, Refractory Small Lymphocytic Lymphoma, Stage II Pancreatic Cancer AJCC v8, Stage III Pancreatic Cancer AJCC v8, Stage IV Pancreatic Cancer AJCC v8, Stage IV Prostate Cancer AJCC v8, Unresectable Pancreatic Adenocarcinoma
    View official trial listing →
  • Active, not recruiting NCT NCT03896737

    Daratumumab-bortezomib-dexamethasone (Dara-VCd) vs Bortezomib-Thalidomide-Dexamethasone (VTd), Then Maintenance With Ixazomib (IXA) or IXA-Dara

    Not yet reported European Myeloma Network B.V. 401 participants Est. completion 2027-09-15 24 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03908138

    RDD Versus VDD in Newly Diagnosed Patients With Multiple Myeloma

    Not yet reported Shandong Provincial Hospital 120 participants Est. completion 2022-12-31 1 site
    Other conditions: Hematologic Neoplasms, Multiple Myeloma, Efficacy, Safety
    View official trial listing →
  • Completed NCT NCT03909464

    Non-Invasive Neurosensory Testing For Chemotherapy-Induced Peripheral Neuropathy

    Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins 26 participants Est. completion 2019-11-25 1 site
    Other conditions: Cancer, Malignancy, Malignant Neoplasm, Neuropathy, Neuropathies Sensory, Chemotherapy-induced Peripheral Neuropathy
    View official trial listing →
  • Status unknown NCT NCT03942224

    Daratumumab, Ixazomib, & Dexamethasone or Daratumumab, Bortezomib, & Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Emory University 49 participants Est. completion 2026-07-31 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT03945591

    High-Dose Post-Transplant Cyclophosphamide and Bortezomib (CyBor) for the Prevention of Graft-versus-Host Disease Following Allogeneic Hematopoietic Stem Cell Transplantation (HSCT)

    Not yet reported NYU Langone Health 23 participants Est. completion 2024-01-04 1 site Stand-alone
    Other conditions: GVHD
    View official trial listing →
  • Status unknown NCT NCT03982771

    BCD Regimen in Newly Diagnosed Idiopathic Multicentric Castleman's Disease (iMCD)

    Not yet reported Peking Union Medical College Hospital 30 participants Est. completion 2023-01-01 1 site Stand-alone
    Other conditions: Idiopathic Multicentric Castleman's Disease
    View official trial listing →
  • Completed NCT NCT03984097

    A Study to Evaluate Subcutaneous TAK-079 Added to Standard of Care Regimens in Participants With Newly Diagnosed Multiple Myeloma (NDMM)

    Not yet reported Takeda 50 participants Est. completion 2026-03-25 9 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT03989414

    A Study to Determine the Recommended Dose and Regimen and to Evaluate the Safety and Preliminary Efficacy of CC-92480 in Combination With Standard Treatments in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) and Newly Diagnosed Multiple Myeloma (NDMM)

    Not yet reported, Not yet reported Celgene 424 participants Est. completion 2026-11-30 49 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT03997981

    Chemotherapy Induced Peripheral Neuropathy Natural History Study (EPIPHANY)

    Disarm Therapeutics 200 participants Est. completion 2024-04-09 10 sites
    Other conditions: Chemotherapy-induced Peripheral Neuropathy
    View official trial listing →
  • Status unknown NCT NCT04008888

    a Clinical Trial of Efficacy and Safety of the Holistic Treatment of Young High-risk Multiple Myeloma Patients

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 50 participants Est. completion 2020-08-01 1 site Stand-alone
    Other conditions: Multiple Myeloma, Plasma Cell Leukemia, Extramedullary Plasmacytoma, Loss of Chromosome 17p, t(14;16), t(4;14), T(14;20), 1Q21 Amplification, Complex Karyotype
    View official trial listing →
  • Completed NCT NCT04052880

    Study of SubQ Dara With Dose-Attenuated Bortezomib, Lenalidomide, Dexamethasone in Elderly NDMM

    Not yet reported Larysa Sanchez 20 participants Est. completion 2026-05-27 1 site Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT04061772

    A Study of Bortezomib Combined With CHEP in Peripheral T Cell Lymphoma

    Not yet reported Zhejiang Cancer Hospital 54 participants Est. completion 2021-12-05 1 site Stand-alone
    Other conditions: Peripheral T Cell Lymphoma
    View official trial listing →
  • Status unknown NCT NCT04065308

    Daratumumab With DCEP for Multiple Myeloma With Plasmacytoma

    Not yet reported Seoul National University Hospital 33 participants Est. completion 2021-09-30 1 site
    Other conditions: Multiple Myeloma in Relapse, Plasmacytoma, Daratumumab
    View official trial listing →
  • Completed NCT NCT04065789

    Carfilzomib in Combination With Daratumumab, Lenalidomide and Dexamethasone in Transplant-ineligible NDMM Patients

    Not yet reported Tel-Aviv Sourasky Medical Center 41 participants Est. completion 2021-11-12 14 sites
    Other conditions: Myeloma Multiple, Myeloma, Plasma-Cell, Myeloma-Multiple, Plasma Cell Myeloma
    View official trial listing →
  • Completed NCT NCT04083014

    Single-dose Anti-CD20 Antibody With Bortezomib for Relapsed Refractory Autoimmune Hemolytic Anemia

    Not yet reported Peking Union Medical College Hospital 33 participants Est. completion 2024-03-20 1 site Stand-alone
    Other conditions: Autoimmune Hemolytic Anemia, Autoimmune Hemolytic Anemia and Autoimmune Thrombocytopenia
    View official trial listing →
  • Active, not recruiting NCT NCT04091126

    Study of Belantamab Mafodotin Plus Standard of Care (SoC) in Newly Diagnosed Multiple Myeloma

    Not yet reported GlaxoSmithKline 118 participants Est. completion 2026-12-31 30 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04131309

    A Study of Daratumumab Monotherapy in Previously Untreated Patients With Stage 3B Light Chain (AL) Amyloidosis

    Not yet reported Stichting European Myeloma Network 40 participants Est. completion 2025-01-27 5 sites Stand-alone
    Other conditions: Light Chain (AL) Amyloidosis, Stage 3B
    View official trial listing →
  • Active, not recruiting NCT NCT04133636

    A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 208 participants Est. completion 2028-08-25 47 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04140162

    Phase 2 Study With Minimal Residual Disease (MRD) Driven Adaptive Strategy in Treatment for Newly Diagnosed Multiple Myeloma (MM) With Upfront Daratumumab-based Therapy

    Not yet reported University of Michigan Rogel Cancer Center 57 participants Est. completion 2026-09-02 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04151615

    VMP Regimen - Safety, Efficacy, and Optimal Dose Finding Study for Patients With Multiple Myeloma

    Boryung Pharmaceutical Co., Ltd 203 participants Est. completion 2023-01-11 24 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04151667

    Daratumumab Based Response Adapted Therapy for Older Adults With Newly Diagnosed Multiple Myeloma

    Not yet reported H. Lee Moffitt Cancer Center and Research Institute 33 participants Est. completion 2026-03-16 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04166565

    Daratumumab Combined With Bortezomib, Cyclophosphamide and Dexamethasone for the Treatment of Multiple Myeloma Patients Presenting With Extramedullary Disease

    Not yet reported Stichting European Myeloma Network 41 participants Est. completion 2027-03 8 sites Stand-alone
    Other conditions: Multiple Myeloma, Extramedullary Plasmacytoma
    View official trial listing →
  • Completed NCT NCT04173585

    TEAM-Trial: Targeting Epigenetic Therapy Resistance in AML With Bortezomib

    Not yet reported University Hospital Heidelberg 50 participants Est. completion 2023-03-24 1 site Stand-alone
    Other conditions: Acute Myeloid Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT04181827

    A Study Comparing JNJ-68284528, a CAR-T Therapy Directed Against B-cell Maturation Antigen (BCMA), Versus Pomalidomide, Bortezomib and Dexamethasone (PVd) or Daratumumab, Pomalidomide and Dexamethasone (DPd) in Participants With Relapsed and Lenalidomide-Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 419 participants Est. completion 2027-03-31 88 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Enrolling by invitation NCT NCT04210791

    Autologous Stem Cell Transplantation for Patients With AL Amyloidosis

    Nanjing University School of Medicine 500 participants Est. completion 2030-12-31 1 site
    Other conditions: AL Amyloidosis, Plasma Cell Dyscrasia
    View official trial listing →
  • Completed NCT NCT04224571

    CCCG Relapsed Acute Lymphoblastic Leukemia 2017 Study in Children

    Not yet reported Chinese University of Hong Kong 208 participants Est. completion 2023-02-15 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, in Relapse
    View official trial listing →
  • Terminated NCT NCT04243109

    Study of Pomalidomide, Oral Dexamethasone and Very Low-dose Cyclophosphamide in Patients With Refractory Multiple Myeloma Who Have Received Lenalidomide and Bortezomib

    Not yet reported Maimónides Biomedical Research Institute of Córdoba 6 participants Est. completion 2019-05-07 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04246047

    Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 494 participants Est. completion 2028-06-30 69 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04258683

    A Study of Pembrolizumab Added to the Standard First-Line Therapy of Cyclophosphamide, Bortezomib, and Dexamethasone (CyBorD) for NDMM NTE

    Not yet reported Canadian Myeloma Research Group Est. completion 2022-10-31 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04268498

    A Study of Daratumumab, Carfilzomib, Lenalidomide, and Dexamethasone in Patients With Newly-Diagnosed Multiple Myeloma

    Not yet reported University of Miami 310 participants Est. completion 2027-02-01 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT04277845

    Randomized Phase II Study in Elderly Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Samsung Medical Center 49 participants Est. completion 2025-03 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04285268

    Rituximab, Venetoclax, and Bortezomib for the Treatment of Relapsed or Refractory Diffuse Large B-Cell Lymphoma

    Not yet reported Rutgers, The State University of New Jersey Est. completion 2024-09-30 1 site Stand-alone
    Other conditions: High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Burkitt Lymphoma, Recurrent Diffuse Large B-Cell Lymphoma, Recurrent High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements, Refractory Burkitt Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Refractory High Grade B-Cell Lymphoma With MYC and BCL2 or BCL6 Rearrangements
    View official trial listing →
  • Completed NCT NCT04304144

    A Study to Evaluate the Safety and Tolerability of CAEL-101 in Patients With AL Amyloidosis

    Not yet reported Alexion Pharmaceuticals, Inc. 25 participants Est. completion 2023-11-14 3 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Completed NCT NCT04309942

    Evaluation Study on Performance of Guided Clinical Pharmacy Consultation in Patients With Multiple Myeloma on First Oral Anticancer Treatment

    Not yet reported Centre Hospitalier Universitaire de Nīmes 60 participants Est. completion 2023-05-30 3 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04348006

    Assessment of Bortezomib (Alvocade ®) Efficacy and Safety in Newly Diagnosed Multiple Myeloma Patients

    Not yet reported Al-Rasheed University College Est. completion 2021-07-30 1 site Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04352205

    Daratumumab-Based Therapy for the Treatment of Newly Diagnosed Multiple Myeloma With Kidney Failure

    Not yet reported Emory University 17 participants Est. completion 2024-01-19 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma, Renal Failure
    View official trial listing →
  • Withdrawn NCT NCT04392648

    A Study to Evaluate the Safety, Tolerability and Efficacy of Intravenous TAK-573 as Part of Combination Therapy in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

    Not yet reported Teva Branded Pharmaceutical Products R&D LLC Est. completion 2023-11-10 Stand-alone
    Other conditions: Relapsed and/or Refractory Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04393363

    Early Detection of Neuropathy and Cognitive Impairment Following Treatment for Haematological Malignancies

    Aalborg University Hospital 20 participants Est. completion 2030-12-31 1 site
    Other conditions: Chemotherapy-induced Peripheral Neuropathy
    View official trial listing →
  • Completed NCT NCT04423367

    Bortezomib Plus Dexamethasone for Acquired Pure Red Cell Aplasia Failure or Relapse After First-line Treatment

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 18 participants Est. completion 2024-09-30 3 sites Stand-alone
    Other conditions: Acquired Pure Red Cell Aplasia
    View official trial listing →
  • Completed NCT NCT04433156

    VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

    Not yet reported Henan Cancer Hospital 26 participants Est. completion 2026-03-31 1 site Stand-alone
    Other conditions: Marginal Zone Lymphoma
    View official trial listing →
  • Completed NCT NCT04445701

    Study of AO-176 as Monotherapy and in Combination With Bortezomib/Dexamethasone in Relapsed/Refractory Multiple Myeloma

    Not yet reported, Not yet reported Arch Oncology 10 participants Est. completion 2022-11-14 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT04474938

    Daratumumab Combined With Bortezomib and Dexamethasone in Mayo 04 Stage III Light Chain Amyloidosis

    Not yet reported Peking Union Medical College Hospital 40 participants Est. completion 2024-03 1 site Stand-alone
    Other conditions: Amyloidosis; Systemic
    View official trial listing →
  • Active, not recruiting NCT NCT04484623

    Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 302 participants Est. completion 2029-06-25 122 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04504825

    A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIb AL Amyloidosis (CARES)

    Not yet reported Alexion Pharmaceuticals, Inc. 125 participants Est. completion 2027-10-22 90 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT04512235

    A Study to Evaluate the Efficacy and Safety of CAEL-101 in Patients With Mayo Stage IIIa AL Amyloidosis (CARES)

    Not yet reported Alexion Pharmaceuticals, Inc. 281 participants Est. completion 2027-04-08 110 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Terminated NCT NCT04570631

    Study to Determine Recommended Phase 2 Dose of Intravenous (IV) Eftozanermin Alfa in Combination With IV or Subcutaneous (SC) Bortezomib and Oral Dexamethasone Tablet and to Assess Change in Disease Symptoms in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported AbbVie 4 participants Est. completion 2025-05-05 19 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT04612582

    Comparison of BTD and BCD Based Regimens in the Treatment of AL Amyloidosis

    Not yet reported Guangdong Provincial People's Hospital 70 participants Est. completion 2023-06-30 1 site Stand-alone
    Other conditions: Immunoglobulin Light-Chain Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT04626791

    Modified VR-CAP and Acalabrutinib as First Line Therapy for the Treatment of Transplant-Eligible Patients With Mantle Cell Lymphoma

    Not yet reported Academic and Community Cancer Research United 41 participants Est. completion 2028-08-03 3 sites Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Active, not recruiting NCT NCT04653246

    Isatuximab, Lenalidomide, Bortezomib, and Dexamethasone in NDMM

    Not yet reported Jacob Laubach, MD 52 participants Est. completion 2029-01-13 1 site Stand-alone
    Other conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma (NDMM), Autologous Stem Cell Transplant
    View official trial listing →
  • Active, not recruiting NCT NCT04656951

    Daratumumab for First Line Treatment of Transplant-ineligible Myeloma Patients Followed by Daratumumab Re-treatment at First Relapse

    Not yet reported University of Cologne 67 participants Est. completion 2031-12 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT04678089

    Evaluation of Clinical Treatment of Multiple Myeloma Based on Multi-omics

    Beijing Chao Yang Hospital 350 participants Est. completion 2023-12 1 site
    Other conditions: Multiple Myeloma, Bortezomib
    View official trial listing →
  • Active, not recruiting NCT NCT04717700

    Selinexor With Alternating Bortezomib or Lenalidomide Plus Dexamethasone in TIE Newly Diagnosed MM Patients

    Not yet reported Ida Bruun Kristensen 50 participants Est. completion 2029-06-01 11 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04722146

    A Study of Teclistamab With Other Anticancer Therapies in Participants With Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 140 participants Est. completion 2027-10-13 27 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04751877

    Multicenter Open Label Phase 3 Study of Isatuximab Plus Lenalidomide and Dexamethasone With/Without Bortezomib in the Treatment of Newly Diagnosed Non Frail Transplant Ineligible Multiple Myeloma Elderly Patients (≥ 65; < 80 Years).

    Not yet reported Poitiers University Hospital 270 participants Est. completion 2027-08-17 1 site Stand-alone
    Other conditions: Multiple Myeloma, Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04754945

    Isatuximab as Upfront Therapy for the Treatment of High Risk AL Amyloidosis

    Not yet reported Emory University 11 participants Est. completion 2028-07-24 6 sites Stand-alone
    Other conditions: AL Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT04775550

    DARA RVD For High Risk SMM

    Not yet reported Omar Nadeem, MD 61 participants Est. completion 2030-12-08 6 sites Stand-alone
    Other conditions: High-risk Smoldering Multiple Myeloma, Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT04776850

    Pre-transplant Immunosuppression and Donor Stem Cell Transplant for the Treatment of Severe Hemoglobinopathies

    Not yet reported M.D. Anderson Cancer Center Est. completion 2022-12-05 Stand-alone
    Other conditions: Beta Thalassemia Major, Sickle Beta 0 Thalassemia, Sickle Beta Plus Thalassemia, Sickle Beta Thalassemia, Sickle Cell Disease, Sickle Cell-SS Disease
    View official trial listing →
  • Active, not recruiting NCT NCT04786028

    A Study of Isatuximab Added to Standard CyBorD Induction and Lenalidomide Maintenance Treatments in ND-TEMM

    Not yet reported Canadian Myeloma Research Group 72 participants Est. completion 2027-06 7 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04790474

    Ixazomib-pomalidomide-dexamethasone as Second or Third-line Combination Treatment for Patients With Relapsed and Refractory Multiple Myeloma Previously Treated With Daratumumab, Lenalidomide and Bortezomib

    Not yet reported Tel-Aviv Sourasky Medical Center 61 participants Est. completion 2028-01-01 7 sites Stand-alone
    Other conditions: Multiple Myeloma in Relapse, Refractory Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04802356

    Belantamab Mafodotin in Newly Diagnosed Transplant Eligible Multiple Myeloma Patients

    Not yet reported PETHEMA Foundation 50 participants Est. completion 2026-06 12 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04892446

    Study of Magrolimab Combinations in Patients With Relapsed/Refractory Multiple Myeloma

    Not yet reported Gilead Sciences 36 participants Est. completion 2024-04-25 22 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04912427

    Isatuximab, Velcade, and Dexamethasone in Patients With Multiple Myeloma and Severe KIDNEY Disease

    Not yet reported Washington University School of Medicine 1 participants Est. completion 2024-01-26 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT04923893

    A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy

    Not yet reported Janssen Research & Development, LLC 743 participants Est. completion 2036-09-22 136 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04939142

    A Study of Evaluating the Safety and Efficacy of ATG-010, Bortezomib, and Dexamethasone (SVd) Versus Bortezomib and Dexamethasone (Vd) in Patients With Relapsed or Refractory Multiple Myeloma (RRMM)

    Not yet reported Antengene Corporation 154 participants Est. completion 2025-10-30 33 sites Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04939844

    REST - Replacing Steroids in the Transplant Ineligble

    Not yet reported Oslo University Hospital 51 participants Est. completion 2024-08-31 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT04956302

    Panobinostat in Combination With Daratumumab, Bortezomib and Dexamethasone for the Treatment of Relapsed/Refractory Multiple Myeloma

    Not yet reported Abdullah Khan 1 participants Est. completion 2022-06-16 1 site Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT04973137

    A Study to Evaluate the Efficacy and Safety of Birtamimab in Mayo Stage IV Patients With AL Amyloidosis

    Not yet reported Prothena Biosciences Ltd. 208 participants Est. completion 2025-06-20 110 sites Stand-alone
    Other conditions: Light Chain (AL) Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT04975997

    Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM)

    Not yet reported Celgene 939 participants Est. completion 2032-06-25 259 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT04996160

    Palbociclib in Combo w/Chemotherapy in Peds Relapsed/Refractory Acute Lymphoblastic Leukemia

    Not yet reported Tanja Andrea Gruber 2 participants Est. completion 2023-10-16 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, Pediatric, Relapsed Acute Lymphoblastic Leukemia, Refractory Acute Lymphoblastic Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT05013190

    A Study of NINLARO® in Chinese Adults With Multiple Myeloma

    Takeda 72 participants Est. completion 2026-12-31 12 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05052970

    Mitoxantrone Hydrochloride Liposome Injection, Bortezomib and Dexamethasone in the Treatment of R/R MM

    Not yet reported CSPC Zhongnuo Pharmaceutical (Shijiazhuang) Co., Ltd. 60 participants Est. completion 2024-06-20 1 site Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT05054478

    Primary Plasma Cell Leukemia: a Prospective Phase 2 Study Incorporating Daratumumab to Chemotherapy and Stem Cell Transplantation

    Not yet reported Assistance Publique - Hôpitaux de Paris 29 participants Est. completion 2028-02 Stand-alone
    Other conditions: Plasma Cell Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT05083169

    A Study of Teclistamab in Combination With Daratumumab Subcutaneously (SC) (Tec-Dara) Versus Daratumumab SC, Pomalidomide, and Dexamethasone (DPd) or Daratumumab SC, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 587 participants Est. completion 2028-09-15 176 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05123131

    Isa-RVD Study in Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported Cancer Trials Ireland 54 participants Est. completion 2027-12-15 5 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05135442

    Efficacy and Safety of Bortezomib as First-line Treatment of Acquired TTP

    Not yet reported Peking Union Medical College Hospital 30 participants Est. completion 2025-11-30 1 site Stand-alone
    Other conditions: Thrombotic Thrombocytopenic Purpura, Acquired
    View official trial listing →
  • Status unknown NCT NCT05137860

    Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

    Not yet reported Hospital General de Mexico 56 participants Est. completion 2023-06-23 1 site Stand-alone
    Other conditions: Acute Lymphoblastic Leukemia, in Relapse, Chemotherapeutic Toxicity, Minimal Residual Disease
    View official trial listing →
  • Status unknown NCT NCT05147493

    A Phase 2 Study of Isatuximab in Combination With Bortezomib, Cyclophosphamide and Dexamethasone Followed by Isatuximab and Lenalidomide Maintenance in Newly Diagnosed Patients With Multiple Myeloma and Severe Renal Impairment

    Not yet reported Hellenic Society of Hematology 51 participants Est. completion 2025-02 6 sites Stand-alone
    Other conditions: Multiple Myeloma, Renal Impairment, Neoplasms, Plasma Cell, Neoplasms by Histologic Type, Neoplasms, Paraproteinemias, Blood Protein Disorders, Hematologic Diseases
    View official trial listing →
  • Completed NCT NCT05163405

    Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.

    Karin B. Ø. Dieperink 10 participants Est. completion 2022-06-01 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05218603

    Evaluation of Maintenance With Bortezomib Plus Daratumumab (V-Dara) After Induction With Bortezomib, Melphalan, Prednisone Plus Daratumumab (VMP-Dara) in Newly Diagnosed Multiple Myeloma (MM) Patients Non-eligible for autoSCT

    PETHEMA Foundation 100 participants Est. completion 2025-11-06 32 sites
    Other conditions: Multiple Myeloma, Non-eligible for Autologous Stem Cell Transplantation (ASCT)
    View official trial listing →
  • Active, not recruiting NCT NCT05231629

    Sequential Therapy in Multiple Myeloma Guided by MRD Assessments

    Not yet reported University of Alabama at Birmingham 300 participants Est. completion 2029-12 10 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05250973

    A Study of Daratumumab-Based Therapies in Participants With Amyloid Light Chain (AL) Amyloidosis

    Not yet reported Janssen Research & Development, LLC 151 participants Est. completion 2026-11-23 46 sites Stand-alone
    Other conditions: Amyloidosis
    View official trial listing →
  • Active, not recruiting NCT NCT05257083

    A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma

    Not yet reported Stichting European Myeloma Network 759 participants Est. completion 2040-08 106 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Withdrawn NCT NCT05293509

    Pharmacologic Pretransplant Immunosuppression (PTIS) + Reduced Toxicity Conditioning (RTC) Allogeneic Stem Cell Transplantation in Inherited Hematologic Disorders

    Not yet reported M.D. Anderson Cancer Center Est. completion 2023-09-18 1 site Stand-alone
    Other conditions: Stem Cell Transplantation
    View official trial listing →
  • Status unknown NCT NCT05383547

    Bortezomib for Treating Glomerular Diseases

    Not yet reported Ruijin Hospital 20 participants Est. completion 2023-12-31 1 site Stand-alone
    Other conditions: Bortezomib, Glomerulonephritis, MN, MPGN, FSGS, IgA Nephropathy
    View official trial listing →
  • Active, not recruiting NCT NCT05392946

    Iberdomide, Daratumumab, Bortezomib, and Dexamethasone for Treatment of Newly Diagnosed Multiple Myeloma, IDEAL Study

    Not yet reported, Not yet reported Mayo Clinic 49 participants Est. completion 2028-09-29 1 site Stand-alone
    Other conditions: Plasma Cell Myeloma
    View official trial listing →
  • Withdrawn NCT NCT05408026

    Study of Combination POM, BTZ, Low-Dose DEX, and DARA (PVD-DARA) in Patients With RRMM

    Not yet reported, Not yet reported Alliance Foundation Trials, LLC. Est. completion 2026-02 Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05422027

    Selinexor Plus VRd in High Risk Newly Diagnosed Multiple Myeloma

    Not yet reported, Not yet reported Xia Zhongjun 42 participants Est. completion 2025-12-31 4 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05432414

    PVd Versus Vd in NDMM Patients With RI

    Not yet reported RenJi Hospital 79 participants Est. completion 2024-07-31 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05514990

    Bortezomib and Pembrolizumab With or Without Pelareorep for the Treatment of Relapsed or Refractory Multiple Myeloma, AMBUSH Trial

    Not yet reported, Not yet reported University of Southern California 10 participants Est. completion 2027-08-22 2 sites Stand-alone
    Other conditions: Recurrent Plasma Cell Myeloma, Refractory Plasma Cell Myeloma
    View official trial listing →
  • Terminated NCT NCT05556616

    A Study of Modakafusp Alfa in Adult Participants With Multiple Myeloma

    Not yet reported Teva Branded Pharmaceutical Products R&D LLC 15 participants Est. completion 2024-06-04 21 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05561049

    Efficacy and Safety of Daratumumab in Combination With Bortezomib, Thalidomide, and Dexamethasone Regimens in Newly Diagnosed Multiple Myeloma

    The First Affiliated Hospital of Soochow University 120 participants Est. completion 2025-09-30
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT05564052

    A Study of Ibrutinib With Rituximab in Relapsed or Refractory Mantle Cell Lymphoma

    Not yet reported Janssen Research & Development, LLC 36 participants Est. completion 2024-09-26 66 sites Stand-alone
    Other conditions: Lymphoma, Mantle-Cell
    View official trial listing →
  • Active, not recruiting NCT NCT05572515

    A Study Comparing Teclistamab Monotherapy Versus Pomalidomide, Bortezomib, Dexamethasone (PVd) or Carfilzomib, Dexamethasone (Kd) in Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 614 participants Est. completion 2031-08-31 211 sites Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Terminated NCT NCT05675319

    Allogeneic Stem Cell Transplantation vs. Conventional Therapy as Salvage Therapy for Relapsed / Progressive Patients With Multiple Myeloma After First-line Therapy

    Not yet reported Universitätsklinikum Hamburg-Eppendorf 28 participants Est. completion 2025-03-21 30 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT05724966

    Anti-neoplastic Treatment, Based on PRO Data Reported Through a MHealth App Solution in Multiple Myeloma

    Thomas Lund 33 participants Est. completion 2022-11-15 1 site
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05776940

    Probiotic Supplementation Reduces Gastrointestinal Symptoms During the Therapy and Improves Therapeutic Response in AL Amyloidosis

    Not yet reported Air Force Military Medical University, China 116 participants Est. completion 2026-03-31
    Other conditions: Immunoglobulin Light-chain Amyloidosis
    View official trial listing →
  • Completed NCT NCT05781425

    Prediction of Getting Peripheral Neuropathy in Patients Treated With Bortezomib?

    Odense University Hospital 20 participants Est. completion 2025-07-29 2 sites
    Other conditions: Chemotherapy-induced Peripheral Neuropathy
    View official trial listing →
  • Completed NCT NCT05804032

    Lenalidomide, Bortezomib and Dexamethasone Induction Therapy With Either Intravenous or Subcutaneous Isatuximab in Patients With Newly Diagnosed Multiple Myeloma

    Not yet reported University of Heidelberg Medical Center 514 participants Est. completion 2026-01-30 91 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05805891

    Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

    Not yet reported Chinese SLE Treatment And Research Group 20 participants Est. completion 2025-12 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Active, not recruiting NCT NCT05849610

    Teclistamab-Daratumumab and Talquestamab-Daratumumab in Newly Diagnosed High-risk Multiple Myeloma

    Not yet reported PETHEMA Foundation 30 participants Est. completion 2029-07 10 sites Stand-alone
    Other conditions: High-Risk de Novo Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05850286

    A Study of VRd-based Regimen Combined With CART-ASCT-CART2 Treatment in NDMM Patients With P53 Abnormalities

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 20 participants Est. completion 2028-04 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05860036

    A Study of VRd-based Regimen Followed by BCMA CAR-T Therapy in Transplant-Ineligible Patients With New-diagnosed Multiple Myeloma

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 40 participants Est. completion 2028-03-10 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05870917

    A Study of VRD-based Regimen Combined With CART-ASCT-CART2 Treatment in Patients With Primary Plasma Cell Leukemia

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 20 participants Est. completion 2027-04 1 site Stand-alone
    Other conditions: Plasma Cell Leukemia
    View official trial listing →
  • Active, not recruiting NCT NCT05889221

    Multicenter Phase 2 Study of Subcutaneous Isatuximab Plus Bortezomib, Lenalidomide and Dexamethasone in the Treatment of Newly Diagnosed Transplant Ineligible Multiple Myeloma

    Not yet reported Poitiers University Hospital 74 participants Est. completion 2028-09-01 1 site Stand-alone
    Other conditions: Multiple Myeloma, Myeloma Multiple, Myeloma
    View official trial listing →
  • Withdrawn NCT NCT05895201

    High-Dose Post-Transplant Cyclophosphamide, Bortezomib, and Sitagliptin for the Prevention of GVHD

    Not yet reported, Not yet reported Indiana University Est. completion 2025-12 1 site Stand-alone
    Other conditions: Bone Marrow Transplant Complications, Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, Adult, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia
    View official trial listing →
  • Completed NCT NCT05900882

    SVRd for the Treatment of Newly Diagnosed Multiple Myeloma Patients Presenting With Extramedullary Disease

    Not yet reported The First Affiliated Hospital with Nanjing Medical University 29 participants Est. completion 2026-08-30 6 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT05954780

    Selinexor (Nexpovio®) (SVd) in Patients With Relapsed or Refractory Multiple Myeloma

    iOMEDICO AG 75 participants Est. completion 2026-10-30 2 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT05982756

    Bortezomib Combined With DAG Regimen in the Treatment of Refractory/Relapsed AML

    Not yet reported Zhongnan Hospital 40 participants Est. completion 2023-12-01 1 site Stand-alone
    Other conditions: Bortezomib, Acute Myeloid Leukemia
    View official trial listing →
  • Completed NCT NCT06012383

    Alvocade® (Bortezomib) Safety and Effectiveness Study

    NanoAlvand 57 participants Est. completion 2022-12
    Other conditions: Multiple Myeloma, Refractory
    View official trial listing →
  • Withdrawn NCT NCT06015750

    Mitigate Immune-Mediated Loss of Therapeutic Response to Asfotase Alfa (STRENSIQ®) for Hypophosphatasia

    Not yet reported Alexion Pharmaceuticals, Inc. Est. completion 2030-03-13 Stand-alone
    Other conditions: Hypophosphatasia
    View official trial listing →
  • Active, not recruiting NCT NCT06029998

    Bortezomib in Patients With Metastatic Castration-Resistant Prostate Cancer With PTEN Deletion

    Not yet reported University of Utah 22 participants Est. completion 2028-12 1 site Stand-alone
    Other conditions: Metastatic Castration-resistant Prostate Cancer
    View official trial listing →
  • Active, not recruiting NCT NCT06158841

    Study Assessing Activity of Intravenous (IV) Etentamig Monotherapy Versus Standard Available Therapies in Adult Participants With Relapsed or Refractory Multiple Myeloma

    Not yet reported AbbVie 421 participants Est. completion 2027-12 166 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06169215

    Comparing the Combination of Selinexor-Daratumumab-Velcade-Dexamethasone (Dara-SVD) With the Usual Treatment (Dara-RVD) for High-Risk Newly Diagnosed Multiple Myeloma

    Not yet reported National Cancer Institute (NCI) 58 participants Est. completion 2027-09-23 27 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT06189833

    Phase 2 Study Applying MRD Techniques for Participants With Previously Untreated Multiple Myeloma Treated With D-VRd Prior To and After High-dose Therapy Followed by ASCT - TAURUS

    Not yet reported Stichting European Myeloma Network 200 participants Est. completion 2025-12 31 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT06203145

    A Clinical Study on the Whole-course Management (BCD-KPD-AutoHSCT) Scheme for Patients With RIMM

    Not yet reported Peking University First Hospital 30 participants Est. completion 2025-11-30 1 site Stand-alone
    Other conditions: Multiple Myeloma, Renal Injury
    View official trial listing →
  • Active, not recruiting NCT NCT06208150

    A Study Comparing Talquetamab Plus Pomalidomide, Talquetamab Plus Teclistamab, and Elotuzumab, Pomalidomide, and Dexamethasone or Pomalidomide, Bortezomib, and Dexamethasone in Participants With Relapsed or Refractory Myeloma Who Have Received an Anti-CD38 Antibody and Lenalidomide

    Not yet reported Janssen Research & Development, LLC 838 participants Est. completion 2028-12-31 242 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT06212596

    Selinexor, Cyclophosphamide and Prednisone in Myeloma

    Not yet reported University of Leeds 66 participants Est. completion 2023-11-14 13 sites Stand-alone
    Other conditions: Relapsed or Refractory Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT06215638

    An Exploratory Clinical Study on Bortezomib for the Treatment of Refractory Rheumatoid Arthritis

    Not yet reported Peking Union Medical College Hospital 30 participants Est. completion 2024-12-30 1 site Stand-alone
    Other conditions: Rheumatoid Arthritis
    View official trial listing →
  • Status unknown NCT NCT06284395

    Two Schemes Response in Multiple Myeloma

    Hospital General de Mexico 83 participants Est. completion 2024-10-30 1 site
    Other conditions: Response, Acute Phase, Survivorship
    View official trial listing →
  • Status unknown NCT NCT06297681

    Combination of Daratumumab and BD Regimen and Dapagliflozin in the Treatment of M-protein Related Cardiac Disease

    Beijing Chao Yang Hospital 40 participants Est. completion 2025-12-31
    Other conditions: M-protein Related Cardiac Disease
    View official trial listing →
  • Withdrawn NCT NCT06348147

    Dara-RVd Induction for Newly Diagnosed Multiple Myeloma With Autologous Stem Cell Transplantation

    Not yet reported UNC Lineberger Comprehensive Cancer Center Est. completion 2029-05 1 site Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma, Multiple Myeloma, Autologous Stem Cell Transplantation
    View official trial listing →
  • Active, not recruiting NCT NCT06353022

    Minimal Residual Disease-based Strategy With T-Cell Redirector After Treatment With Daratumumab, Bortezomib, Lenalidomide, and Dexamethasone (D-VRd) in Newly Diagnosed Multiple Myeloma

    Not yet reported Nantes University Hospital 103 participants Est. completion 2030-06-26 19 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06413498

    A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma

    Not yet reported Kite, A Gilead Company 452 participants Est. completion 2031-07 117 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Status unknown NCT NCT06457464

    Clinical Outcomes and Prognostic Factors in Multiple Myeloma Patients

    Assiut University 100 participants Est. completion 2025-10-01
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06577025

    A Study of Different Sequences of Cilta-cel, Talquetamab in Combination With Daratumumab and Teclistamab in Combination With Daratumumab Following Induction With Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in Participants With Standard-risk Newly Diagnosed Multiple Myeloma

    Not yet reported Janssen Research & Development, LLC 43 participants Est. completion 2030-09-30 16 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT06656221

    A Prospective, Single-Center Study Evaluating the Efficacy and Safety of Glofitamab Combined With Orelabrutinib and Bortezomib in Patients With High-Risk Mantle Cell Lymphoma

    Not yet reported Ruijin Hospital 29 participants Est. completion 2028-05-01 Stand-alone
    Other conditions: Mantle Cell Lymphoma
    View official trial listing →
  • Not yet recruiting NCT NCT06771180

    Dara-BCD for Rare MGRS

    Not yet reported Peking University People's Hospital 10 participants Est. completion 2026-06-30 Stand-alone
    Other conditions: Monoclonal Gammopathy of Renal Significance (MGRS)
    View official trial listing →
  • Active, not recruiting NCT NCT06853080

    Feasibility of Using Bortezomib With or Without Chemotherapy in Patients With Atypical Teratoid/Rhabdoid Tumors

    Not yet reported Taipei Medical University 6 participants Est. completion 2025-12 1 site Stand-alone
    Other conditions: Atypical Teratoid/Rhabdoid Tumors (AT/RTs), Central Nervous System (CNS) Tumors
    View official trial listing →
  • Active, not recruiting NCT NCT06868654

    China Subpopulation: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 72 participants Est. completion 2028-06-30 11 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06868667

    Japan Expansion Cohort: Evaluation of Efficacy and Safety of Belantamab Mafodotin, Bortezomib and Dexamethasone Versus Daratumumab, Bortezomib and Dexamethasone in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 24 participants Est. completion 2028-06-30 16 sites Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT06876298

    Role of Uromodulin in Management of Multiple Myloma

    Not yet reported Assiut University 30 participants Est. completion 2027-03-25 1 site
    Other conditions: Multiple Myloma
    View official trial listing →
  • Not yet recruiting NCT NCT06913192

    Efficacy of Sequential BCMA CAR-T Cell Therapy Following Autologous Hematopoietic Stem Cell Transplantation in Transplant-eligible Newly Diagnosed Multiple Myeloma

    Not yet reported Xuzhou Medical University 50 participants Est. completion 2028-02-28 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Active, not recruiting NCT NCT06956170

    All Japanese Population: Belantamab Mafodotin Plus Pomalidomide and Dexamethasone (Pd) Versus Bortezomib Plus Pd in Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 21 participants Est. completion 2029-06-25 13 sites
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07072585

    Testing the Addition of Daratumumab to Chemotherapy for Treating Patients With Newly-Diagnosed T-Cell Lymphoblastic Leukemia (T-ALL) and T-Cell Lymphoblastic Lymphoma (T-LL)

    Not yet reported, Not yet reported Children's Oncology Group 1708 participants Est. completion 2035-09-01 Stand-alone
    Other conditions: Stage II T Lymphoblastic Leukemia/Lymphoma, Stage III T Lymphoblastic Leukemia/Lymphoma, Stage IV T Lymphoblastic Leukemia/Lymphoma, T Acute Lymphoblastic Leukemia, T Lymphoblastic Lymphoma
    View official trial listing →
  • Completed NCT NCT07200583

    Protein A Immunoadsorption in Highly Sensitized Haplo-HSCT Patients

    Ting YANG 50 participants Est. completion 2025-08-31 1 site
    Other conditions: Hematologic Malignancies, Hematologic Disorders, Allogeneic Hematopoietic Stem Cell Transplantation (HSCT), Graft Failure
    View official trial listing →
  • Completed NCT NCT07206810

    A Study of the Bortezomib, Lenalidomide, and Dexamethasone Regimen for the Treatment of Newly Diagnosed Multiple Myeloma Patients

    The First Affiliated Hospital of Soochow University 419 participants Est. completion 2025-02-01 1 site
    Other conditions: Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07247097

    ELDORADO: Elranatamab Versus Daratumumab in Combination With RVd Lite for Newly Diagnosed Transplant Ineligible/Deferred Multiple Myeloma

    Not yet reported Massachusetts General Hospital 160 participants Est. completion 2035-12-01 3 sites Stand-alone
    Other conditions: Multiple Myeloma, Newly Diagnosed Multiple Myeloma, Transplant Ineligible, Newly Diagnosed Multiple Myeloma (NDMM)
    View official trial listing →
  • Not yet recruiting NCT NCT07334535

    Isa-VRD in TIE HRMM

    Not yet reported Peking Union Medical College Hospital 117 participants Est. completion 2029-01 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07403071

    Validating Fish Oil's Role in Alleviating Bortezomib-Induced Neuropathy: A Multi-Method Study Integrating Big Data, Experimental, and Clinical Research

    The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School 200 participants Est. completion 2027-12-31
    Other conditions: Multiple Myeloma, Peripheral Neuropathy Due to Chemotherapy
    View official trial listing →
  • Withdrawn NCT NCT07428369

    A Study of Linvo-VR vs DVRd in Transplant-Eligible Adult Participants With Newly Diagnosed Multiple Myeloma (NDMM)

    Not yet reported, Not yet reported Regeneron Pharmaceuticals Est. completion 2038-05-21 Stand-alone
    Other conditions: Multiple Myeloma (MM)
    View official trial listing →
  • Not yet recruiting NCT NCT07464210

    Nemtabrutinib, Bortezomib, and Rituximab for WM

    Not yet reported Seoul National University Hospital 19 participants Est. completion 2030-08-01 1 site Stand-alone
    Other conditions: Waldenstrom Macroglobulinemia
    View official trial listing →
  • Not yet recruiting NCT NCT07600151

    Etenta-Isa-VRd in Newly Diagnosed High-Risk Multiple Myeloma

    Not yet reported, Not yet reported Universitätsklinikum Hamburg-Eppendorf 220 participants Est. completion 2036-12-31 1 site Stand-alone
    Other conditions: Myeloma Multiple, Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07601100

    Isatuximab, Iberdomide, Bortezomib, Dexamethasone in Transplant Ineligible/Deferred Newly Diagnosed Myeloma

    Not yet reported, Not yet reported Dana-Farber Cancer Institute 88 participants Est. completion 2034-07-01 2 sites Stand-alone
    Other conditions: Newly Diagnosed Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07609706

    A Study of the Combination of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Multiple Myeloma and Moderate Hepatic Impairment

    Not yet reported GlaxoSmithKline 20 participants Est. completion 2031-08-22 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT07614243

    Long Non-coding RNA (lncRNA) ZFAS1-Mediated Mechanism of Roasted Nux Vomica in Intervening Bortezomib-Induced Peripheral Neuropathy

    Not yet reported The First Affiliated Hospital of Zhejiang Chinese Medical University 22 participants Est. completion 2022-08-31 1 site Stand-alone
    Other conditions: Multiple Myeloma, Chemotherapy-Induced Peripheral Neuropathy
    View official trial listing →
  • Not yet recruiting NCT NCT07614360

    Study of Alternative and Approved Dosing Regimens of Belantamab Mafodotin, Bortezomib, and Dexamethasone (BVd) in Participants With Relapsed/Refractory Multiple Myeloma

    Not yet reported GlaxoSmithKline 150 participants Est. completion 2031-02-11 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07635511

    Acalabrutinib Maleate and Bortezomib for Patients With HLA Antibodies

    Not yet reported The First Affiliated Hospital of Soochow University 42 participants Est. completion 2029-05-31 Stand-alone
    Other conditions: Hematological Malignancies, Platelet Transfusion Refractoriness (PTR), HLA Antibodies
    View official trial listing →
  • Not yet recruiting NCT NCT07637526

    Study to Evaluate Efficacy and Safety of Belantamab-based Combinations for Relapsed Multiple Myeloma

    PETHEMA Foundation 100 participants Est. completion 2027-12-31
    Other conditions: Relapse Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07671287

    GMMG-HD11/DSMM XXI/64007957MMY3010

    Not yet reported University of Heidelberg Medical Center 399 participants Est. completion 2033-01-30
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07675174

    Phase I-II PTCy, Bortezomib and Sitagliptin for Prevention of GvHD Following Allogeneic HSCT

    Not yet reported, Not yet reported Northwell Health 72 participants Est. completion 2032-07-01 1 site Stand-alone
    Other conditions: GVHD - Graft-Versus-Host Disease
    View official trial listing →
  • Completed NCT NCT07689006

    Real-World Clinical Outcomes in Relapsed/Refractory Multiple Myeloma Treated With Pomalidomide Regimens

    Bristol-Myers Squibb 341 participants Est. completion 2025-03-28 1 site
    Other conditions: Relapsed/Refractory Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07709715

    A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of NXC-201 Compared With Daratumumab With Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) in Newly Diagnosed Systemic AL Amyloidosis

    Not yet reported Nexcella Inc. 260 participants Est. completion 2032-12
    Other conditions: Light Chain (AL) Amyloidosis
    View official trial listing →
  • Not yet recruiting NCT NCT07732712

    Isa-VRdlite for of Frail and/or Much Older Patients With High Risk Newly Diagnosed Multiple Myeloma Base on Circulating Plasma Cells

    Not yet reported, Not yet reported The Affiliated People's Hospital of Ningbo University 15 participants Est. completion 2030-12-31 Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Completed NCT NCT07774988

    Individualized Education for Bortezomib-Related Symptom Management in Multiple Myeloma

    Not yet reported Can Lafci 49 participants Est. completion 2018-08-31 1 site Stand-alone
    Other conditions: Multiple Myeloma
    View official trial listing →
  • Not yet recruiting NCT NCT07789522

    Safety and Efficacy of Elranatamab Plus Isatuximab, Bortezomib, and Lenalidomide in Ultra-High-Risk Multiple Myeloma

    Not yet reported Institute of Hematology & Blood Diseases Hospital, China 15 participants Est. completion 2028-10-30
    Other conditions: Multiple Myeloma (MM)
    View official trial listing →
  • Not yet recruiting NCT NCT07793422

    Study to Evaluate Change in Disease Activity and Adverse Events of Subcutaneous Etentamig Compared With Daratumumab Plus Cyclophosphamide Plus Bortezomib Plus Dexamethasone (Dara-CyBorD) in Adults With Amyloid Light Chain (AL) Amyloidosis

    Not yet reported AbbVie 370 participants Est. completion 2034-12
    Other conditions: Amyloid Light Chain (AL) Amyloidosis
    View official trial listing →
Efficacy history

Not yet reported.

Safety

Not yet reported.

Sources
Related On The Pen coverage

No related coverage yet.

This drug may be investigational and not yet approved for any use. Whether someone can join a clinical trial is determined only by that trial's own study team — On The Pen does not determine eligibility. Information here can change; always confirm current details on the official ClinicalTrials.gov listing or with the sponsor.